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Many biosynthetic steps in the mupirocin (pseudomonic acids) biosynthetic pathway 
of Pseudomonas fluorescens NCIMB 10586 have already been deduced.  Putative functions 
of most of the genes of the mup cluster have been assigned, although, exact sequence of steps 
in the pathway and their timings are not yet known.  Thiomarinols are another group of anti-
bacterials produced by Pseudoalteromonas sp. SANK73390. Very little is known about the 
biosynthesis of thiomarinols that share striking structural similarity with pseudomonic acids 
in their polyketide and fatty acid moieties. This similarity is reflected at genetic level as 
significant similarity in amino acid identity between the products of at least 27 open reading 
frames in the biosynthetic clusters.  
This project aimed to learn more of biosynthetic steps in the biosynthesis of 
mupirocin and thiomarinol antibiotics by testing for functional cross-complementation 
between pair of genes or a group of genes whose products show significant homology.  
Surprisingly only two genes tmlJ and tmlS out of nine studied showed complementation in 
the mup system.  Findings suggested protein-protein interactions limited interchangeability of 
equivalent functions between two biosynthetic systems.  It was shown by expressing related 
genes as groups for complementation in the mup system that it was possible to confirm 
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The discovery of antibiotics has been one of the most important historical milestones 
for improving the health conditions of humans and animals since their discovery decades ago.  
Any compound that either arrests the growth of microorganisms or kills them is called an 
antibiotic.  Antibiotics are not only synthesised by bacteria, fungi and some plants but also 
reported from organisms as diverse as insects, dinoflagellates, molluscs etc. Though the first 
discovered antibiotic-penicillin was a peptide antibiotic, naturally produced antibiotics have 
diverse chemical nature with majority of these being polyketides that are produced as a result 
of secondary metabolism by producing organisms.  Bacteria and fungi make antibiotics to 
protect themselves from surrounding organisms with which they face competition for 
survival (for space and/or nutrition etc.).  It is hypothesised that these chemical compounds 
are exported out of the cell to kill competitors or to serve other functions like signalling.  
 Today hundreds of antibiotics are used therapeutically, the majority of which are 
produced by bacteria belonging to actinomycetes or Streptomyces (Hopwood, 2007, Mahajan 
and Balachandran, 2012, de Lima Procópio et al., 2012). But because microorganisms have 
the inherent ability to develop resistance over a period against all the microbial agents 
whether natural or synthetic, today there is the growing problem of bacterial resistance shown 
by pathogenic microorganisms to many of the known antibiotics (Levy and Marshall, 2004, 
Ventola, 2015). Bacteria employ various molecular mechanisms like random mutations or 
acquisition of genes from other bacteria by horizontal transfer to evolve resistance to specific 
antibiotics (Kuroda et al., 2001).  The problem of bacterial resistance has also increased due 
to unregulated use of antibiotics in certain parts of the world (Ventola, 2015).  Some of the 
pathogenic bacteria over the period of time have developed resistance to all known 





2010).  One such bacterium is Methicillin-resistant Staphylococcus aureus (MRSA) which 
causes surgical wound infection, pneumonia and systemic infections.  This bacterium has 
become resistant to all β-lactam antibiotics as well as to most of the non β-lactam antibiotics 
and therefore poses a serious health threat (Hiramatsu et al., 2001).  Mupirocin, a polyketide 
antibiotic which is produced by bacterium Pseudomonas fluorescens, until recently has been 
very effective against MRSA until the development of resistance to it was reported by 
Rahman et al. in 1987.  Various S. aureus strains have developed resistance to mupirocin.  
While low-level resistance can be developed as a result of point mutations in its gene, ileS, 
that encodes enzyme isoleucine t-RNA synthetase (IleRS), high level resistance is caused as a 
result of it acquiring mupA gene that encodes a different eukaryotic type IleRS protein which 
is not inhibited by mupirocin (Hodgson et al., 1994).  Isoleucine t-RNA synthetase (IleRS) is 
the target of mupirocin for its antibacterial action (Antonio et al., 2002).   
As a result of the increasing problem of drug resistance among pathogens, in general, 
and in particular to this antibiotic due to their indiscriminate and unregulated use, demand for 
novel antibiotic molecules with novel and improved/useful activities is ever increasing 
(Walsh, 2003, Ventola, 2015).  To tackle this urgent need for molecules with novel activity, 
new molecules are being explored and tested for novel activities that are produced by diverse 
organisms from different habitats ranging from extreme climates; deserts to deep sea. Other 
approaches involve improving the activity of existing molecules by modifying them 
chemically or biosynthetically. Attempts are being made to develop novel hybrid molecules 
by integrating the components from different biosynthetic pathways by applying the 
knowledge of genetic engineering and approaches of the combinatorial biosynthesis. 
 
It has been shown that biosynthesis of polyketide antibiotic molecules which is 





genetic level of the producer organism to make them produce their altered derivatives which 
may have novel and useful/improved activity towards the pathogens.  
Polyketides are present in nature in diverse forms like polyphenols, macrolides, 
enediynes and polyethers. They have distinct functions which include a wealth of clinically 
important activities such as antibiotics (erythromycin, tetracycline, rifampicin, picromycin, 
kirramycin etc.), antifungal, anticancer (epothilone B), antiparasitic (avermectin) and 
immunosuppressive properties (rapamycin), anti-cholesterol (lovastatin) and have great 
pharmacological potential.  All polyketides are known to have been derived from the 
molecules that have the characteristic repetitive  “-CH2-CO-” moiety. 
 









                                                
   
 
   





Thiomarinols is another group of compounds produced by marine bacterium designated 
as Alteromonas rava sp. nov. SANK 73390 that has strong antimicrobial activity (Shiozawa 
et al., 1993) and therefore has potential to be developed as a strong antibiotic.  It has been 
shown that these molecules are hybrid of two types of existing antibiotics; pseudomonic acids 
and pyrrothines (Shiozawa et al., 1993). Holomycins belong to pyrrothine class of antibiotics.  
Thus, thiomarinols are hybrid molecules that are coded by a hybrid of polyketide synthase 
and non-ribosomal peptide synthase gene cluster known as the tml cluster (Fukuda et al., 
2011).  
  Mechanism of polyketide and fatty acid biosynthesis 
Polyketides like fatty acid biosynthesis are produced as a result of simple sequential 
addition/condensation of 2-Carbon keto units, in repeated/recurring decarboxylative 
condensation reactions chemically known as Claisen condensation that are catalysed by 
gigantic multifunctional enzymes called as polyketide synthetases (PKS).  PKSs also have 
similarity with the enzymes of fatty acid synthesis- fatty acid synthases (FAS).   The PKS and 
FAS have also been shown to be evolutionary related (Smith and Tsai, 2007).  Biosynthesis 
of both, polyketides and fatty acids, is initiated by an initial reaction in which a starter 
carboxylic acid unit condenses with a dicarboxylic acid.  
In both, PKS and FAS, the priming/initiator (activated) carboxylic acid moiety is 
attached to the cysteine residue at the active site of the ketosynthase (KS) domain of 
synthase, which is condensed with the chain extender substrate. During the biosynthesis of 
polyketides for each round of condensation the acyl transferase (AT) region selects and loads 
the extender unit on the serine residue present in its active site which is then followed by 
transfer and attachment of the selected unit onto the thiol group of phosphopantetheine arm of 





which remains bound to ACP as β-keto ester which is subjected to β carbon 
processing/reduction before starting another round of elongation.  In both, the reductive steps 
catalysed by ER/KR domains involve NADPH.  This way when the chain of required length 
is reached by such successive addition of two carbon atoms followed by reduction, it is 
finally released from phosphopantetheine by the action of the thioesterase (TE) domain 
(Hopwood and Sherman, 1990). In both the synthases, all reaction intermediates remain 













Figure 1.2 Basic mechanisms involved in fatty acid and polyketide 
biosynthesis.KS, ketosynthase; AT, acyl transferase; DH, dehydratase; ER, enoyl 
reductase; KR, ketoreductase; ACP, acyl carrier protein (Adapted from(Hertweck, 
2009). 
 
The polyketide biosynthesis differs from fatty acid biosynthesis on two counts. Firstly, 
in the set of reactions catalysing reduction of β-carbons which is optional in PKS 
biosynthesis compared to in the fatty acid biosynthesis.  This is on account of the variable 
presence (or complete absence) of different reducing domains in PKSs compared to in FASs 







all of which have complete set of the reducing domains and therefore always catalyse a 
uniform set of reductions. Secondly, PKSs and FASs differ in their choice of carbon-
substrates used for biosynthesis.  PKSs can use a variety of carbon substrates compared to 
FASs which utilize only acetyl Co-A and malonyl Co-A as starter and extender units, 
respectively (Figure 1.4). PKSs can use primer units with 2, 3 or 4 carbon atoms and can 
accept β-keto or β-hydroxy or enoyl or saturated substrates (Figure 1.4).  It is on account of 
these two factors polyketides can have many different types of structures compared to that of 
fatty acids.  Further diversity is added to the polyketides by the action of another set of 
enzymes called tailoring enzymes which may cause further oxidative-reduction, the addition 
of moieties or various functional groups or cyclization.  Diversity is also present in PKS on 
account of the stereochemistry of hydroxy and alkyl side groups and in the way various 
carbon atoms of the newly formed molecule cyclise.  Normally in PKSs, different dedicated 
AT modules are used for loading of primer and extender units unlike in FASs.  This results in 
the flexibility of utilization of different substrates for each condensation cycle in PKS 
biosynthesis that imparts additional diversity to them (Figure 1.3). Furthermore, the 
difference between PKSs and FASs is in the manner by which they extend the chain. FASs 
function in an iterative manner by which the same ACP is used in all the chain condensation 
reactions for transferring of substrates. While in modular PKSs for such role each module has 
got its own ACP, which may be present on the same or another polypeptide.  In PKS, an ACP 
on one hand coordinates with KS region of its module for chain elongation and on the other 
hand also coordinates with the KS domain of next module ‘downstream’ to facilitate chain 
transfer of processed intermediate (condensed and β-carbon processed).  Same role in the 































Figure 1.3 Schematic representation of levels in the biosynthetic pathway of 
polyketides where diversity can be introduced(Adapted from(Hertweck, 2009). 
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Figure 1.4 Various starter and extender units utilized by FASs and PKSs. Those 
used by FASs are labelled in red. A range of starter units used by PKSs are labelled in 
black while extender units used by them are labelled in blue.  
 
  Polyketide synthases (PKS)  
These are multifunctional enzymes that are responsible for the biosynthesis of 
polyketide molecules and are of various types.  A minimal type I PKS has three essential 
catalytic regions that are acyltransferase (AT), ketosynthase (KS) and acyl carrier protein 
(ACP) domain which are responsible for the extension of carbon chain; while terminal 
thioesterase domain (TE) catalyses the final release of polyketide molecule.  In fact, there are 
various domains/mechanisms for the release of extended polyketide molecule. Apart from 
N-methyl anthraniloyl-CoA





















these minimal catalytic regions a PKS can have any or all of many other catalytic regions like 
ketoreductase (KR), dehydratase (DH), enoyl reductase (ER) that catalyse the reduction of 
the β-keto groups in the polyketide, and other domains like methyltransferase that add a 
methyl group. As per the level of organization of protein structure (architectural organization) 
PKSs are of three major types viz type I PKS, type II PKS and type III PKS that are further 
sub-divided on the basis of their mode of action during biosynthesis which may be linear or 
iterative. These are described below.  
1.3.1 Type I (modular) polyketide synthases    
Type I PKS (modular) synthases are large (megadalton) multienzyme protein 
complexes made of several large polypeptides which have a set of separate catalytic active 
sites for each cycle of carbon chain elongation and modification in the polyketide 
biosynthetic pathway.  Each active site is known as a “domain” and a set of domains is called 
a “module” for which reason these are also known as modular PKS.  All the necessary 
domains that are KS, ACP and AT required to complete one elongation cycle along with any 
or all of the optional β-keto processing domains are all present in one module.  This way one 
module is responsible for completing one elongation cycle.  Several modules are present in 
these synthases that are covalently attached to each other making them as one integrated 
structure. The number of modules present in these synthases directly correlates with the 
number of carbon atoms in the polyketide products they synthesize. Similarly, the number 
and type of β-keto processing units that are present also directly relate to the nature and 
degree of reduction of the synthesized polyketide.  As a result, there is direct correlation 
between  composition of PKS architecture (one-to-one correspondence of the  
domain/module present in it) and  the structure of product that it encodes or vice versa 





Various degrees of colinearity exist between PKS architecture and the product that it encodes 
depending upon whether the PKS is an iterative type or non-iterative and whether all the 
domains/modules present in them are functional.  A non-iterative polyketide synthase uses its 
each module for chain elongation/processing during a biosynthetic cycle only once. 
Therefore, colinearity between PKS architecture and its product is highest in type I non- 
iterative (modular) PKS, which on account of their organization functions like an assembly 
line.  As a result of this, usually the final number of ketide units synthesized by Type I 
(modular) PKS equals the number of carbon chain extension modules present in the PKS.  In 
fact, in the biosynthesized product even level, nature, and position of reductions are also a 
clear-cut reflection of the type, nature, number and position of the various reducing domains 
present in the PKS structure (Keatinge-Clay, 2012).  This way there is colinearity between 
PKS structure and the structure of the molecule that it encodes.  Type I PKS may also contain 
a loading module to initiate biosynthesis. The final product is cleaved by thioesterase (TE) 
domain.   
The type I PKS are further sub-divided into iterative and non-iterative based on the use 
of modules/domains for biosynthesis whether they are used for repeated chain extensions or 
are used for just one extension cycle. An example of a non-iterative type I PKS is 6-
deoxyerythronolide B synthase that synthesises the core of erythromycin antibiotic. Other 
examples are avermectin and rapamycin. Modular type I (non-iterative) PKSs are analogous 
to vertebrate FAS and mostly present in bacteria while modular iterative PKSs are mainly 
found in fungi. 
1.3.1.1 Erythromycin- a non-iterative type I PKS 
 The 6-deoxy erythronolide (DEBS) polyketide core of erythromycin antibiotic is the most 





erythrae. Erythromycin polyketide gene cluster (eryPKS) consists of three genes eryAI, 
eryAII and eryAIII (Donadio and Katz, 1992) which encode three multifunctional proteins 
named deoxyerythronolide B synthase 1, 2 and 3 designated as DEBS1, DEBS2 and DEBS3 
respectively (Figure 1.5).  All non-iterative type I PKS of these three multifunctional proteins 
have two modules each of which in turn consists of three domains that are required to 
complete one cycle of chain elongation; ketosynthase, acyltransferase, and acyl carrier 
protein (Swan et al., 1994).  The polyketide core of erythromycin-A molecule is thus 
biosynthesized by six successive condensation/chain elongation reactions with each module 
catalysing two condensation steps. The DEB core of erythromycin is derived from the 
condensation of one propionyl-CoA starter unit and six methyl malonyl-CoA extender units 
(Marsden et al., 1994).   Apart from chain extender domains each of module 1, 2, 5 and 6 
have one or more β-keto reductions domains that are ketoreductase (KR), dehydratase (DH) 
and enoyl reductase (ER) while no such domain is present in module 3.  The N-terminal end 
of the DEBS-1 module has an extra module called a loading module which consists of an AT 
and an ACP domain.  It has been proposed that this module plays a role in improving the 
efficiency of the PKS system. In this PKS system, the genetic organization is clearly reflected 
in the biochemical sequence of events that result in the biosynthesis of heptaketide 
intermediate (Donadio et al., 1991). That is finally cleaved by thioesterase (TE) domain 
present at the C-terminal end of the DEBS-3 module.  This release by TE domain results in 













               
                                                                                                                                             
 
   







                                  














Figure 1.5 Biosynthesis of 6-dEB (erythromycin aglycon).The protein assembly 
line involved in the biosynthesis is present as 6-dEB synthase, a type I PKS that 
consists of three polypeptides DEBS1, DEBS2 and DEBS3 encoded by three ORFs 
eryAI, eryAII and eryAIII, respectively. Biosynthesis is initiated by loading of 
activated propionate (starter unit) on the loading domain and activated methyl 
malonate (extender unit) on the first module of DEBS1 that primes the first 
condensation reaction. The final molecule is released from assembly line by the action 
of TE domain after elongation of the polyketide chain by the remaining five modules 
of the assembly line each catalysing condensation reaction between the elongated 
polyketide chain and a molecule of methyl malonate. KS, ketosynthase; AT, acyl 
transferase; DH, dehydratase; ER, enoyl reductase; KR, ketoreductase; ACP, acyl 
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1.3.1.2 Iterative type-I PKS  
 Iterative type I PKSs are characteristic of fungal polyketide biosynthesis that produces 
molecules like lovastatin, 6-MSA. These PKS enzymes have modular covalent architecture 
like that of type I non-iterative PKS but have only single module which functions repetitively 
for chain extension (Figure 1.6A) (Fujii et al., 2001).  And for each round of chain extension, 
the degree of β-keto reduction may vary.  It was first reported from the avilamycin cluster of 
Streptomyces viridochromogens (Gaisser et al., 1997b). Other reported iterative type I PKS 
examples are lovastatin nonaketide synthase (LNKS) and 6-methyl salicylic acid synthase.  
Recently this type of PKS has been identified in bacteria. One such example is C-1027 
biosynthetic cluster reported from Streptomyces globisporus that codes for C-1027 an anti-












































Figure 1.6 Schematic presentation of mode of action of iterative polyketides. (A) Type I 
iterative PKS (Source:(NII, 2010) (B) Type II iterative PKS with examples (Reproduced 
from(Gokhale and Tuteja, 2008). 
 
 
1.3.2 Type II PKS (aromatic)  
The organization of Type II PKSs differ from that of type I PKSs because these are 
present as discrete proteins that are not covalently linked to each other but are present as 
complexes of separate mono-functional units/polypeptides (Figure 1.6 B). They function in 







cyclization. They are similar to bacterial fatty acid synthase. Type II PKS are also known as 
minimal PKS because they just have KS and ACP domains in which KS has two subunits 
KSα and KSβ (McDaniel et al., 1995, Schneider, 2005). While KSα is responsible for repeated 
condensation of malonyl-CoA extender units, the length of growing chain is decided by KSβ 
(Bisang et al., 1999).  Additional (accessory)  domains that are found in them are cyclases 
(CYC) and aromatases (ARO) which do not play role in the elongation of polyketide chain 
but modify the poly β-ketoacyl carrier protein intermediate to give the aromatic polycyclic 
product (Bisang et al., 1999). This type of PKS is found in actinomycetes. A well-studied 
example of it is actinorhodin PKS which is produced by Streptomyces coelicolor. 
1.3.3 Type III PKS system (chalcone/stilbene synthase) 
Type III PKSs are chalcone synthase (CHS) (Hugler et al., 2002) (Hugler et al., 2002) 
(Hugler et al., 2002) (Hugler et al., 2002) (Hugler et al., 2002) (Hugler et al., 2002) (Hugler 
et al., 2002) or stilbene synthase (STS) like proteins that are comparatively small and have 
single polypeptide chains (Figure 1.7).  These are usually found in plants (Schroder, 1999), 
and are unique in not having phosphopantetheine (P-pant) arm which is characteristic of all 
the PKS and on which the growing polyketide chain is tethered in all.  Instead of using acyl 
carrier proteins for translocation of substrates and intermediates during biosynthesis CHS 
uses CoA thioesters.  It acts as a unimodular PKS to carry out all the reactions like 
decarboxylative condensation, cyclization and aromatization. CHS catalyses biosynthesis of 
the precursor of flavonoids and isoflavonoids, which is 4, 2’, 4’, 6’ tetrahydroxychalcone (Jez 






Figure 1.7 Structure of chalcone synthase-a type III PKS(Source:(NII, 2010). 
 
  Initiation/priming of polyketide biosynthesis and various starter units 
of PKS systems   
Biosynthesis of most of the polyketides is derived from acetate/malonate and propionate/ 
methylmalonate moieties that are usually available in the metabolic pool.  It begins with the 
loading of acetyl-CoA onto synthases. Biosynthesis of erythromycin starts with the loading of 
propionyl-CoA starter units (Hertweck, 2009).  Apart from these, several alternative starter 
units are also used for priming the biosynthesis of PKS that are utilized as CoA thioesters 
(Figure 1.4).  Alternative initiation strategies using acetate starter units have been reported 
from trans-AT PKS systems like pederin and curacin.  Loading modules of these systems  
have domains with distinct structural features for which these are known as GNATL domains. 
These domains belong to GNAT superfamily of N-acyl transferase enzymes. But in systems 
like curacin it is involved in transfer of acyl group to thiol group of ACP which is a role that 
is normally performed in most of the PKS loading modules by specific ATL domain that loads 
an acyl substrate to the neighbouring ACPL domain. And this reaction is followed by 





which is present at its N-terminal (Figure 1.8).  The GNATL domain is widespread in trans-
acetyltransferase systems which may be present as a tridomain (along with other domains) or 
as didomain like in onnamide A biosynthetic pathway. These loading domains exhibit 
decarboxylase and S-acyl transferase activities essential for the loading of substrate (Figure 
1.8) (Piel et al., 2004, Gu et al., 2007).  Knowledge about the mechanism of supply, 
activation and loading of diverse starter units has created ways to broaden the horizons for 
the development of novel polyketide derivatives with novel/enhanced activity (Lee et al., 












































Figure 1.8 Priming of PKSs with acetyl starter units involves different loading 
domains in different biosynthetic clusters.Positions of groups derived from starter 
units in the final molecules are marked with red squares. KS, ketosynthase; KSQ, 
ketosynthase domain in which active site cysteine is replaced with glutamine residue; 
AR, adapter domain; ACP, acyl carrier protein; AT, acyl transferase; ATL, loading 
acyl transferase; GNATL, N-acetyl transferase of loading domain (Adapted from 













































Figure 1.9 Priming by various non-acetate CoA thioesters is used to initiate biosynthesis 
of some polyketidesKS, ketosynthase; ACP, acyl carrier protein; AT, acyl transferase; ATL, 
loading acyl transferase; KR, ketoreductase (Adapted from(Hertweck, 2009). 
Avermectin 














 Diversity of extender units in polyketide biosynthesis 
Most of the PKS systems found in bacteria use malonyl-CoA (MCoA) or 
methylmalonyl-CoA (mMCoA) for chain elongation of the polyketide.  It has been shown by 
domain swapping and mutagenesis experiments that specific motifs in particular AT domains 
govern the choice for selection of the type of extender unit (Liou and Khosla, 2003).  A rare 
extender unit that is reported to be utilized in bacterial systems is 2 ethyl malonyl-CoA 
(eMCoA) which is used in the biosynthesis of antibiotic niddamycin by Streptomyces 
caelestis (Stassi et al., 1998) and ascomycin (immunosuppressant FK 520) from Streptomyces 
hygroscopicus var. ascomyceticus (Wu et al., 2000) as well as tylosin, concanamycin and 
kirramycin. Figure 1.10 shows various malonyl derived extender units that are utilized by 
modular PKSs. In some complex polyketide structures incorporation of heterosubstituted 
malonyl derivatives has been reported. Hydroxymalonylate (hoM) and aminomalonate (aM) 
are other extender units that are used in the biosynthesis of zwittermicin antibiotic produced 
by Bacillus cereus (Figure 1.11) (Emmert et al., 2004). A variety of other extender units have 




























                                                               
                                                                       
 
 






Figure 1.11 Biosynthesis of hydroxyl, methoxy and aminomalonyl-ACP extender 
units by zwittermicin biosynthetic pathway.Aminomalonyl-ACP is derived from 
serine while methoxymalonyl-ACP is derived from glycolyl intermediates as a result 
of methylation of hydroxymalonyl-ACP by SAM derived methyl group. ZmaE, 
oxygenase; SAM, S-adenosylmethionine (Adapted from(Hertweck, 2009).  
 
 Auxiliary proteins in PKS systems    
Apart from core PKS genes that are responsible for the biosynthesis of carbon 
backbone (carbon-carbon bonding) of polyketides, PKS systems also have other enzyme 
activities that are mostly mono-functional and which are crucial for the production and 
activity of the final PKS molecule. Domains for these auxiliary proteins encode enzymes for 
the biosynthesis of alternative or specialized starter and extender units, enzymes for antibiotic 
resistance or the enzymes for modification of intermediate PKS during polyketide 
biosynthesis as well as a number of tailoring enzymes responsible for the modification of 
core PKS moiety after it is synthesized etc. The auxiliary enzymes that modify the core 


















PKS tailoring enzymes and the modifications caused by them are known as post-PKS 
modifications which are discussed in next section.   
Domains for auxiliary functions like enoylreductase, dehydratase and ketoreductase 
that catalyse reduction of double bond, hydroxyl group and keto group, respectively, or for 
methyltransferases that are responsible for insertion of methyl group may be found within 
modules of type I PKSs.  These modify the biosynthetic intermediates accordingly during the 
polyketide biosynthesis. Such modules are widely found in polyketide biosynthetic clusters 
like erythromycin gene cluster (Donadio and Katz, 1992), mupirocin biosynthetic cluster 
(Thomas et al., 2010), kalimantacin/batumin gene cluster (Mattheus et al., 2010), avermectin 
biosynthetic cluster (Ikeda et al., 1999) etc. Auxiliary proteins for these functions are also 
found as standalone proteins in the polyketide biosynthetic clusters where these are present as 
discrete proteins which act in trans, to modify the biosynthetic intermediates selectively.  It 
has been shown that standalone auxiliary protein LovC having enoyl reductase activity is 
necessary for the proper functioning of LNKS-the nonaketide synthase of lovastatin 
biosynthetic cluster (Kennedy et al., 1999).  In many biosynthetic clusters such standalone 
auxiliary proteins represent two or more activities that are fused together. For example, 
MmpC of mupirocin biosynthetic cluster in which enoyl reductase activity is present along 
with acyl transferase activity and both these functions are supplied in trans, for the reduction 
of biosynthetic intermediates and for the loading of extender units respectively during the 
biosynthesis (Hothersall et al., 2007, Thomas et al., 2010).  A group of trans acting auxiliary 
proteins together known as HCS cassette has been shown to be involved in the β- carbon 
branching of the polyketides during their biosynthesis (Haines et al., 2013a). This 





biosynthetic clusters like pederin, mupirocin, bacillaene, thiomarinol, curacin, jamaicamide, 
and kalimantacin/batumin (Piel, 2010, Helfrich and Piel, 2016). 
Apart from enzymatic roles that auxiliary proteins play in polyketide biosynthetic 
clusters these are also found to be involved in non-enzymatic functions.  It has been shown in 
different polyketide biosynthetic systems that auxiliary proteins are essential for the proper 
functioning of glycosylating enzymes that are involved in the glycosylation of polyketide 
moieties.  For example, DesVIII auxiliary protein improves transfer of TDP-D-desosamine by 
DesVII; a glycosyltransferase in the biosynthesis of macrolide antibiotics, neomethymycin, 
pikromycin and methymycin in Streptomyces venezuelae ATCC15439 (Hong et al., 2007). 
Several homologues of DesVIII auxiliary protein have been reported in different biosynthetic 
clusters like  EryCII  from erythromycin biosynthetic cluster of Sacchropolyspora erythraea 
(Hong et al., 2007), AknT from aclacinomycin A biosynthetic cluster of Streptomyces 
galilaeus (Lu et al., 2005), DnrQ from doxorubicin biosynthetic cluster of Streptomyces 
peucetius (Hong et al., 2007), MydC from mycinamycin biosynthetic cluster 
of Micromonospora griseorubida (Melancon et al., 2004), TylM3 from tylosin biosynthetic 
cluster of Streptomyces fradiae (Melancon et al., 2004) and OleP1 from the oleandomycin 
biosynthetic cluster of  Streptomyces antibioticus (Doumith et al., 1999). Similarly, Srm6 and 
Srm28 auxiliary proteins are found in spiromycin biosynthetic cluster of Streptomyces 
ambofaciens that aid glycotransferases Srm5 and Srm29 respectively (Nguyen et al., 2010). 
These auxiliary proteins are required by respective glycotransferases for different reasons.  
Some auxiliary proteins are predicted to have chaperone like function with partner 
glycotransferases like EryCII which enhances the activity of EryCIII by allosteric binding 
(Moncrieffe et al., 2012), while others like DesVII/DesVIII have been found to be involved 





while playing no role in actual catalysis (Borisova and Liu, 2010).  Auxiliary proteins 
sometimes are dispensable as well, like Srm6 of spiromycin cluster as it has been found that 
glycosylation of Srm5 is also supported by Srm28 (Nguyen et al., 2010).   
Auxiliary proteins which include post PKS tailoring enzymes may act in cis or in trans 
during the biosynthesis of polyketides depending on the location of genes that encode them 
and where they finally act. Auxiliary proteins coded by genes that are found embedded with 
PKS genes (in modules) or by those that are found adjacent to them and which work 
alongside products of PKS genes act in cis during the biosynthesis, while trans acting 
auxiliary proteins are coded by gene functions located elsewhere as standalone or fused with 
other gene functions away from their site of action.  
  Post-PKS modification of polyketides 
The core polyketide structure that is synthesised by PKS is subjected to 
further/secondary modifications by the action of various enzymes to modulate its 
functionality or to turn it into the bioactive compound.  Post-PKS modifications are crucial 
for the final activity of PKS molecules (Weymouth-Wilson, 1997, Weissman and Leadlay, 
2005). These post PKS-tailoring enzymes add diversity to polyketide molecules by acting on 
the core polyketide moiety after its biosynthesis by the PKS (Staunton and Weissman, 2001). 
The tailoring enzymes may oxidise the molecule with the introduction of new carbonyl or 
hydroxyl groups, or these may methylate the molecule at different atoms/centres like 
oxygen/nitrogen or carbon.  These may also glycosylate or halogenate the polyketide 
molecule.  In erythromycin biosynthesis, the 6-DEB molecule which is released from PKS is 
hydroxylated, glycosylated and acted upon by methyltransferase before giving rise to active 





  Post-polyketide modifications in erythromycin biosynthesis 
Before erythromycin is produced as an active molecule and after its core polyketide 
structure, which is 6-deoxyerythronolide B- a macrolactone, is biosynthesized by type I PKS 
DBS it is acted upon by many processing enzymes.  The first tailoring modification of the 
polyketide core of erythromycin is done by P450 hydroxylase enzyme EryF that causes 
hydroxylation of the C-6 carbon of the basic macrolactone ring.  By mutating eryF it was 
possible to obtain erythromycin molecules without this modification (Weber et al., 1991).  
The next tailoring modification is the addition of two sugar molecules L-mycarose and D-
desosamine.  Products of genes eryBII to eryBVII with the exception of eryBV are involved in 
the biosynthesis of L-mycarose from TDP-4, 6-deoxyglucose. In addition, the product of 
eryBV participates in the attachment of L-mycarose at the C-3 hydroxyl group of core 
macrolactone unit.  Similarly, D-desosamine is also synthesized from TDP-4, 6-deoxyglucose 
by the action of enzymes coded by eryCI to eryCVI except of eryCIII which is involved in its 
attachment to the C-5 hydroxyl group of the macrolactone unit (Summers et al., 1997).  These 
three modifications result in the production of erythromycin D, a metabolic intermediate in 
the biosynthesis of active erythromycin A. Depending upon the action of further tailoring 
enzymes, erythromycin D is either converted into erythromycin C or erythromycin B.  
Erythromycin D is acted upon by products eryK and eryG which causes hydroxylation at C-
12 and O-methylation of the C-3” hydroxyl group of the attached mycarose molecule 
respectively (Lambalot et al., 1995, Paulus et al., 1990).  Depending upon the order in which 
either of these modifications occur (i.e. the order of action of enzymes), erythromycin D is 
converted into intermediate metabolites either erythromycin B or C.  If erythromycin D acted 
upon by EryK firstly it was converted into erythromycin C, but if EryG acted upon it firstly 
this resulted in the formation of erythromycin B which was a shunt product.  Finally, 





reported that EryG shows four-fold preference for erythromycin C over D as a substrate 
(Paulus et al., 1990) while EryK shows a 1200-1900 fold preference for erythromycin D over 
B as a substrate (Lambalot et al., 1995).  The importance of tailoring regions in the 













































  Table 1.1 Functions of non-PKS genes involved in the biosynthesis of erythromycin     
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  Exploitation of tailoring enzymes for the development of new 
polyketide molecules with novel/ improved bioactivities  
Tailoring enzymes provide another way of getting novel molecules with improved bioactivity 
as they can be easily manipulated with minimum invasion of the PKS clusters along which 
these are typically located.  Because they are often present as discrete ORFs and their activity 
is not because of being part of a multifunctional polypeptide, they can be easily genetically 
manipulated.  Manipulation of just one or two tailoring enzymes that modify a functional 
group on the core polyketide framework like hydroxylation or addition or deletion of sugar 
moiety or its modification may result in novel /altered activity of basically the same 
polyketide molecule.   In fact, genetic manipulation of tailoring enzymes provides the best 
and potentially easiest way of producing novel polyketides with new/enhanced activities 
(Katz and Donadio, 1993, Olano et al., 2010).  By manipulating the carE tailoring region 
gene of biosynthetic pathway of carbomycin antibiotic a novel polyketide molecule was 
created.  The carE gene codes for acylase whose proposed activity is to attach the isovaleryl 
or butyryl to mycarose moiety of this antibiotic.  Expression of the carE gene in Streptomyces 
ambofaciens that endogenously produces antibiotic spiramycin led to the isolation of 
modified antibiotic isovaleryl-spiramycin (Epp et al., 1989).  Similarly, another tailoring 
region gene of the carbomycin biosynthetic cluster from Streptomyces thermotolerans, 
namely acyA, that encodes 3-O-acyltransferase activity, was expressed in a tylosin producer 
Streptomyces fradiae which resulted in the isolation of 3-O-acetyltylosin (Arisawa et al., 
1994).  Many times some of the tailoring region genes are required to be expressed together 
to bring about an effect in the polyketide structure like those for attachment of sugars or those 
involved in oxidation reactions. Different tailoring enzymes were coexpressed in 
heterologous E. coli host to achieve diversification of glycosylation in order to get better 





19-O-perosaminyl-amphoteronolide B was engineered in Streptomyces nodosus by co-
expressing Streptomyces aminophilus perDII perosamine synthase and a hybrid of perDI 
perosaminyltransferase and amphDI genes (Hutchinson et al., 2010). In such cases, 
concerned tailoring functions were required to be expressed together to bring about the 
desired change/modification in polyketide structure.  Substrate specificities of tailoring genes 
have also been one of the major concerns in producing altered polyketide moieties for 
example in erythromycin biosynthesis deletion of eryF gene blocks the hydroxylation of 6-
deoxyerythronolide-B at C-6.  On the other hand, this change does not affect subsequent 
attachment of the sugars, mycarose and desoamine, by glycosyltransferases (Weber et al., 
1991). 
 Resistance in polyketide producers   
The organism that produces antibiotics also has mechanisms/strategies to protect itself 
from them.  Thus it has been found that genes for particular antibiotic production and those 
for resistance from it are not only found together within the natural PKS gene clusters but 
also co-regulated together to protect them from the effect of produced polyketide.  Therefore, 
it has been suggested that mechanisms for self-protection have co-evolved with the 
biosynthetic pathways of antibiotics (Fischbach and Walsh, 2006, Walsh, 2006). The gene for 
the resistance from erythromycin, that is ermE, is found in erythromycin gene cluster of S. 
erythraea (Dhillon et al., 1989).  Similarly, genes for the resistance from actinorhodin are 
found with the genes responsible for its biosynthesis in Streptomyces coelicolor (Caballero et 
al., 1991).  Genes for resistance to carbomycin are located on either side of the gene cluster 






 The trans-AT polyketide synthases 
There is a class of type I modular PKSs that do not follow the colinearity principle of 
biosynthesis between the genetic organization of biosynthetic cluster or enzyme structure and 
the structure of the metabolite that they produce, which is because some of the domains in 
their enzyme architecture are not at all used or are redundant during biosynthesis.  To the 
contrary, some are used more than once resulting in metabolites whose structure does not 
clearly reflect structure/organization of their enzyme/genes in the cluster.  This class of type I 
modular PKSs is characterized by the lack of cognate (cis) AT domain in their structure 
which is present separately in trans as one or more trans-ATs. These PKS systems utilize 
discrete AT functions encoded by different genes to load ACPs and are therefore called trans-
AT type I modular systems as against to the classical which are cis-AT PKS (Piel, 2010, 
Musiol and Weber, 2012, Helfrich and Piel, 2016).  
                          
                                                               
Figure 1.12 Domain architectures of type I PKS.(A) a cis-AT type I PKS and (B) 
trans-AT type-I PKS (Reproduced from Musiol 2012). 
The trans-AT PKSs do not obey the colinearity rule about PKS structure and the 
metabolic product or any other colinearity between the order of genes encoding a PKS and 
the steps involved in its biosynthesis which is observed about erythromycin gene cluster.  
Examples of such peculiarities are the presence of unusual domain orders, repeated domains 






of these PKSs has revealed that those KS modules share more similarities with each other 
which process similar substrates (Nguyen et al., 2008).  Similarly, apart from the single type 
of dehydrating modules found in cis-AT PKS systems, two types of dehydrating bimodules 
are commonly found in trans-AT PKS systems. These are: type A which has domain 
structure KS KR ACP KS0 DH ACP and type B that has KS KR ACP KS DH ACP KR; each 
of which introduces characteristic double bonds (Piel, 2010).  While KS0 is the KS domain 
that lacks the specific histidine residue at its active site which is required for elongation of the 
carbon chain. Examples of trans-AT PKS are mupirocin, thiomarinol, kalimantacin/batumin, 
myxovirescin, kirramycin etc. It has been shown that among fused tandem free-standing/trans 
AT’s the function of other AT (AT2) is not to load the substrate units but is exclusively 
dedicated to proofreading activity (Jensen et al., 2012).  The trans acting oxidoreductase 
domain is also reported to be found fused with tandem or single ATs, as trans-acting ER 
(Musiol and Weber, 2012) among trans-AT polyketide systems. The trans-AT polyketide 
systems also show both types of carbon branching in their structures.  Methyl, ethyl or 
another carbon branching at α-position in their structures results either from the incorporation 
of corresponding branched derivative substrate or by S-adenosylmethionine (SAM)-
dependent α-methylation which involves a methyltransferase (MT) domain in their 
corresponding module. Instead, β-branching is the result of functions acting in trans that 
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BaeC (PksC) and BaeD (PksD) of 
Bacillaene, FenF of Mycosubtilin, 
KirCII of Kirramycin, OzmC of 
Oxazolomycins, 
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Zwittermicin LkcD of Lankacidin. 
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  Structural model for type I polyketide synthases   
Till now no experimental data was available about structures of polyketide synthases 
but now there is some structural insight available to test models that were proposed about 
their structures.  Now new models have been suggested based on the structural data made 
available by using techniques of SAXS and cryo-EM (Weissman, 2015).  Earlier, two models 
were proposed for the structure of erythromycin polyketide synthase based on the data of 






















Figure 1.13 Cambridge model for type I PKS of erythromycin (DEBS).This 
model proposed head-to-head and tail-to-tail arrangement of homodimeric PKS 
modules. According to this model DEBS PKS subunits were twisted together to form 
double helical architecture. This model gave most acceptable arrangement of domains 
and convincingly explained their interaction during functioning of the PKS. Recent 
data about structure of PKS generated by using techniques of cryo-EM and SAXS 
also supported these features proposed in this model. All the new models that are 
proposed about PKS architecture are based on these features of this model 










                                                                                                                                                   
 
Figure 1.14 Head-to-tail model for the structure of type I PKS of erythromycin 
(DEBS).This was the first model that was proposed about the structure of type I PKS. 
It failed to support experimental data of proteolytic digestions of DEBS PKS 





 Protein-protein interactions in polyketide biosynthesis   
Biosynthesis of polyketides by PKS requires communication between different 
components present in its architecture like successive modules, domains, etc.  Whenever 
modules are split into two polypeptides they need to interact with each other to permit 
transfer of intermediate metabolites. For example, in the case of DEBS, which is present as 
three polypeptides, the interaction among them should occur in a certain specific manner so 
that the reaction intermediates encounter different active sites present in various 
modules/domains in the correct order.  For successful biosynthesis of erythromycin aglycon, 
C-terminus of DEBS1 module should interact in a proper way with the N-terminus of 
DEBS2, not of DEBS3. Short stretches of amino acids called as linkers that join various 
domains and modules covalently in the PKS architecture play a crucial role in the passage of 
acyl intermediates during polyketide biosynthesis (Donadio and Katz, 1992). Short stretches 
of amino acids which join domains within modules are known as inter-domain linkers while 
longer linkers called inter-modular linkers join modules covalently.  Still larger linkers which 
connect C-terminal of a module with N-terminal of another module which is present on 
different polypeptide (PKS subunit) are called docking domains (Gokhale et al., 1999).  It has 
been reported using genetic engineering that mismatched linker pairs in a PKS significantly 
impair protein-protein interactions (Tsuji et al., 2001a, Tsuji et al., 2001b, Wu et al., 2001, 
Weissman et al., 2006, Weissman, 2006).  Apart from mismatched linkers, the correct pairing 
of donor ACP in the biosynthetic machinery with its natural downstream acceptor KS domain 
is very crucial for inter-modular transfer of intermediates (Wu et al., 2002). 
  Combinatorial biosynthesis of polyketides/synthases 
The principle of colinearity about PKSs combined with the flexibility of various 





very promising tool in the drug discovery using combinatorial biosynthesis and approaches of 
combinatorial genetics (Cane et al., 1998, Weissman and Leadlay, 2005, Wong and Khosla, 
2012, Ladner and Williams, 2016, Till and Race, 2016).  One-to-one correspondence between 
complement of enzymes/enzyme activities in PKSs with the biosynthetic steps for 
biosynthesis of metabolites and their modular structure in which such activities are 
unambiguously represented in the form of specific discrete domains gives the platform for 
combinatorial biosynthesis of polyketides.  On account of linear nature of correlation 
between PKS structure and product, particularly for type I PKS, these are amenable to genetic 
manipulation (Kittendorf and Sherman, 2006).  Methods of genetic engineering are used to 
modify them for addition or deletion of domains or modules or just few amino acids to affect 
docking so as to alter the activity of enzymes or to alter their substrate specificity etc. by 
adding or deleting gene(s) responsible for the same. Thus, when the specific change(s) are 
made in PKS structure by targeting particular genes(s) it is often possible to predict correctly, 
assuming the various PKS domains act independently, which biosynthetic step(s) will be 
affected and what product it will result in.  This way of considering the colinear relationship 
between the PKS structure and enzymatic steps in the biosynthetic pathway of polyketide 
antibiotics theoretically means that it is possible to create such novel/modified molecules by 
manipulating biosynthetic pathways by recombining various components (modules or 
domains) of relevant biosynthetic genes from two similar systems (Kumar et al., 2004, 
Reeves et al., 2004, Weissman, 2004, Weissman and Leadlay, 2005). Using such approaches, 
it was possible to produce analogues of avermectins with the desired changes (Figure 1.15) or 
to engineer biosynthesis of triketide by DEBS 1 polypeptide alone (Figure 1.16). There are 
many polyketide antibiotic biosynthesizing systems similar to the mupirocin biosynthetic 
cluster like kalimantacin/batumin, myxovirescin etc. whose components could be engineered 





combinatorial biosynthesis (Kumar et al., 2004, Menzella et al., 2005, Zhou et al., 2008) in 
order to produce mupirocin like novel structures/derivatives which may have novel useful 
activities. In practicality, there are several limitations to this approach as this not only 
requires complete knowledge of relevant biosynthetic steps but also deeper knowledge on 
specific issues like substrate preference/tolerance of specific domains, interaction between 
various catalytic domains and proper folding of hybrid proteins etc. (Khosla et al., 1999, 
Rowe et al., 2001).  In practice it has been observed that despite various specific enzymatic 
activities clearly and exclusively assigned to specific domains, the efficiency of 
combinatorial biosynthesis is marred by the fact that PKS behaves like assembly lines, as a 
result the processing of metabolic intermediates by engineered/hybrid PKSs is not efficient 
(Figures 1.15 and 1.17).  Success in combinatorial biosynthesis relies not only upon 
recognition of specific enzymes of their substrates but also upon successful passage of 
metabolic intermediates during the course of synthesis through its assembly line architecture 
right from its N-terminal until their end at C-terminal. There the TE domain finally releases 
the product for further modification cyclization and/or for the action of tailoring enzymes, if 
any.  It has been dissected that various non-covalent (docking etc.) and covalent protein-
protein interactions between elements of the PKS architecture are responsible for the 
successful passage of metabolites through it (Tsuji et al., 2001a, Tsuji et al., 2001b, 
Weissman and Muller, 2008).  In multimodular PKSs, a module is responsible for one round 
of elongation after which the elongated intermediate is transferred to the next module. 
Various recognition and protein-protein interactions ensure that the intermediate is 
transferred from ACP to KS of next module and not back to the earlier module (Kapur et al., 
2012). The ACP, which is present in each module, on one hand coordinates with the KS of its 
own module for chain elongation at the catalytic site while on the other hand coordinates with 





the assembly line system where it accepts the intermediate chain only if it recognizes it 
(Kapur et al., 2010). Thus, a large number of issues like substrate specificity/tolerance of 
various domains, communication between different modules (inter-modular as well as intra-
modular) and even linkers joining the various domains/modules have been found to play 




































Figure 1.15 Production of ivermectins and related drugs-analogues of 
avermectins by genetic engineering of the natural avermectin biosynthetic 
cluster.(A) Avermectins that are produced by natural biosynthetic pathway have 
unsaturation at C22-C23 or hydroxyl group at C23. (B) Replacement of the cognate 
module responsible for these modifications by a module from rapamycin PKS that 
had complete set of reducing domains (all the three DH, ER and KR) needed to 
achieve complete reduction resulted in the production of various analogues of 
avermectins (ivermectins) in which these carbons were fully reduced. Hybrid PKS 
also produced unreduced avermectins that they naturally produce, which appeared to 
be the result of incomplete processing of biosynthetic intermediates. KS, 
ketosynthase; AT, acyl transferase; DH, dehydratase; ER, enoyl reductase; KR, 
ketoreductase; ACP, acyl carrier protein and AVES, avermectin PKS (Reproduced 













       
 








Figure 1.16 Domain organization of an engineered PKS, a bimodular synthase, 
comprising DEBS-1 and TE.The ketide produced by this bimodular synthase in vivo 
was the triketide lactone which was expected (Reproduced from(Rowe et al., 2001). 
 
 
    











Figure 1.17 Domain organization of an engineered hybrid PKS: A trimodular 
synthase, obtained by insertion of module-2 of rapamycin PKS between C-
terminus of module 1 and N-terminus of module 2 of DEBS-1 polypeptide.Two 
types of ketides were produced by this trimodular synthase in vivo. The expected 
product was minor while triketide lactone 1, which was produced by bimodular 
synthase shown above, was the major product. This was explained on the basis of 
phenomenon called ‘skipping’(Reproduced from(Rowe et al., 2001). 
[1,3] R= Et 
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Several hybrid polyketides have been reported to be made using these approaches 
(Staunton and Wilkinson, 2001, Menzella et al., 2005). Identification of various compatible 
domains particularly KS, AT motifs and ACP domains can be exploited for engineering novel 
PKS molecules with novel bioactivities (Weissman, 2004, Weissman and Leadlay, 2005). 
  Nonribosomal peptide synthetases 
Nonribosomal Peptide examples include various antibiotics tyrocidine, bactracin, 
vancomycin, daptomycin, cyclosporin A, penicillin anticancer drugs like bleomycin etc.  
NRPS has modular organization analogous to type I PKS systems or FAS in which catalytic 
units are folded into distinct domains that are arranged as an assembly line (Figure 1.18 and 
1.19). These multimodular synthetases have well-defined initiation, elongation and 
termination modules. Elongation modules comprise distinct domains: a condensation (C) 
domain, an adenylation (A) domain and a peptidyl carrier protein (PCP or ArCP) or thiolation 
(T) domain which is equivalent to ACP in polyketide synthases (Figure 1.18). As in PKS or 
FAS systems, the condensation domain is the point of attachment of activated monomers. 
Similarly, other domains for methylation (M) or reduction (R domain) or epimerization (E) or 
cyclization (Cy), that are found in PKS, can also be present in NRPS which modify the 
functionality of amino acid molecules by methylation/ reduction or epimerization or 
cyclization respectively during the cycles of chain elongation (Ehmann et al., 1999).  
Domains for oxidation or hydroxylation (Silakowski et al., 1999) are also found. Owing to 
their modular organization as in PKS, the number and order of modules in an NRPS protein 
directly correspond to the sequence and number of amino acids in the resulting peptide 
(Figures 1.18 and 1.19) (Fischbach and Walsh, 2006). 
As against to the PKS multimodular assembly lines that are dimeric, NRPS assembly 















Figure 1.18 Simplified representation of modular organization and mechanism of 
biosynthesis by NRPS. Various NRPS domains are arranged into modules that play defined 

















Figure 1.19 Organization of domains in type I NRPS for the biosynthesis of tyrocidine    





 Biosynthesis of combined peptide-polyketide natural products and 
hybrid multimodular synthetases  
  The multimodular synthetases that are described above are also found in nature as 
hybrid fused synthetases either as PKS-NRPS or as NRPS-PKS synthetases or in various 
combinations,  in which the polyketide synthetase part can be type I or II, and it may be 
iterative or non-iterative, etc (Fischbach and Walsh, 2006). Some natural products are 
produced by the action of both NRPS and PKS whereby a moiety biosynthesized by one 
synthetase is taken as substrate by the other synthetase to deliver the final product molecule.  
Numerous  such biosynthetic clusters are also suspected to be associated with fatty acid 
synthetase  activity like the product of mmpB of the mup cluster (Thomas et al., 2010).  In 
hybrid multimodular synthetase systems, the PKS and NRPS components fuse together, and 
there is functional hybridization between modules of both types such that the metabolic 
intermediate synthesized by one is transferred directly onto the other synthetase for 


























 Figure 1.20 Schematic representation of modular organization of hybrid NRPS-
PKS and PKS-NRPS synthases and of posttranslational modification of apo ACP 
or apo PCP into holo ACP or holo PCP by PPTase(Adapted from(Du et al., 2001). 
 
In the coronatine  biosynthesis  polyketide  component, coronafacic acid and amino 
acid component coronamic acid are individually biosynthesized by PKS and NRPS 










cyclosporin biosynthesis a polyketide intermediate is first converted into an amino acid and 
then it is incorporated into the natural product by an NRPS (Figure 1.21)   
             
  




Figure 1.21 Biosynthetic pathway for cyclosporin in T. niveum(Reproduced 
from(Du et al., 2001). 
 
There exist numerous combinations of NRPS and PKS hybrid multimodular systems, 
for example, biosynthesis of pristinamycin by S. pristinaespiralis involves 
PKS/NRPS/PKS/NRPS  hybrid system while biosynthesis of bleomycin by S. verticillus 
represents PKS/NRPS/PKS hybrid system (Figure 1.22).  Rapamycin is biosynthesized by S. 

















Figure 1.22 Biosynthetic pathway of bleomycin in S. verticillus involving a 













Among trans-AT systems, thiomarinol, mupirocin and kalimantacin/batumin related 
gene clusters (kal/bat) are other mixed hybrid multimodular systems. Out of these, the 
thiomarinol and kal/bat clusters which produce antibiotics thiomarinol and 
kalimantacin/batumin in Pseudoalteromonas sp. SANK 73990 (Fukuda et al., 2011), and 
Pseudomonas fluorescens BCCM_ID9359 (Mattheus et al., 2010), respectively are PKS-
NRPS hybrid multimodular systems.  Mupirocin producing (mup) cluster in Pseudomonas 
fluorescens NCIMB10586 consists of a mix of type I and II PKSs and is suspected of 
including an iterative FAS (mmpB) (Thomas et al., 2010).   
 Pseudomonic acids (mupirocin) 
Mupirocin is a polyketide antibiotic which was first isolated as pseudomonic acid by Fuller et 
al. in 1971 by the fermentation of soil bacteria Pseudomonas fluorescens NCIMB 10586.  
These bacteria are mainly found associated with plant rhizosphere and on the surface of plant 
leaves along with closely related other strains of Pseudomonas sp. (Couillerot et al., 2009). 
Pseudomonads belong to Gamma subclass of Proteobacteria; order Pseudomonadales, and 
family Pseudomonadaceae (Palleroni, 1984, Palleroni, 2008). They show remarkable 
ecological and metabolic diversity.  Their existence is widespread in nature where they are 
found in soil, water, plant surfaces, organic matter, animals, insects, and humans (Gross and 
Loper, 2009, Palleroni, 2010).  Pseudomonas spp. are Gram-negative rod shaped which have 
diameter of 1 μm and length 1.5 to 5 μm.  They are motile as they have one or more polar 
flagella and are non-sporulating (Couillerot et al., 2009, Palleroni, 2010).  These are catalase 
positive aerobic bacteria though some species can utilize nitrate as electron acceptor 
(Couillerot et al., 2009).  The GC content of different pseudomonads ranges from 58-69 % 
(Palleroni, 2008, Silby et al., 2011) falling within this range (averaging 61%) is that of 





an array of substrates as source of energy and produce a range of secondary metabolites 
(Palleroni, 2010). This includes a number of bioactive and antimicrobial compounds that are 
known to positively impact plant growth by controlling phytopathogens (Haas and Defago, 
2005, Couillerot et al., 2009). All fluorescent pseudomonads including Pseudomonas 
fluorescens produce fluorescent compounds particularly pyoverdins (Palleroni, 2010).  
Mupirocin produced by Pseudomonas fluorescens NCIMB 10586 is produced as a mixture of 
four types of pseudomonic acids (A, B, C and D) (Fuller et al., 1971).  At least two other 
strains of pseudomonas isolated from sediment ground water have also been reported to 
produce pseudomonic acid A (Fritz et al., 2009).   
1.17.1 Structure and composition  
 All the pseudomonic acids share a common structure in which a C-17 unsaturated 
polyketide moiety called monic Acid, that contains a pyran ring, is esterified to a C-9 
saturated fatty acid, 9-hydroxynonanoic acid (9-HN) (Chain and Mellows, 1977b, Chain and 
Mellows, 1977a).  The difference among different pseudomonic acid types is because of the 
way various carbons of this basic structure are modified in each of them (Figure 1.23).  
Pseudomonic Acid A is the primary natural product (90%) in the mupirocin mixture while 
pseudomonic acid B which has an extra hydroxyl group at C-8 makes up 8% of the mupirocin 
mixture. PA-C that has a double bond instead of epoxide group at C 10-11 accounts only 2%. 




















Figure 1.23 Structures of pseudomonic acid (PA) A, B, C and D(Reproduced from 
(Thomas et al., 2010). 
 
1.17.2 Antimicrobial activity 
Mupirocin has activity against Gram-positive bacteria as well as against a few Gram-
negative bacteria.  It is primarily used against Staphylococcus aureus and specifically against 
methicillin-resistant S. aureus (MRSA) (El-Sayed et al., 2003, McConeghy et al., 2009, 
Thomas et al., 2010). Because of the side effects it induces in the tissues in which it is 
introduced, mupirocin is used topically only against bacterial skin infections and to clear 
nasal passage and as a pre-operative scrub for medical staff (Thomas et al., 2010).  It is 
effective under the conditions when other antibiotics like vancomycin and ciprofloxacin fail 
to bring any effect (Ha et al., 2008).  Several factors limit the use of mupirocin apart from its 
toxicity to the tissues in which it is introduced.  Firstly, it gets quickly deactivated once it is 
in the body fluids because of the hydrolysis of the ester bond between its Monic acid and 9-
HN moiety.  Secondly, it strongly binds to serum proteins thereby reducing its bioavailability.  
Finally, its biological activity is lower at higher pH (Thomas et al., 2010).  It is for these 
factors and despite the fact that it is proved to be many-many times more potent on bacterial 





choice, mupirocin cannot be used systemically (Nakama et al., 2001).  Additionally, there is 
the problem of increasing mupirocin resistance and of which high level mupirocin resistance 
is a cause for concern as the same can be acquired through horizontal gene transfer, may be 
through plasmid carriage (Thomas et al., 2010).  Because of the limitations in the use of 
mupirocin, there is need to find ways to produce alternative compounds that may be having 
the novel or improved activities.  These compounds may be derived from mupirocin, thus 
having similar or altered structures but without the limitations put on their use like mupirocin.  
1.17.3 Mechanism of action  
Mupirocin targets bacterial isoleucyl-tRNA synthetase enzyme (IleRs) to which it 
competitively and reversibly binds to inhibit protein synthesis (Hughes and Mellows, 1978).  
IleRS catalyses the transfer of amino acid isoleucine by charging it so that it can be joined to 
its cognate tRNA prior to protein synthesis.  Structural examination of IleRS with and 
without mupirocin bound to it, revealed that the 14 methyl end of the pseudomonic acid 
mimics side-chain of Isoleucine (Nakama et al., 2001), while the region of C1-to C-3 of 
mupirocin molecule and its pyran ring occupy the ATP binding groove of IleRS as it mimics 
the structure of adenine and ribose (Yanagisawa et al., 1994). The 9-hydroxylnonanoic acid 
portion of the mupirocin molecule stabilizes this complex by fitting into the hydrophobic 
groove of the complex of IleRS with bound mupirocin (Brown et al., 2000). 
1.17.4 Self-Resistance to mupirocin   
  Two types of self-resistance have been reported against mupirocin by Pseudomonas 
fluorescens NCIMB 10586, low and high (resistance to more than 512 µg/ml-1 of mupirocin). 
These are related to the presence of two types of IleRS (IleRS-R1 and IleRS-R2) encoded by 





the presence of a typical bacterial IleRS. The high-level resistance is attributed to the 
presence of a eukaryotic-like IleRS which is the product of mupM present in the tailoring 
region of the mupirocin biosynthesis cluster of P. fluorescens (El-Sayed et al., 2003).  The 
product of mupM gene, the eukaroyotic like IleRS, shares similarity with the other ileS 
reported from other bacterial species that are naturally resistant to mupirocin, for example the 
product of mupA of S. aureus strains which is present on its plasmids that are acquired by 
horizontal gene transfer. 
1.17.5 Mupirocin biosynthetic cluster 
The mupirocin gene cluster, which is a trans-AT PKS cluster of about 75 kb, was first 
identified by transposon mutagenesis (Whatling et al., 1995, Thomas et al., 2010).  Later it 
was analysed by DNA sequencing, specific gene knockouts and complementation studies (El-
Sayed et al., 2003).  It is found to encode 35 open reading frames (ORFs) which could be 
classified into two parts.  The first part comprises of 3 larger multifunctional proteins while 
the second group includes another three smaller multifunctional proteins along with 29 
individual genes called ‘tailoring genes’. The multifunctional genes of the cluster are 
designated as mupirocin multifunctional polypeptides (mmpA to mmpF) (El-Sayed et al., 
2003) five of which are PKS while mmpB is a fatty acid synthase (El-Sayed et al., 2003, Gao 
et al., 2014). Some of these genes show similarity with type II PKS systems indicating that 
the mupirocin PKS system is a mix of both type I and type II. While individual genes are 
designated as mupA-X and macpA-E (El-Sayed et al., 2003). The putative functions of 
various tailoring region genes as well as different domains present in multifunctional proteins 












Figure 1.24 The organization of mupirocin biosynthetic cluster                                                                                 
(Adapted from Thomas, et al., 2010). 
 
 
Table 1.3 List of putative gene functions of mupirocin biosynthetic cluster 








Reduced flavin mononucleotide (FMNH2) oxygenase 
mmpA 
 







PKS: KS, DH, KR, ACP, ACP, ACP, TE 
mmpC 
 
Dual AT and putative ER 
mmpD 
 
PKS: module 1 KS, DH, KR, MT, ACP; module 2 KS, DH, KR, 


































Enoyl CoA hydratase 
mupK 
 
Enoyl CoA hydratase 
mmpE 
 




















































N-Acyl homoserine lactone synthase 
Abbreviations: mmp, mupirocin multifunctional polypeptide gene; PKS, polyketide synthase; KS, 
ketosynthase; DH, dehydratase; KR, ketoreductase; ACP, acyl carrier protein; TE, thioesterase; AT, 
acyltransferase; ER, enoyl reductase; MT, methyltransferase; macp, mupirocin acyl carrier protein 
gene; ORF, open reading frame. 







1.17.6 Mupirocin biosynthetic pathway 
It has been pointed out that the mupirocin biosynthetic pathway does not follow the 
principle of colinearity which is that the order of genes in the cluster does not match with the 
biosynthetic steps as reported in many other PKS type I systems like erythromycin (Donadio 
and Katz, 1992).  Thus, it has neither separate loading domain for loading of activated starter 
unit covalently on the first KS domain, nor a cognate AT domain for sole use of any of its 
modules.  Apart from these peculiarities, it also has some other unique features like tandemly 
repeated ACPs in its modules and the presence of ER domains/activity in trans. The 
biosynthesis of both the components of pseudomonic acid i.e. monic acid and 9-
hydroxynonanoic is now thought to take place together, which explains why transposon 
mutation or targeted mutagenesis to abolish production of either of the two components failed 
(El-Sayed et al., 2003, Cooper et al., 2005b, Hothersall et al., 2007).  Mutational and re-
feeding studies done by Gao et al. (2014) showed that the biosynthesis of mupirocin by the 
mup cluster   involves two biosynthetic pathways running in parallel at the same time. Both 
the pathways are proposed to start from the same precursor, but branches at the point of 
action of MmpEOR whose role in epoxidation has been established.  Out of these two 
pathways, the major pathway, all of the products of which are epoxide derived and in which 
pseudomonic acid B is an intermediate, finally results in the production of pseudomonic acid 
A as the main product while the minor pathway results in the biosynthesis of pseudomonic 
acid C-an alkene derivative which is produced in a minor amount.  It has been shown that 
epoxidation, tetrahydropyran (THP) ring formation and 6-hydroxylation are essential for 
downstream processing by the biosynthetic assembly line (Gao et al., 2014).  The gene 
function responsible for 6-hydroxylation is not known yet.  It has also been shown that once 
the fatty acid side chain biosynthesis is underway, the formation of THP ring is not possible 





(Cooper et al., 2005a, Gao et al., 2014).  Also, the modification of the pyran ring by tailoring 
genes occurs after biosynthesis and esterification of 9-HN on monic acid (Gao et al., 2014). 
The biosynthesis of mupirocin by mup cluster represents an assembly line process as it 
involves orderly and coordinated action of various enzymes represented in the assembly line 
that are coded by the genes in this cluster.  Mupirocin is produced by the action of different 
enzymatic units represented in the mup assembly line on the same building blocks (starter 
unit acetyl-CoA and extender unit malonyl-CoA) in a set pattern as described in section 
(1.17.7-1.17.9). During the biosynthesis some of these enzymatic units act iteratively and 
some non-iteratively to complete a cycle for the production of mupirocin molecule. MmpD 
and MmpA multifunctional proteins act non-iteratively to produce monic acid C-14 precursor 
while others (MmpB) act iteratively to elaborate fatty acid component of the mupirocin 
molecule. During biosynthesis some of the enzymatic functions (AT and ER) are provided, in 
trans by mmpC, that are common to all the steps in the biosynthetic pathway during chain 
elongation. Role of MupE (alone or together with MupD) is also predicted in the biosynthesis 
of mupirocin as trans acting enoyl reductase that also commonly affects various steps during 
biosynthesis (Hothersall et al, 2007, Gao et al, 2014).  None of the modules of mup cluster 
has domains with enoyl reductase activity. By mutational and knock out studies it has been 
shown that the biosynthesis of mupirocin is an integrated process because mutation in most of 
the several components of the mup cluster either resulted in complete loss of production of 
pseudomonic acids or drastically reduced their production (El-Sayed et al., 2003, Hothersall 
et al., 2007, Thomas et al., 2010). This mutational analysis of mup cluster also revealed 
“leaky hosepipe” behaviour of the biosynthetic pathway further supporting the integrated 
nature of the mup assembly line (Wu et al., 2008). This name has been adopted to describe 
the behaviour of mup biosynthetic pathway whereby mutation in many of the several gene 





mupB, mupL, mupQ and mupS, as well as point mutations in mmpB (S1390A) and mmpF 
(C183A),  resulted in essentially identical phenotype which was identified by complete loss 
of mupirocin production and accumulation of same intermediates (mupiric acid and/or 
mupirocin H) (Wu et al., 2008, Cooper et al., 2005a, Hothersall et al., 2007).  This has been 
described due to the existence of labile points in the mup biosynthetic pathway. It has been 
hypothesized that these labile points, from which preferential and spontaneous release of 
biosynthetic intermediates occurs, come into play whenever any mutation blocked the 
passage of biosynthetic intermediates through the mup assembly line. These labile points are 
predicted to be independent of the site of blockage in the mup biosynthetic pathway which 
may be close to them or located distantly (Wu et al., 2008).  
1.17.7 Monic acid backbone biosynthesis                                                                                          
It has been proposed that C-17 ketide backbone of monic acid is synthesised by six 
condensation reactions of acetate derived units which are catalysed by MmpD and MmpA 
that are predicted to have three and four modules respectively (Figure 1.25) (El-Sayed et al., 
2003).  The synthesis begins at MmpD as was evidenced by the isolation of mupiric acid as a 
result of active site mutation in ketoreductase domain of its putative module four (Thomas et 
al., 2010).  For the biosynthesis to begin, the trans acting AT domains, which are part of the 
MmpC module, load an activated starter unit (acetyl-CoA intermediate) onto the 4’-
phosphopantethein arm of ACP of the first module of MmpD.  An activated extender unit like 
malonyl-CoA is then transferred by these acyl transferases to the ACP of first module of 
MmpD. The active site of which becomes vacant in the meantime by transferring starter unit 
onto thiol group of cysteine present at the active site of KS domain of the same module of 
MmpD, which catalyses first decarboxylative (Claisen) condensation leading to chain 





methylation, respectively.  The same process of extension and modifications of carbon 
backbone is repeated by all the remaining three modules of MmpD after which the elongated 
chain is transferred to MmpA module. The first module of MmpA is non-elongating because 
of the presence of KSo domain which does not have an active site his residue that is critically 
required by all the elongating KSs to perform their function. This non-elongating domain 
plays an active role in biosynthesis which is evidenced by complete abolition of mupirocin 
production on mutating its active site or upon its complete deletion (El-Sayed et al., 2003). It 
has been speculated that this module may have a role in transferring elongated intermediate 
from MmpD to MmpA (Thomas, et al. 2010).  Two further rounds of chain elongation by the 
remaining two elongating modules of MmpA on the intermediate that is transferred to it from 
MmpD finally result in the heptaketide precursor of monic acid. Figure 1.25 below shows this 









































































































































































































































































































































































































































































































































































































































































































































































































































Figure 1.26 Modifications of monic acid moiety during the biosynthesis of 
pseudomonic acids. The Monic acid structure is modified in the order shown by the 
action of several enzymes of the mup cluster that act in trans during the biosynthesis.  
After the addition of C-15 methyl group by HCS cassette, epoxide group is added at 
C-10,11 by the action of oxidoreductase domain of MmpE in the intermediates that 
are processed to become PA-B and finally PA-A. Pyran ring formation is catalysed by 
MupW and MupT on epoxidised and unepoxidised intermediates. The site of these 
reactions (concerned ACPs) is not known yet. Thereafter, pyran ring is modified by 
the action of MupO, U, V, C and F when the moiety is tethered to ACPE. 
Unepoxidised intermediates yield PA-C. MmpEOR, mupirocin multifunctional 
protein oxidoreductase domain; ACP, acyl carrier protein (Adapted from(Gurney and 
Thomas, 2011). 
 
1.17.8 9-Hydroxynonanoic biosynthesis (9-HN)  
To date it has been very difficult to predict the source of biosynthesis of 9-HN which is 
fully saturated nine carbon fatty acid chain (Thomas et al., 2010).  Since direct evidence has 
implicated mmpD and mmpA in monic acid backbone synthesis, it must be one of the 
remaining modules that is involved in 9-HN biosynthesis. The MmpB module which could 
not be characterized either as PKS or FAS and which has unusual structure in that it has just 





mechanism although there is no direct published evidence to support this (however, 
unpublished data about involvement of tmlU-induced truncation of the 9-HN moiety and 
mutations of the TE domain do support this).  Feeding experiments of labelled precursors are 
consistent with biosynthesis of 9-HN coming from 3-hydroxypropionate (3-HP) which 
primes its synthesis by mmpB. Circumstantial evidence indicates that products of macpD, 
mupS and mupQ are involved in the biosynthesis of 3-hydroxypropionate (Thomas et al., 
2010).  With 3-HP as starter unit three rounds of condensation of with malonate extender unit 
should result in the synthesis of 9-HN backbone.  However, since this module does not have 
an ER domain to account for saturated fatty acid chain it has been proposed that MupE, 
which shows sequence similarity with ER domains, is involved in enoyl reduction (Hothersall 
et al., 2007). Mutation in MupE resulted in the incorporation of a double bond in the fatty 
acid chain of 9-HN between C6’-C7’ in pseudomonic acid A (Hothersall et al., 2007).  
However, the fact that this did not result in complete unsaturation of 9-HN indicated that this 
enoyl reductase along with other enzymes is responsible for the reduction (Gao et al., 2014).  
The third domain in MmpC is also predicted to have ER activity which may also be involved 
in the reduction of 9-HN.  The terminal TE domain is proposed to catalyse release of the 
saturated 9-HN moiety (El-Sayed et al., 2003, Hothersall et al., 2007).   
1.17.9 Tailoring of monic acid backbone (biosynthesis of active mupirocin)  
Monic acid in the pseudomonic acid backbone (i.e. the monic acid esterified with 9-HN) 
needs to be worked upon by products of several genes of the mup cluster, each having 
different individual activities in order to make the biologically active mupirocin molecule. 
Mutagenesis has showed that all 26 tailoring ORFs are required for normal mupirocin 
production (Hothersall et al., 2007).  These enzymes modify the PKS-bound intermediate in 





hydroxylation at C-6, epoxidation at C-10,11, incorporation of a methyl group at C-15, 
oxidation of C-16 to form tetrahydropyran ring (THP) are carried out by tailoring enzymes    
(Cooper et al., 2005a, Cooper et al., 2005b, Hothersall et al., 2007). Bioinformatic and 
mutational analyses have indicated that in the biosynthesis of pseudomonic acids, several 
tailoring genes work together in groups.  Product analysis of various gene knock-outs has 
shown that sets of genes are involved in the particular type of modification of mupirocin 
structure (Hothersall et al., 2007, Gao et al., 2014). One such group hydroxymethylglutaryl-
CoA synthase (HCS) cassette that is revealed, which includes genes macpC, mupG, mupH 
mupJ, mupK that are located in mup cluster next to each other, is implicated in β-methyl 
branching in the molecule (Figure 1.25).  The other group of genes macpD, mupS, mupQ, 
mmpF that are proposed to act together in a block, which are also located next to each other, 
is implicated 9-HN biosynthesis (Figure 1.25).  Similarly, another group of genes, mupD and 
mupE, that are located next to each other in mup cluster, is implicated in providing enoyl 
reductase activity that is predicted to result in the reduced 9-HN (Gao et al., 2014). Mutation 
in mupW resulted in the biosynthesis of mupirocin derivative without THP ring named as 
mupirocin W, which was also produced when mupT gene was knocked out indicating the two 
genes work together in the oxidation of C-16 to form pyran ring (Figure 1.26) (Cooper et al., 
2005a). Knockouts of either of macpE/ mupO/ mupU/ mupV resulted in the biosynthesis of 
pseudomonic acid B only and at the same time entirely abolished the production of 
pseudomonic acid A, indicating that products of these genes work together in reducing C8-C9 
double bond (Hothersall et al., 2007).  Similarly, deletion of mupC and mupF resulted in 
novel metabolites that were named mupirocin C and mupirocin F, respectively (Hothersall et 
al., 2007, Gao et al., 2014) (Figure 1.28).  From the structures of these compounds it was 
proposed that mupF encodes a ketoreductase and is involved in the reduction of 7 keto group 





bond.  By double knockout studies it has been established that MupW acts early before the 
action of MupO, MupU, MupV and MupC and that the 7-hydroxyl group is required for the 
action of mupW/T and MmpEOR (Figure 1.28). Double knock-out study has also confirmed 
that MupF acts only after MupC in the biosynthetic pathway (Gao et al., 2014).  Deletion of 
mupH resulted in the isolation of a novel metabolite mupirocin H, the structure of which 
pointed towards  its action early in the mupirocin biosynthetic pathway (Figure 1.27 )(Wu et 
al., 2007).  Apart from these, there is no information about the point of action of products of 
the other tailoring genes in the mupirocin biosynthetic pathway.  All mutant strains of either 
mupG/mupJ or mupK produced mupirocin H as a major product (Wu et al., 2007). Products 
of all these enzymes together with MupH are implicated in the introduction of the C-15 
methyl group in pseudomonic-A biosynthesis as pointed out above.  
 


















Figure 1.27 Mechanisms proposed for the biosynthesis of mupirocin H and 










































































































































































1.17.10 Regulation of the mup cluster 
Quorum sensing is used to control the expression of genes of the mup cluster (El-Sayed 
et al., 2001).  In quorum sensing bacterial populations communicate with each other through 
a diffusible signal molecule which is called an auto-inducer.  There is constitutive expression 
of autoinducer by bacteria and with the increase in bacterial population; there is a consequent 
increase in the concentration/level of auto-inducer. At a certain population density of bacteria 
which is called a quorum, the concentration of autoinducer becomes such that it induces the 
target gene expression resulting in consequent target action. In the mupirocin cluster, mupR 
and mupI are found to be involved in quorum regulation of cluster.  MupR is the 
transcriptional activator which activates mup promoter while MupI is an inducer that 
responds to it (El-Sayed et al., 2003).  This way transcription of mup operon is activated upon 
binding to lux box promoter regions of mupF, macpC and mupA. mupI is reported not to have 
lux box region (El-Sayed et al., 2001). 
1.17.11 Characteristic features of mup cluster 
Mupirocin producing (mup) cluster has some of the unique characteristic features 
which distinguishes it from PKS system that encodes erythromycin antibiotic-a prototype of 
PKS systems. The following sections list the distinguishing features of the mup system. 
1.17.11.1 Mix type hybrid PKS 
As discussed above mup cluster does not comprise just type I PKS like DEBS PKS 
system.  Instead, it is a combination of type I non-iterative and type II iterative PKS which is 
also suspected to include iterative FAS system (Thomas et al., 2010). 





Unlike DEBS PKS system whereby each module of the PKS has got its own cognate 
AT domains, in mup cluster function of AT for each module is done by standalone ATs that 
are part of MmpC. A similar arrangement is found in kirramycin and Oxazolomycins 
antibiotic clusters (Piel, 2010, Musiol and Weber, 2012).  As a consequence of this in the 
mup system, each module does not have a choice of selecting particular extender unit for 
incorporation in the growing polyketide chain, a liberty that DEBS system may have.     
1.17.11.3 Lack of integrated ER domains  
There are no well-defined integrated ER domains as found in DEBS PKS system. ER 
activity that is known, is provided in trans by one of the tailoring region genes mupE and 
may be by mupD as well (El-Sayed et al., 2003, Hothersall et al., 2007).  Like other trans AT 
systems ER activity is also suspected to be provided by other proteins (Weber et al., 2008), 
for which MmpC of the mup system is under investigation. 
1.17.11.4 Methyl group incorporation    
During biosynthesis methyl groups are incorporated in the mupirocin molecules in both 
the positions α as well as β. While α groups are incorporated owing to the presence of cis 
acting MT domains in module one and three, methyl group in β position is inserted by a 
group of trans acting auxiliary genes described above which functions together as a cassette 
known as HCS cassette (Thomas et al., 2010).  The α methyl groups are inserted in the 
growing polyketide chain as C-16 and 17 in the final mupirocin molecule while methyl group 
at position C-15 appears as β-branch. Methyl groups at α position are derived from S-
adenosyl methionine (SAM) (Feline et al., 1977, El-Sayed et al., 2003, Wu et al., 2008). 





Tandem repeats of ACPs are present in mup cluster. Two ACPs are present in the 
MmpA module while three ACPs are found in its MmpB (El-Sayed et al., 2003).  Thus it 
belongs to the group of other trans AT PKS systems having such unusual architecture of 
domains like bacillaene, lankacidin, virginamycin and difficidin etc. (Chen et al., 2006, 
Mochizuki et al., 2003, Pulsawat et al., 2007, Schneider et al., 2007).  It has been shown that 
just one ACP among these double/triplets is essential and sufficient for the production of 
mupirocin, while extra number of ACPs only contributed to increase mupirocin production 
significantly, indicating that extra ACPs are redundant (Rahman et al., 2005).  It has been 
shown that each of the ACPs at the end of mmpA has unique recognition motif specific for 
their interaction with the HCS cassette proteins that are involved in introduction of the 15 
methyl group (β-branching) (Haines et al., 2013a).  
 
 Thiomarinols  
Thiomarinols represent another class of antibiotics which is in fact a hybrid of two known 
antibiotics (Figure 1.30) for which independent biosynthetic pathways already exist in nature 
(Fukuda et al., 2011).  One of these is monic acid which is the polyketide part of mupirocin 
antibiotic and the other one is pyrrothine moiety which is part of antibiotic holomycin and 
related compounds produced by Streptomyces clavuligerus (Kenig and Reading, 1979). 
Pyrrothine is a yellow chromophore that imparts yellow colour to the molecule (Fukuda et al., 
2011).  Isolation of thiomarinol (Thiomarinol A) was first reported by the fermentation of 
marine bacterium Alteromonas rava sp. nov. SANK73390 collected from the sea water of 
Japan (Shiozawa et al., 1993).  Later, different forms of thiomarinol named as B-to-G were 
also reported to be produced by these bacteria (Shiozawa et al., 1995, Shiozawa et al., 1997).  





called thiomarinols.  This producer of thiomarinols was later classified to belong to a new 
genus named as Pseudoalteromonas different from Alteromonas and therefore was renamed 
as Pseudoalteromonas rava sp. nov. SANK 73390 (Gauthier et al., 1995). The 
Pseudoalteromonas genus belongs to the gamma subclass of Proteobacteria of the order 
Alteromonadales (Bowman, 2007). Pseudoalteromonads are found in marine water at 
different levels from surface to deeper sea.  These are often found associated with higher 
eukaryotes (Holmstrom and Kjelleberg, 1999).  They can be pigment producing or non-
pigmented type. Pigmented Pseudoalteromonas sp. are involved in the production of 
bioactive substances (Bowman, 2007). Several strains of Pseudoalteromonas rava sp. nov. 
SANK have been isolated from marine water at different places in Japan which either 
produced black pigment or yellow pigment (Fukuda et al., unpublished data).  Thiomarinol 
producer Pseudoalteromonas rava sp. nov. SANK73390 is yellow pigmented (Fukuda et al., 
2011).  Pseudoalteromonads are Gram-negative bacteria that are rod shaped.  They have one 
or more polar or lateral flagella making them motile (Bowman, 2007).  These are non-spore 
forming strict aerobes which have chemoautotrophic metabolism. These are oxidase positive 
and are able to grow well at 23 oC (Gauthier et al., 1995).  The GC content of genomic DNA 
for thiomarinol producer strain Pseudoalteromonas rava sp. nov. SANK 73390 is 40.6 % 
(Fukuda et al., 2011).   
1.18.1 Structure and activity  
In thiomarinols, the pyrrothine moiety is attached to the 8-hydroxyoctanoic acid side chain of 
a mupirocin-like derivative known as marinolic acid via amide bond. Marinolic acid derives 
its name because of its structural analogy with the mupirocin molecule in which monic acid is 
found attached to a fatty acid (Figure 1.30) (Fukuda et al., 2011, Murphy et al., 2014). Thus, 





fatty acid component that is present in pseudomonic acids has a nine carbon chain which is 9-
HN.  In both these molecules, thiomarinols and pseudomonic acids, the fatty acid chain is 
attached to the polyketide moiety by an ester linkage.  The polyketide moiety in both the 
molecules is very similar with slight differences in the side groups present.  Various types of 
thiomarinols differ from each other only in the presence or absence of different/ additional 
side groups around their one primary structure (Figure 1.29) (Shiozawa et al., 1993, 
Shiozawa et al., 1995, Shiozawa et al., 1997).  Among all pseudomonic acids, pseudomonic 
acid C is structurally closest to thiomarinols and lacks the epoxide ring like them (Shiozawa 





Figure 1.29 Structures of some thiomarinol compounds(TMs) (Reproduced 
from(Thomas et al., 2010). 
 
While mupirocin is effective against Gram-positive bacteria, thiomarinols are also effective 
against many Gram-negative bacteria as well. The antimicrobial activity of thiomarinols is 
stronger than the combined activity of both the known antibiotics the components of which 
thiomarinols have. Thiomarinol A has more potency than any of the pseudomonic acids 
which is about twenty fold more against organisms like MRSA (Shiozawa et al., 1993). The 
increased strength of thiomarinols over mupirocin could be due to many reasons: increased 
uptake; targeting of more than one cellular function; or increased activity against the usual 





2010).  Despite their strong antimicrobial properties, thiomarinols are not currently used as an 












Figure 1.30 A comparative account of the structures of pseudomonic acid A and 
thiomarinol A(Adapted from (Fukuda et al., 2011). 
 
1.18.2 The thiomarinol gene cluster 
Efforts by Fukuda et al. (2011) led to the identification of thiomarinol gene cluster (tml) from 
marine bacterium Pseudoalteromonas sp. SANK 73390, which was found to be entirely 
located on a 97 kb circular plasmid named pTML1 (Figure 1.31).  Out of the 97 kb of this 
plasmid, 7.6 kb is occupied by five ORFs that are commonly present in mobile DNA like 
replication, partitioning, integration and transposition. Apart from this mobile DNA and 7 
ORFs coding for NRPS component of thiomarinols, the other 27 ORFs of this cluster are very 
similar to mupirocin biosynthetic cluster.  Even the gene order for type I PKS from tmpA to 
tmpD was the same as in mup cluster and both are trans-AT type clusters.  Some notable 





similarities are (1) presence of an extra ACP in the third module of TmpD, (2) an extra ACP 
in the last module of TmpA and (3) two extra ACPs in TmpB, one of which is present as 
extra module together with a KS0.  Also, the GC content of thiomarinol encoding genes 
(43.2%) is significantly less than that of mupirocin encoding gene cluster (56%) found in P. 
fluorescens NCIMB 15860. Contrary to the notable similarities in PKS genes of two clusters, 
the tailoring region genes are significantly rearranged in the tml cluster compared to in mup 
cluster. No putative regulatory gene/protein was initially detected on plasmid pTML1.  The 
entire gene set was found to split into five transcriptional units (Fukuda et al., 2011). 
Bioinformatics analysis revealed that there has been conservation of PKS and associated 
genes in the biosynthetic clusters of these two antibiotics (Figure 1.32).  In fact, amino acid 
sequence alignments of products predicted of tml cluster showed significant identity (40% to 










Figure 1.31 The genetic organization of thiomarinol biosynthetic cluster (tml) 
found on plasmid pTML1(Reproduced from(Fukuda et al., 2011). 
 
1.18.3  Thiomarinol biosynthetic pathway 
The biosynthetic pathway for thiomarinols is predicted to be same as for mupirocin 
biosynthetic pathway as far as biosynthesis of marinolic acid- a monic acid analogue is 
concerned (Figure 1.32) (Fukuda et al., 2011).  Differences from the biosynthetic scheme of 
mupirocin, that are evident on account of the presence or absence of particular gene functions 
or were evident by mutasynthesis experiments, were accounted for in the predicted scheme 
(Figure 1.32) (Fukuda et al., 2011).  Suicide mutagenesis in tmpD (PKS) gene led the cells to 
produce only pyrrothine while suicide mutagenesis in holA (NRPS) gene produced only 
marinolic acid. Similarly, suicide mutagenesis of tmlU led to the production of both marinolic 
acid as well as pyrrothine but not of thiomarinols that indicated the role of tmlU in joining the 





of macpE in the tml cluster, product of which is proposed to be involved in the last step of 
pseudomonic acid production while the presence of an extra module in TmpB indicated that 
all tailoring region steps take place at TmpB (Figure 1.32) (Fukuda et al., 2011). Similarly, 
absence of function of the second hydratase, that is encoded by MupK of mup cluster and 
which is implicated in the insertion of C-15 methyl group along with other genes of HCS 
cassette in mupirocin biosynthesis, is accounted for in thiomarinol cluster by the fact that N-
terminal end of TmpE aligns with the MupK protein.  Under this context, work was 
undertaken to test those tailoring region gene functions of thiomarinols, products of which 
share significant amino acid sequence identity with the corresponding mup tailoring genes to 



































Figure 1.32 Scheme predicted for thiomarinol biosynthesis.Biosynthesis of 
thiomarinols is hypothesized to occur in the same way as that of mupirocin is done by mup 
cluster using same substrates by equivalent tml gene functions. TmpD module 1-4 and 
module 1 and 2 of TmpA are involved in the biosynthesis of polyketide component while 
TmpB elaborates 8-ON acid. Pyrrothine part of thiomarinols is elaborated separately by 
NRPS and then it is joined to the marinolic acid component to give thiomarinols. KS, 
ketosynthase; ACP, acyl carrier protein; DH, dehydratase; ER, enoyl reductase; KR, 
ketoreductase; MT, methyl transferase; TE, thioesterase; C, condensation; T, thiolation 
domain or peptidyl carrier protein; A, aminoacyl adenylation domain (Reproduced 




















































































































Figure 1.34 Comparison of the organization of the part of thiomarinol gene 
cluster that codes for its polyketide and fatty acid components with the 
mupirocin biosynthetic gene cluster. Upper line represents tml cluster while lower 
line represents mup cluster. Only equivalent gene functions (ORFs) are shown 




























 Aims and objectives 
  The general aim of the doctoral work described in this thesis was to increase our 
understanding of the mupirocin and thiomarinol biosynthetic pathways to underpin their 
manipulation to create novel molecules, particularly production of hybrid pathways.  
Production of hybrid pathways involves the elements of different pathways working together 
and so understanding the extent to which related proteins from different pathways can be 
moved between pathways should help us to identify factors such as substrate specificity and 
protein-protein interactions that limit the creation of hybrid pathways.  A major part of my 
project, therefore, aimed to investigate the extent to which genes could be swapped between 
the related mupirocin and thiomarinol pathways.  The specific project follows from a study 
published by Fukuda et al., 2011 and aimed, in the first place, at testing functional cross-
complementation by in trans expression of singular genes out of 22 homologous 
auxiliary/tailoring genes of the mupirocin and thiomarinol biosynthetic clusters whose 
products share significant identity in amino acid sequences.  Thus, Chapter 4 of thesis is 
about testing cross-complementation by these homologous thiomarinol genes, singularly, in 
the corresponding mup knockouts of Pseudomonas fluorescens NCIMB10586.  With an aim 
of testing reverse complementation of these genes to know more about protein-protein 
interactions between the two biosynthetic pathways and, for deciphering individual roles 
played by each of the tailoring genes in the thiomarinol biosynthetic pathway, this study also 
involved making of in-frame knockouts of single genes in the tml gene cluster. This is 
described in Chapter 3 of the thesis.  Chapter 5 of this thesis is an extension of approach of 
testing functional cross-complementation used in Chapter 4 to investigate cross-
complementation by a group of genes whose products are predicted to work together in the 
















2 CHAPTER 2                                                     















 Bacterial strains and plasmids 
Details of various strains and plasmids that were commonly used throughout this work are 
given in Table 2.1 and Table 2.4 respectively.  Strains and plasmids, that are specific to the 
study of individual chapters, are given in those chapters. Wild type thiomarinol producing 
Pseudoalteromonas sp. SANK 73390 strain was used as the source of thiomarinol coding 
genes. Escherichia coli DH5α strain was used for transformation and propagation of 
plasmids. E. coli S17-1 strain was used for mating/conjugation purpose for the mobilisation 
of expression vectors.  Bioassay was used to test the production/activity of pseudomonic 
acids by the test organisms - various mutants of Pseudomonas fluorescens NCIMB10586 
where wild type was used as one of the controls. Bacillus subtilis 1064 was used as 
mupirocin sensitive organism in the bioassays.  Plasmid pGEM-T Easy vector supplied by 
Promega and plasmid pJH10 were used to clone genes for sequencing/amplification and to 
achieve expression of cloned genes, respectively. Plasmid pAKE604 was used for suicide 
mutagenesis. 


































sp. SANK 73390 
 
 
Wild type (WT) strain producing 
thiomarinol 
 
Fukuda et al., 2011 
 
Escherichia coli DH5α 
 
F-Φ80lacZΔM15, recA1, endA1, 
gyrA86, thi-1, hsdR17 (rk-, m k+) 







Escherichia coli S17-1 
 
 




(Simon et al., 1983) 
 
Escherichia coli C2110 
 
 
K-12 polA1 his rha 
 
(Stachel et al., 1985) 
 
     Escherichia coli ER2925 
 
 
dcm- and dam- 
 








































    Table 2.2 Bacterial strains of Pseudomonas fluorescens used or constructed in    







       Source/ reference 
 
     NCIMB 10586ΔmupO 
 
 
 mupO gene deleted 
 
 




   
           mupS gene deleted 
 
 





mupQ gene deleted 
 
 





macpD gene deleted 
 
                                                    





mmpF gene with point 




      





          mupF gene deleted 
 
 






mupF gene deleted and 
carrying pJH10-mupF in 
trans 
 
                                           





mupC gene deleted 
 
 





mupK gene deleted 
 
 





           mupJ gene deleted 
 
 






      mupO gene deleted and     







    
    mupO gene deleted and     














mupS gene deleted and 








mupS gene deleted and 









mupQ gene deleted and 








mupS gene deleted and 









macpD gene deleted and 








macpD gene deleted and 









mmpF gene deleted and 








mmpF gene deleted and 









mupF gene deleted and 








mupF gene deleted and 









mupC gene deleted and 








mupC gene deleted and 













mupK gene deleted and 




     NCIMB 10586                   
    ΔmupK(pMY16) 
 
mupK gene deleted and 









mupJ gene deleted and 








mupJ gene deleted and 





















































                                           
P. fluorescens mutant with 
mmpF, mupS, mupQ and 








P. fluorescens mutant with 
deleted mmpF, mupS, mupQ 
and macpD genes carrying 






ΔmmpFΔmupSΔmupQ    
ΔmacpD(pMY23) 
 
P. fluorescens with deleted 
mmpF, mupS, mupQ and 
macpD genes carrying 
















































TcR; lacIq, tacp, IncQ replicon, 











pMB1 replicon, ApR, KmR, oriT, 















































530 bp PCR product with 
BamHI and XbaI sticky ends 
(arm1) cloned into pGEM-T 















527 bp PCR product with 
EcoRI and XbaI sticky ends 
(arm2) cloned into pGEM-T 















1063 bp fragment (produced 
by ligating arm1 of 530 bp 
with arm2 of 527 bp using 
XbaI sticky ends) cloned into 
pAKE604 vector at BamHI 
and EcoRI sites. 
 
                              
For the deletion 
of tmlW gene         
(precisely for 
deleting a 











583 bp PCR product with 
BamHI and XbaI sticky ends 
(arm1) cloned into pGEM-T 















591 bp PCR product with 
EcoRI and XbaI sticky ends 
(arm2) cloned into pGEM-T 














                     
8.3 
 
1180 bp fragment (produced 
by ligating arm 1 of 583 bp 
with arm2 of 591 bp using 
XbaI sticky ends) cloned into 
pAKE604 vector at BamHI 
and EcoRI sites.  
 
For the deletion 
of tmlT gene         
(precisely for 
deleting a 


















500 bp PCR product with 
BamHI and XmaI sticky ends 
(arm1) cloned into pGEM-T 
















489 bp PCR product with 
EcoRI and XmaI sticky ends 
(arm2) cloned into pGEM-T 
















995 bp fragment (produced 
by ligating arm1 of 500 bp 
with arm2 of 489 bp using 
XmaI sticky ends) cloned 
into pAKE604 vector at 
BamHI and EcoRI sites.  
 
For the deletion 
of tmlO gene                 
(precisely for 
deleting a 












490 bp PCR product with 
BamHI and XbaI sticky ends 
(arm1) cloned into pGEM-T 
















492 bp PCR product with 
XbaI and EcoRI sticky ends 
(arm2) cloned into pGEM-T 
















988 bp fragment (produced 
by ligating arm1 of 490 bp 
with arm2 of 492 bp using 
XbaI sticky ends) cloned into 
pAKE604 vector at BamHI 
and EcoRI sites.  
                                        
For the deletion 
of tmlS gene 
(precisely for 
deleting a 

























488 bp PCR product with 
XmaI and XbaI sticky ends 
(arm1) cloned into pGEM-T 





of the PCR 
product 












518 bp PCR product with 
EcoRI and XbaI sticky ends 
(arm2) cloned into pGEM-T 














536 bp PCR product with 
XmaI and XbaI sticky ends 
(arm1) cloned into pGEM-T 














528 bp PCR product with 
EcoRI and XbaI sticky ends 
(arm2) cloned into pGEM-T 














530 bp PCR product with 
BamHI and XbaI sticky ends 
(arm1) cloned into pGEM-T 














519 bp PCR product with 
XmaI and XbaI sticky ends 
(arm2) cloned into pGEM-T 





















     Table 2.6 Plasmids constructed in Chapter 4. 
           
Plasmid 
 
                  
Size (kb) 
                                                                   
Description 




tmlO ORF of 1352 bp cloned in  









tmlO ORF of 1352 bp cloned in pJH10 
using KpnI and XbaI  
 
 
      This study 
pMY3 3.75 
 
tmlS ORF of 752 bp cloned in  










tmlS ORF of 725 bp cloned in pJH10 









tmlQ ORF of 1337 bp cloned in 










tmlQ ORF of 1337 bp cloned in pJH10 








tacpD ORF of 335 bp cloned in 
pGEM-T Easy vector after A-tailing 
 








tacpD ORF of 335 bp cloned in pJH10 









tmpF ORF of 2252 bp cloned in 
pGEM-T Easy vector after A-tailing 
 








tmpF ORF of 2252 bp cloned in pJH10 
using EcoRI and XbaI  
 
 







tmlF ORF of 1053 bp cloned pGEM-T 
Easy vector after A-tailing 
 












tmlF ORF of 1053 bp cloned in 










tmlC ORF of 1140 bp cloned in 















tmlC ORF of 1140 bp cloned in 
pJH10 using KpnI and SacI  
 
 







tmlK1 ORF of 749 bp cloned in 
pGEM-T Easy vector after A-
tailing 
 








tmlK1 ORF of 749 bp cloned in 










tmlJ ORF of 767 bp cloned in 
pGEM-T Easy vector after A-
tailing 
 








tmlJ ORF of 767 bp cloned in 




     1tmlK gene is non-existent in tml cluster. It is the ORF at the N-terminal end of TmpE that aligns with      
MupK because it shares significant amino acid sequence identity with it, which was supplied with                    





























548 bp EcoRI-XbaI PCR 
product containing arm1 
cloned into pGEM-T Easy 
vector  
 
Sequencing of PCR 
product (arm1) for 
creating quadruple 











505 bp XbaI-BamHI PCR 
product containing arm2 




Sequencing of PCR 
product (arm2) for 
creating quadruple 












pAKE604 with fragment of 
1053 kb (obtained by 
joining arm1 and arm2 
using XbaI sticky ends) 




For deletion of block 
of four genes (ΔmmpF, 
ΔmupS, ΔmupQ, 











pGEM-T Easy vector with 
cloned PCR amplified 
fragment XbaI-SacI 
carrying ORFs for tmlQ, 
tmlS and tacpD. 
 
 
Sequencing of PCR 
amplified fragment for 
expression of tmlQ, 











integrate obtained by 
ligating plasmids pMY10 
(carrying tmpF as EcoRI 
and XbaI fragment) and 
pMY22 (carrying fragment 
with ORFs of genes tmlQ, 
tmlS and tacpD), using 














  Growth, media and culture conditions  
All Pseudomonas strains were grown at 30 oC either in L broth or on L agar. 
Pseudoalteromonas sp. SANK 73390 strain was grown at 23 oC on M agar or M broth. L 
broth had composition as yeast extract (10 g/l), NaCl (10 g/l), tryptone (5 g/l) and glucose (1 
g/l) while L agar additionally included 15 g/l of agar. Marine broth comprised of peptone (5.0 
g/l), yeast extract (10 g/l), NaCl (19.45 g/l), ferric citrate (0.1 g/l), magnesium chloride (5.9 
g/l), magnesium sulphate (3.24 g/l), CaCl2 (1.80 g/l), KCl (0.55 g/l), NaHCO3 (0.16 g/l), 
strontium chloride (0.034 g/l), boric acid (0.022 g/l), sodium silicate (0.004 g/l), sodium 
fluoride (0.0024 g/l), ammonium nitrate (0.0016 g/l) and disodium phosphate (0.008 g/l).  In 
M agar all components were same as in M broth except magnesium sulphate, MgCl2 (8.8 g/l), 
sodium sulphate (3.24 g/l) and agar (15.0 g/l) which were additionally added. These media 
were supplemented with antibiotics in required concentrations as and when needed (as 
mentioned in Table 2.8 below). E. coli strains were grown at 37 oC on L broth or L agar 
supplemented with tetracycline 15 μg/ ml or IPTG 0.5 μl/l (in L agar) as and when required. 
Bacillus subtilis 1064 strain was grown at 37 oC on L agar or L broth without any antibiotic 
selection. All media were sterilized by autoclaving  at a pressure of 15 pounds per square 
inch at 121 oC for 15 min and whenever any temperature sensitive supplements like 
antibiotics or IPTG were added to it, these were added after filter sterilization through 0.2 μ 
membrane filters.  For HPLC analysis all the strains of Pseudomonas fluorescens NCIMB 
105806 were grown in secondary stage medium (SSM) that contained soya flour 25 g/l, spray 
dried corn liquor 2.5 g/l, (NH4)2SO4 5.0 g/l, MgSO4.7H2O 0.5 g/l, Na2HPO4 1.0 g/l, KH2PO4 
1.5 g/l, KCl 1.0 g/l, CaCO3 6.25 g/l.  This medium was made in distilled water and pH was 
adjusted to 7.5. After sterilizing it by autoclaving, separately autoclaved 40% w/v glucose 
was added to it before any use. For plasmid DNA isolation, cultures were incubated overnight 





production of mupirocin were incubated up to 40 hours (till secondary/stationary stage).  
Liquid cultures were always set up in sterilized containers having volumes four times of the 
amount of culture that was set up.  For the preparation of competent cells of different strains 
of E. coli L broth was used.  All the stock solutions of antibiotics were prepared in suitable 
solvent. Table 2.8 gives the concentrations of all the antibiotics and the other supplements 
used in the cultures. 
 




































































 Polymerase Chain Reaction 
Polymerase Chain reaction was used to amplify segments of DNA (Saiki et al., 1985, 
Saiki et al., 1988) allowing amplification of short DNA sequences with the help of two 
primers designed to complement the ends of the DNA sequence to be amplified.  DNA 
template for the reaction was prepared by adding a loop-full of O/N grown bacteria in 50 μl 
of sterilized distilled water which was suspended by vortexing. Cell suspension was then 
heated in boiling water for 10 min and then centrifuged at 14000×g for 5 min at 4 oC. 
Thereafter supernatant was collected.  This supernatant had bacterial DNA which was used as 
template for PCR and was kept at ice.  This method of preparing template DNA is known as 
boil prep method. The enzyme used for amplification depended upon the size of the DNA 
fragment to be amplified and the desired fidelity.  For most of the amplifications Velocity 
PCR kit (Bioline), that makes the use of velocity DNA polymerase, was used.  For 
amplification of larger fragments of DNA, KOD polymerase (Novagen) was used.  Wherever 
proof-reading activity was not required, for example when checking for cloned inserts, Taq 
polymerase (Invitrogen) was used.  Primers were obtained from Alta Biosciences, University 
of Birmingham upon ordering and supplying their designs.  Primers were dissolved in sterile 
distilled water and stored at -20 oC. These were used after diluting to 10 pmol/μl 
concentration. Primers used in the study are mentioned in respective chapters. Primers were 
designed to have 18-24 bases approximately and to have melting temperatures (Tm) between 
55 and 60 oC. Designed primers were checked for melting temperature and for secondary 
structure formation, if any, by on-line OligoCal software of Northwestern University, USA. 
For thorough analysis of primers NetPrimer (www.premierbiosoft.com/netprimer) was used. 
Annealing temperature was roughly set at 4 oC less than melting temperature (Tm), which was 
calculated using equation given below. 





                                                    
Tm=4 (G+C) + 2 (A+T) oC 
       
Extension time was calculated after considering the rate of addition of base per second 
specified by the manufacturer for the polymerase enzyme used and the size of fragment to be 
amplified.  All the PCR reactions were carried out (incubated) using laboratory thermal 















































































          
SA1R 






                   
36 











                  
XbaI 
SA2R 








                
EcoRI 






            
77074 
                                                                           
GGTGGATCCCATTAACAT
CAGGTGCAACGCTTAGC 




 OA1R                    
76575            








 OA2F     
   75269 








 OA2R                       
74781 




                 
33 
    
EcoRI 





   
82631 
 
                                                                           
GGTGGATCCCCAGGAGAA
AGCAGGCAGGCTATAC 
                  
34 
   
BamHI 
       
WA1R 
              
83160 





          
39 
  





 WA2F                
84538 




                 
36 
                  
XbaI 
 WA2R                
85064 





            
43 
               
EcoRI 









         
1745 





               
37 
                
BamHI 
 TA1R                
1155 




               
36 
                
XbaI 
  TA2F  
851 





              
39 
                 
XbaI 
 TA2R  
269 




        
33 
                
EcoRI 







               
13793 




            
36 
                
BamHI 
TMA1R                
13264 




                  
33 
                   
XbaI 
TMA2F               
11100 




           
33 











              
36 























                   
37 
                   
XmaI 







                 
45 
                     
XbaI 









                    
60 
                   
XbaI 
 QA2R           
14063 





                
39    EcoRI 













                    
37 












             
42 
                  
XbaI 
 TcpA2F              
13504 





          
39 




                  
12987 




                
36 
             
EcoRI 
1For all the amplifications using these primers, plasmid pTML1 from WT Pseudoalteromonas sp. SANK 73390 
was used as template DNA.  
2Coordinates given in column 3 indicate the base numbers of pTML1plasmid. These represent the arms that 
were PCR amplified.                                                                                                                                             
3Restriction sites, start and stop codons in primers are shaded in turquoise, green and red colours respectively.  
  
 


































































































































































































































































































































































1For all amplifications using these primers, plasmid pTML1 from WT Pseudoalteromonas sp. SANK 73390     
 was used as template DNA. 
     2Restriction sites, start and stop codons in primers are shaded in turquoise, green and red colours respectively.  
3tmlK gene is non-existent in tml cluster. It is the ORF for N-terminal end of TmpE that share significant 
amino acid sequence identity with MupK, which was supplied with external stop codon for which primers 






























                   
 
Deletion of 
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65463 




















             
BamHI 
                                                                                                                  
RQE3 











      13491 
 







  SacI 
     
FQE3 
15922 





























   
14160 




















  1For amplifications using primers for deletion, genomic DNA from Pseudomonas fluorescens NCIMB 10586   
  was used. For the amplification of plasmid DNA fragments and for their sequencing, pTML1 plasmid DNA   
  from WT Pseudoalteromonas sp. SANK 73390 was used as template DNA.  
   2Coordinates given in column 3 indicate for primers for the deletion of genes, the base numbers of   
  Pseudomonas fluorescens NCIMB 10586 genome and those for amplification/sequencing of plasmid DNA, the   
  base numbers of pTML1 plasmid of WT Pseudoalteromonas sp. SANK 73390. 




2.3.1 PCR using KOD polymerase (Novagen)  
KOD polymerase is a recombinant DNA polymerase with high fidelity and 
elongation rate compared to other DNA polymerases like Pfu or Taq.  It is derived from 
Thermococcus kodakarensis KOD DNA polymerase. This enzyme also has proof-reading 
activity and can amplify up to 2 kb of target DNA fragment from genomic template and up to 
6 kb from plasmid DNA template. It produces blunt-ended DNA products. Following mix 
(Table 2.12) was prepared for each PCR reaction which was incubated as per programme 











                  Table 2.12  Reaction conditions for KOD polymerase. 
 
 
















       




























                                                          
Reagent 
                                                        




Final concentration in 




                                                                  
1 
 
50 pg-10 ng 
 
10x Buffer 1 
 





KOD DNA polymerase     
(2.5 U/ μl) 
 





dNTPs (2.5 mM each) 
 
                                                                 
5 
 
250 μM (each) 
 
Forward primer  
(15 μM stock) 
 




                                        
Reverse primer  
(15 μM stock)                         
 
                                                    
1.3 










MgSO4 (25 mM) 
 











Total reaction volume 
 














































   













                                           






                                              
7 min 72 
 
1 
  *For 1-2 kb target DNA, annealing time was 2 s and elongation time was 20 s; for 3-4 kb target      
  annealing time was 5 s and elongation time was 40 s. 
 
2.3.2 PCR using VelocityTM DNA Polymerase (Bioline) 
For amplification of most of the DNA fragments, VelocityTM DNA polymerase was 
used which was supplied with Velocity PCR kit (Bioline). This polymerase amplifies DNA 
fragment at a rate of 15-30 s/ kb and generates products with blunt ends.  For each reaction 

















                              
Volume added (μl) 
per reaction 
 








50 pg-10 ng 
 



















250 µM (each) 
 





 0.6 pmol 
 





 0.6 pmol 
 
Velocity Taq polymerase 




























































































     *Length of the DNA fragment to be amplified in terms of base pair was taken to calculate the     
     elongation time in view of capacity of VelocityTM DNA polymerase to catalyse the reaction. 
 
 
2.3.3  PCR using Invitrogen Taq polymerase             
This was used for checking any mutations (insertions or deletions) introduced in the DNA 
plasmid/bacterial genome. The PCR reaction used Taq DNA polymerase isolated from 
Thermus aquaticus.  A typical PCR reaction was set up in the total volume of 50 μl with the 
following composition (Table 2.16) which was incubated as per programme given in Table 
2.17. 












      Table 2.16 Taq polymerase PCR reaction conditions. 




Volume added (μl) 
per reaction 
 























250 µM (each) 
 
Taq DNA polymerase  















































 Depending on the number of clones to be checked for mutation, a master mix with above 
composition was prepared (without adding template DNA) and 45 μl of which was aliquoted 
for each reaction. Template DNA obtained by boil-prep method (as described above in 





control reaction, instead of DNA, 5 μl of sterile distilled water was added. Other controls 
were set up by using DNA obtained from wild type strain and the plasmid construct that was 
used to create the desired effect (insertion or deletion).  
                                                                                                                                                                                                       































































       *Length of the DNA fragment to be amplified in terms of base pair was taken to calculate the elongation     
        time in view of capacity of Taq polymerase to catalyse the reaction which was 90 s/ kb. 
 
 
  Manipulation of DNA 
2.4.1 Plasmid extraction using Alkaline SDS method   
 As per this method of Birnboim and Dolly (1979) overnight cultures of plasmid 
carrying bacteria were set up in 5 ml of L broth supplemented with appropriate antibiotic. 
Cells in the overnight grown culture were pelleted by centrifugation at 14000×g for 5 min in 
a microfuge tube. Supernatant was discarded and cells were resuspended in 100 μl of ice cold 
lysis buffer (25 mM tris pH 8.0, 10 mM EDTA, 50 mM glucose) by vortexing. Thereafter, 
200 μl of NaOH-SDS solution (2% SDS and 0.4 M NaOH) that was kept on ice, was added to 





several times before incubation on ice for 5 min. Afterwards, 150μl of neutralizing solution 
(3 M solution of sodium acetate pH 5.0) was added and mixed by gentle inversion several 
times. Incubation was done on ice again for 5 min.  The entire mix was then centrifuged at 
14000×g at 4oC for 5 min to pellet the cell debris.  The supernatant containing plasmid DNA 
was transferred to another microfuge tube in which it was precipitated by adding 400 μl of 
Isopropanol by mixing and incubating at 15 oC at room temperature.  Plasmid DNA was 
recovered from it by centrifugation of the mix again at 14000×g at 4 oC this time for 10 min. 
The precipitated DNA pellet was resuspended in 100 μl TNE buffer (10 mM tris pH 7.5, 50 
mM NaCl and 5 mM EDTA). 
 
2.4.2 Large scale high quality plasmid DNA extraction (maxi-prep) 
Large scale plasmid DNA was isolated using a method that was basically a modified alkaline-
SDS method of Birnboim and Dolly (1979). In this method usually 400ml of overnight grown 
cultures of bacteria carrying the plasmid of interest was set up in L broth using appropriate 
antibiotic. The culture was spun in centrifuge at 10,000 x g for 10 min at 4 oC in two pots in 
equal amounts of 200 ml.  The bacterial pellet collected from both the pots after discarding 
supernatant was resuspended in a total of 25 mls of lysis buffer (solution 1).  Thereafter 50 
mls of freshly prepared NaOH-SDS solution mix (1:1 mix of 0.4 M NaOH and 2 % SDS; 
solution 2) was added to the resuspended bacterial pellet in the pot.  The pot was inverted 
several times to mix the solutions thoroughly so as to get complete lysis of the bacterial cells.  
It was incubated on ice for 5 min and then 37.5 ml of 3 M sodium acetate solution with pH 5 
(solution 3) was added to neutralise the mixture and precipitate cell debris and chromosomal 
DNA, the contents mixed by inverting the pot several times and after another 5 min 





debris. The collected supernatant was further filtered through Whatman 1 mm paper to 
remove any of the remaining cell debris. 100 ml of isopropanol was added to the filtrate in a 
fresh pot to precipitate the plasmid DNA, mixed and again centrifuged for 15 min at 10,000 x 
g at 4 oC.  After centrifugation the supernatant was discarded and the DNA and RNA pellet 
allowed to dry for 30 min to get rid of any remaining isopropanol.  Then the DNA pellet, free 
from any isopropanol, was dissolved in 3 ml of 1 X TNE buffer (pH 8). The resuspended 
pellet was transferred to a bottle containing 4.62 gms of CsCl and salt was mixed by gentle 
shaking.  The total volume of the mix was measured and raised to 4.5 ml with 1 X TNE and 
0.5 ml of ethidium bromide (10 mg/ml stock) was added to this. After mixing, the solution 
was transferred to two Beckman ultracentrifugation tubes which were balanced using 1 X 
TNE and filled up to the frosted line.  The tubes were then sealed using the cap heating 
machine and centrifuged in Beckman TL 100 ultracentrifuge for overnight at 100,000 rpm at 
20 oC.  
 Next day after overnight centrifugation, the DNA bands in tubes were visualized under 
UV light source.  If two DNA bands were observed there, both of them were collected 
because in that case the upper one might be open circular DNA.  Bands were collected 
separately in clean tubes using a wide bore syringe after puncturing the tube with needle and 
carefully extracting the desired layer of DNA.  To the separated layer collected in tube, an 
equal volume of CsCl/H2O saturated solution of isopropanol was gently added and mixed 
thoroughly. This separated ethidium bromide as a separate pink coloured top layer which was 
carefully removed until no more pink colour was seen indicating that all ethidium bromide 
was removed.  The remaining DNA solution was transferred to another fresh tube.  To 400 μl 
of this DNA solution, 500 μl of distilled water, 100 μl of 3 M Sodium acetate and 530 μl of 
isopropanol were added in a 1.5 ml microfuge tube. Contents were mixed well and 





pellet was re-dissolved in 200 μl of 1X TNE.  25 μl of 3 M Sodium acetate and 500 μl of 
ethanol were added to it and mixed.  The mix was again centrifuged at 10,000 rpm for 10 min 
at the room temperature that resulted in pellet.  This pellet was dried well and resuspended in 
100 μl of 1:10 diluted TNE and stored at -20 oC for further use. 
2.4.3 Plasmid extraction using AccuPrep® kit (Bioneer) 
Plasmid DNA isolation was done using AccuPrep® plasmid extraction kit (Bioneer) as per 
the protocol supplied with it by the manufacturer. Cells in the 5 ml of overnight cultures were 
pelleted by centrifugation at 14000×g for 5 min at room temperature. Supernatant was 
discarded and supernatant free cells were resuspended by vortexing in 250 μl of pre-chilled 
resuspension buffer (buffer1) supplied with the kit. 250 μl of lysis buffer (buffer 2) was 
added to this and the tube was gently inverted 3-4 times to mix the contents. Thereafter, 350 
μl of neutralising buffer (buffer 3) was added immediately and mixed gently by 3-4 
inversions before centrifugation at 14000×g for 10 min and 4 oC to pellet the cell debris. The 
cleared lysate was transferred to the binding column supplied by the manufacturer and 
centrifuged at 14000×g for 1 min. The flow-through was discarded and DNA binding column 
was reassembled with the collection tube. Thereafter, 500 μl of denaturation buffer (buffer D) 
supplied by the manufacturer was added to this and incubation was done for 5 min before 
again centrifuging it for 1 min at 14000×g. The flow-through was again discarded and 
column reassembled with the collection tube.  700 μl of wash buffer supplied with the kit was 
added to this column and column was re-centrifuged for 1 min at 14000×g. Again flow 
through was discarded and column was refitted with the tube and centrifuged for 1 min at 
14000×g.  It was then left for 5 min to dry completely and refitted into fresh microfuge tube. 
Finally, 50-100 μl of elution buffer (buffer 5) was added to the column which was incubated 





collect the plasmid DNA suspension in a microfuge tube which was stored in freezer at -20 
oC. 
2.4.4 Plasmid extraction using Bioline kit                                                                                          
As for the Bioneer kit, plasmid DNA isolation was done following the protocol supplied with 
the Bioline kit by the manufacturer.  5 ml of overnight grown cell cultures were pelleted by 
centrifugation at 11000×g for 30 s at the room temperature.  After discarding supernatant, 
bacteria were resuspended in 500 μl of pre-chilled resuspension buffer (buffer 1) supplied 
with the kit.  Cell lysis was then done by adding 500 μl of denaturation buffer (buffer 2) and 
mixing gently by inverting the tube 6-8 times.  Finally, 600 μl of neutralization buffer (buffer 
3) was added and mixed gently by slowly inverting the tube 6-8 times before centrifugation at 
11000×g for 10 min at room temperature.  The cleared lysate was then filtered through the 
binding column supplied by the manufacturer, in batches of 750 μl followed by centrifugation 
at 11000×g for 1 min.  Each time the flow through was discarded and the DNA binding 
column was reassembled with the collection tube.  Once all the lysate was filtered through 
DNA binding column, 500 ml of wash buffer PW1 (pre-heated to 50 oC) was added to it and 
the column was centrifuged again at 11000×g for 1 min.  After discarding flow through, 
column was refitted back in the tube. 600 μl of wash buffer PW2 (supplemented with 
ethanol) was added to the filter in the column which was centrifuged again at 11000×g for 1 
min.  The flow-through was discarded and filter was refitted into the column.  The filter was 
then dried by centrifuging for 2 min at 11000×g to remove the residual ethanol.  After drying 
the filter was shifted to fresh 1.5 ml micro-centrifuge tube.  50 μl of (pre-heated to 70 oC) 
elution buffer (buffer P) was then added to the filter and incubated for 2 min at 70 oC.  
Finally, plasmid DNA was collected by centrifugation for 1 min at 11000×g at room 





2.4.5 Restriction enzyme digests  
Restriction enzymes from the laboratory stock were used that were either supplied by New 
England Biolabs (NEB), Fermentas or by Invitrogen. Digestions were made in two different 
volumes depending on whether the digests were to be recovered after gel-electrophoresis for 
further use or not.  For recovery, every time 20 μl of plasmid DNA was used in a total 
volume of 40 μl of reaction mix while for other purposes like checking of insert 5-10 μl of 
plasmid DNA stock was used in a total volume of 20 μl of reaction mix. The volume of 
enzyme stock solution used in any case never exceeded 10% of the reaction mix.  
Appropriate concentrated buffer was used along with bovine serum albumin wherever it was 
required. The reaction mix was finally diluted to compensate for concentrated buffer by 
sterilized distilled water. All digestions were typically carried out for 2 hours at 37 oC. 
2.4.6 Agarose gel electrophoresis 
All DNA whether obtained by PCR or restriction digests were analysed by agarose gel 
electrophoresis. 1% agarose gels were made by dissolving 1 gm of agarose in 100 ml of TAE 
buffer (40 mM Tris-acetate, 1 mM EDTA pH 8.0). The agarose solution was prepared by 
heating in a microwave oven for 1 min, stirring and then heating again for 30 s. Before 
pouring it on the casting gel, it was allowed to cool and then 2 μl of ethidium bromide was 
added to it that allowed DNA visualization under UV light. The gel-casting tray was prepared 
by sealing its ends with tapes and inserting combs of different sizes as per the requirement of 
number and size of wells.  After pouring, the gel was allowed to set for about 20 min at room 
temperature. DNA samples were prepared for loading by adding loading-dye in the ratio of 2 
μl dye to 10 μl of DNA. Two types of loading dyes were used depending upon the 
requirement i.e. size of the DNA to be analysed. Top loading dye was composed of 0.25% 





bromophenol blue and 15% w/v ficoll.  Samples were always loaded alongside 1 kb DNA 
ladder (Fermentas). Power for electrophoresis was supplied from power pack at about 100 V 
and 500 mA which took about 45 min to complete the process. DNA was finally visualized 
by UV transilluminator. 
2.4.7 Extraction of DNA from agarose gel  
DNA from electrophoresis gels was extracted by using Illustra GFX PCR DNA purification 
kit (GE Healthcare). The kit comprised of four solutions. The first one was the Capture buffer 
which was added to the gel pieces of interest excised from the electrophoresis gel under UV 
of longer wavelength in the ratio of 10 μl or more of capture buffer per 10 mg of gel slice. 
After adding Capture buffer, the mix was incubated for 15-30 min at 60 oC with intermittent 
mixing every 3 min by inverting the microfuge tube. This resulted in dissolution of the gel 
into capture buffer to give a yellow/pale coloured uniform solution that indicated correct pH 
of this solution which was effective for binding of DNA to the DNA binding column to be 
used in the next step.  If the colour was not yellow or pale, that required an addition of 3M 
sodium acetate to adjust the pH to the level which promotes effective binding of DNA to the 
column. This solution was transferred to the DNA Binding column fixed in collection tube 
and incubation was done for 1 minute at the room temperature before centrifuging it for 30 s 
at 16000 rpm in a microfuge. Flow through was discarded and 500 μl of wash buffer was 
again added to the column and it was re-centrifuged for 30 s at 16000 rpm. Flow through was 
discarded again and the empty column was re-centrifuged for about a minute to dry the 
membrane in column on which DNA was bound.  This DNA was finally eluted from the 
column by adding 15 μl of elution buffer and incubating the column for at least 1 min at the 
room temperature before centrifuging it for 1 min at 16000 rpm. Eluted DNA was stored at    





2.4.8 Addition of ‘A’-overhangs to PCR products 
Amplified DNA fragments obtained by using VelocityTM or KOD DNA polymerase lacked 
‘A’ tails –a stretch of ‘A’s at the 3’ end of the amplified fragment which were required in 
order to facilitate their cloning into pGEM-T Easy vector for sequencing. Therefore ‘A’ tails 
were added to amplified DNA fragments after subjecting them to agarose electrophoresis and 
eluting it from gel as explained earlier. Thereafter, purified PCR product was treated with 1 
μl of Taq polymerase, 10 μl of Taq polymerase buffer, 2 μl of MgCl2 (all the three of 
Invitrogen) and 2 mM dATPs. The volume of mix was made up to 100 μl with sterilized 
distilled water and heated at 70 oC for 30 min. The ‘A’-tailed PCR product was again run on 
agarose gel and extracted from it for ligation into pGEM-T Easy vector.  
2.4.9 DNA ligations  
These were performed using T4 DNA ligase (Invitrogen) and incubating the reaction mix at 4 
oC for overnight. The concentration (ng/μl) of insert and vector digested with the same 
restriction enzyme(s) was estimated by comparing with the respective bands of the 1 kb 
marker ladder (Fermentas) run along with them and the digested DNA to be ligated was 
eluted from the gel. The ratio of insert to vector concentration in the ligation reaction was 
maintained approximately at 3:1 in the standard reaction volume of 10 μl. Using the 
following formula, quantities of vector and insert DNA to be used in ligation reaction were 
estimated.  
 ng of vector  X size of insert(kb)




= ng of insert DNA  
2.4.10 Preparation of competent cells of E. coli 
Competent cells were prepared as per the calcium chloride method of Cohen et al (1972), by 





using an overnight grown (at 37 oC) seed culture.  Inoculation was done in the ratio of 1-part 
seed culture in 100 part of L broth. The culture was incubated for about 2 hr in a shaker at 
200 rpm until OD600 reached at 0.4-0.6. The culture was centrifuged at 5000 rpm at 4 oC for      
7 min.  Supernatant was discarded and pellet of cells was resuspended by vortex in pre-
chilled 100 mM CaCl2 added in the ratio of 2 ml of it per 5 ml of starting culture. After 
incubation on ice for 20 min, the cell suspension was re-centrifuged at 5000 rpm at 4 oC for 7 
min. Supernatant was again discarded and cells were gently resuspended in pre-chilled 100 
mM CaCl2 containing 15% v/v glycerol, this time in the ratio of 0.5 ml for each 5 ml of 
starting culture. The entire suspension was divided into aliquots of 100 μl in sterile microfuge 
tubes which were frozen in liquid nitrogen before being stored at -80 oC.  
2.4.11 Bacterial transformation by DNA and selection of transformants  
Plasmid DNA (20 ng) was added to 100 μl of ice cold competent cells and incubated on ice 
for 30 min followed by a 2 min heat shock in a water bath maintained at 42 oC. Thereafter, 
cells were again kept on ice for 5 min before 1 ml of L broth medium was added and 
incubation was carried out at 37 oC for 1 hour. After 1 hour the cell suspension was plated in 
two volumes of 50-200 μl on separate agar plates with suitable selection medium i.e. 
appropriate antibiotic and/or indicator like X-gal/IPTG (for X-gal assay).  The X-gal assay 
was used to detect transformed bacterial cells in which the pGEM-T Easy vector has an 
insert. Detection relied upon disrupting expression of the gene encoding the lacZα fragment 
because of the insertion of PCR product. An undisrupted lacZα gene that encoded the 
fragment in combination with the chromosomally-encoded β-fragment metabolizes the X-gal 
substrate into blue coloured metabolite allowing one to screen colonies on the basis of their 





2.4.12 DNA sequencing  
The sequence of PCR amplified genes/DNA fragments cloned into pGEM-T Easy vector was 
confirmed by DNA sequencing using universal primers in combination with the Sanger 
dideoxy method (Sanger et al., 1977) carried out by the Functional Genomics Laboratory of 
the University of Birmingham on ABI 3700 analyser. 5 ml overnight cultures were used for 
plasmid DNA extraction using Bioneer AccuPrep® plasmid extraction kit.  The concentration 
of the plasmid DNA preparation which was submitted for sequencing, was determined by 
nanodrop spectrophotometer (NanoDrop ND-100).  Typically, 200-500 ng of plasmid DNA 
was used for the reaction along with 3-4 picomoles of primer in a final volume of 10 μl made 
up with sterile distilled water. Sequences were analysed using Chromas Lite 
(http://www.technelysium.com.au/chromas_lite.html).  
2.4.13  Sequence analysis 
Pairwise alignments of sequences of proteins and DNA were done using EMBOSS Needle 
(http://www.ebi.ac.uk/Tools/psa/emboss_needle/) (Rice et al., 2000), and BLAST 
programmes (https://blast.ncbi.nlm.nih.gov/Blast.cgi) (Altschul et al., 1990).  Local    
alignment of proteins was also performed using EMBOSS Water programme 
(http://www.ebi.ac.uk/Tools/psa/emboss_water/) (Rice et al., 2000).  Default parameters were 
used for all the alignments that were performed online. These programmes were also used to 
verify sequences of cloned fragments obtained by DNA sequencing.  Databases of National 
Centre for Biotechnology (www.ncbi.nlm.nih.gov) and European Bioinformatics Institute 
(http://www.ebi.ac.uk/) were used for obtaining reference (wild type) nucleotide and protein 
sequences of interest. Artemis software 
(http://www.sanger.ac.uk/resources/software/artemis/) was also used for the analysis of 





NetPrimer (www.premierbiosoft.com/netprimer) or OligoCal software programme of 
Northwestern University of USA 
(http://www.basic.northwestern.edu/biotools/oligocalc.html).  Programme NEB cutter2 and 
other tools of New England Biolabs were used for mapping of restriction sites 
(http://tools.neb.com/NEBcutter2/).   
2.4.14 Bi-parental mating (conjugation) and suicide vector excision 
This was used for transferring/mobilization of plasmid DNA carrying cloned inserts into 
Pseudomonas fluorescens strains or Pseudoalteromonas sp. SANK 73390.  These plasmids 
were either expression vector pJH10 (Figure 2.4) or the suicide vector pAKE604 (Figure 2.2) 
that carried cloned inserts of interest.  For this purpose, E. coli S17-1 strain was used which 
was transformed with these plasmids. 0.5 ml of late exponential phase cultures of each of the 
mating strains were mixed in a sterile bottle.  Alternatively, the two cultures to be mated were 
filtered through 0.45 µM Millipore filter.  For mating with Pseudomonas fluorescens strains, 
the mix of two cultures was plated on L agar plate without any antibiotic (or the filter was 
transferred to it) that was incubated at 30 oC for overnight for conjugation to happen.  
Thereafter, cells were scratched from the lawn of bacteria on plate or washed from the filter 
and suspended in 1 ml saline (0.85% NaCl).  Mixture was vortexed and serial dilutions were 
prepared. 100 μl of each dilution was plated on M9 minimal media plates supplemented with 
tetracycline or kanamycin. Minimal media was made by mixing 200 ml of salt solution 
consisting of Na2HP04 (6 g/l), KH2P04 (3 g/l), NH4Cl (1 g/l), MgSO4 (1 mM), thiamine HCl 
(1 mM), CaCl2 (0.1 mM) and glucose (0.2%) with 200 ml of 50% H2O agar.  Plates were 
incubated at 30 oC for 2 days.  Thereafter, single colonies that appeared were picked and 





again incubated at 30 oC for 3-4 days.  Finally, single colonies were purified from these plates 
by restreaking onto L agar plates with tetracycline and ampicillin as supplement. 
Suicide vectors designed and constructed as described below were mobilized into the 
target organism by conjugation and transconjugants were selected and purified as described 
above for the expression vector. Integrant colonies among transconjugants were selected on 
minimal media plates supplemented with antibiotic kanamycin which were purified by 
restreaking on L agar plates. Sucrose sensitivity was checked by streaking kanamycin 
resistant colonies onto L agar plates supplemented with 5.5% w/v sucrose. For excision to 
take place, overnight cultures of integrants were set in 5 ml L broth without any antibiotic 
selection at 30 oC in a shaker at 200 rpm. Serial dilutions of this overnight culture were made 
in L broth to give 10-1-10-5 dilutions which were plated on L agar plates containing 5.5% w/v 
sucrose and incubated for 3-4 days at 30 oC, for the selection of strains in which integrants 
had excised. Single colonies from these plates were initially purified by streaking on L agar 
with ampicillin and by incubating for 3-4 days at 30 oC.  From these, isolated single colonies 
were picked up and were simultaneously restreaked onto L agar plates supplemented with 
ampicillin and on L agar plates supplemented with kanamycin, which were again incubated 
for 3-4 days at 30 oC. Finally, ampicillin resistant and kanamycin sensitive colonies were 
selected which were subjected to the confirmation of desired mutant genotype by PCR. 
 In case of Pseudoalteromonas sp. SANK 73390, the methods for conjugation and 
suicide vector excision were same except as explained in Chapter 3 (under section 3.2).  
 
2.4.15  Strategy for constructing in-frame deletions 
 The strategy for creating in-frame deletions for removing large proportions of the target 





overlapping with the ends of the target gene to be deleted (Figure 2.1).  This  strategy was 
used by Rahman et al., 2005 to create defined mutants of Pseudomonas fluorescens NCIMB 
10586.  Deletions need to be made in-frame to ensure that the implications of polar effects, if 
any, are minimal. This in turn ensured that the resulting phenotype was just the effect of 
lacking the specific gene which was targeted for deletion. Primers that were used to amplify 
these arms using polymerase chain reaction, were designed to have a unique restriction site at 
their 5’ ends and common restriction sites at the other ends. These fragments were then 
cloned into pGEM-T Easy vector and sequenced.  Thereafter, these arms were cut out from 
clones that had got the correct sequence, purified and joined together using common 
restriction site to get a fragment of 1 kb which was then cloned into vector pAKE604 (El-
Sayed, 2001), and this resulting plasmid was transformed into E. coli S17-1 cells for transfer 
by conjugation into wild type target organism. This suicide vector was integrated into the 
host chromosome (or the targeted plasmid pTML1 in case of Pseudoalteromonas sp. SANK 
73390) once after inside the host cell, via homologous recombination between two 500 bp 
arms that it carried and their cellular (chromosomal or plasmid) homologues (Figure 2.3).  
The suicide plasmid that got integrated, carried the sacB gene which encoded enzyme 
levansucrase that catalysed polymerisation of sucrose resulting in levan which was lethal to 
the cell.  For this reason, those cells that had this plasmid integrated into their chromosome 
(or the targeted plasmid pTML1), became sensitive to media supplemented with sucrose. A 
second recombination event could occur between homologous regions resulting into the 
excision of suicide plasmid from the site of its integration in the host cell, thereby causing 
cells to become insensitive to sucrose.  The probability of the second recombination event 
occurring in either arm should be equal so that half of the recombination events will leave the 
target gene intact and the other half produce mutants with in-frame deletion which could be 













Figure 2.1 Strategy for PCR amplification of 500 base pair arms flanking the 
gene targeted for deletion.The arms A and C flank the gene B that was targeted for 
deletion. (Arrows indicate position of forward or reverse primers indicated as FP and 






























Figure 2.2 Map of suicide vector pAKE604 used for creating specific 
vectors that were used for making defined deletions(El Sayeed et al., 2001).      
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Figure 2.3 Scheme depicting outcomes of suicide vector integration and exclusion 
in the host target DNA used for the creation of in-frame deletions. Suicide vector 











   Construction of expression plasmids 
The gene of interest was PCR-amplified and cloned into pGEM-T Easy vector (promega) 
after ‘A’-tailing. The cloned gene with pGEM-T Easy vector (the ligation) mix was 
transformed into E.coli DH5α and transformants were selected on X-gal (80 μg/ml) with 
IPTG (0.5 mM) and ampicillin (50 μg/ml) plates for blue-white screening. Plasmid DNA 
isolated from selected white colonies was digested with those restriction enzymes sites for 
which were present on both sides of the multiple cloning site of pGEM-T Easy vector for 
example EcoRI. Thereafter, the cloned gene was sequenced using universal primers. The 
insert from a clone carrying the correct gene sequence was excised from pGEM-T Easy 
vector by digestion and ligated into expression vector (pJH10) (Figure 2.4) using restriction 
enzymes and T4 DNA ligase respectively. The ligation mix (vector and gene) was 
transformed into E. coli DH5α cells and was selected on L agar antibiotic plates. Plasmid 
DNA from colonies selected in this way was checked for inserted genes by restriction 




































Figure 2.4 Map of expression vector pJH10 used to derive in trans expression of 













 Bioassay for mupirocin production 
For each bioassay, single colonies of Pseudomonas fluorescens (constructed test strains, wild 
type NCIMB 10586, control strains i.e. mutant strains of genes being tested transformed with 
pJH10 plasmid) were inoculated, each in 5 ml L broth with tetracycline for test strains and 
controls with pJH10 plasmid, and ampicillin for all the other control strains and for wild type.  
Cultures were incubated for overnight at 30 oC. Cell density was measured by UV 
spectrophotometer at 600 nm. After normalising cell density of all cultures, spot cultures 
were laid on L agar plates (poured with measured volume) which were left on the bench for 
overnight incubation. Overnight culture of Bacillus subtilis 1064 grown in L broth at 37 oC to 
late log phase was used to test mupirocin production. Overnight grown spot cultures were 
overlaid with equal volumes of molten L agar (100 ml) mixed with 4 ml of Bacillus subtilis 
1064 culture and 0.5 ml of 5% w/v solution of 2,3,5 triphenyl tetrazolium chloride (TTC). 
These overlaid plates were incubated for overnight at 37 oC. The area of zone of clearance 
around spot culture was measured and was taken as an estimate of mupirocin production by 
concerned strains. 
 
  High performance liquid chromatography (HPLC) 
  
2.7.1 Culture preparation for HPLC 
Overnight (16 hours) seed cultures were set up in 5 ml of L broth at 25 oC, 200 rpm. 
Thereafter, 25 ml of culture was set up at 22 oC, 200 rpm for 40 hours in fresh secondary 
stage medium (SSM) using 1.25 ml of this seed culture that was used for inoculation. SSM 
broth comprised of 25 gm Soya flour, 2.5 gm spray dried grown flour, 5.0 gm (NH4)2SO4, 0.5 





ml glucose, all made up to 1 litre with distilled water. After 40 hours of incubation, cultures 
were centrifuged at 13000 rpm for 7 min. Supernatant was collected and its pH was adjusted 
to 4.5 using HCl before being stored at -20 oC. Supernatant was filtered using 0.2 μm PTFE 
syringe filters.  
2.7.2 Sample analysis by HPLC  
HPLC was performed using Unipoint LC system software reverse phase C18 column (15 cm 
× 4.6 mm) with UV detection (Gilson) at 233 nm, and mobile phase water/ acetonitrile 
gradient (5-70%) using acetonitrile with 0.01% triflouroacetic acid, over 60 min at 1 ml/ min 
rate of flow.   
  Liquid chromatography mass spectroscopy (LCMS) 
This was performed by the collaborator of our group (Dr. Zhongshu Song) at the 
University of Bristol, UK. As per the procedure followed by him, L agar plates were 
inoculated with test strains and incubated at 30 °C for 30 hours. A single colony from each 
mutant and wild type strain was picked from the agar plates and inoculated into 12 ml of L 
broth with carbenicillin (50 µg/ ml culture) in a 30 ml universal tube. The seed cultures were 
incubated at 25 °C and 200 rpm overnight. 5 ml of the seed culture was inoculated into each 
500 ml Erlenmeyer flask containing 100 ml of L broth medium enriched with 4% glucose. 
Two flasks for each strain were used in the experiment. These fermentation flasks were 
incubated at 22 °C and 220 rpm for 48 hours.  After the fermentation finished all the flasks 
were examined for pH values, cultural outlook and smell for any sign of contamination. 
Cultures from the 2 flasks for each strain were combined and subjected to chemical 






The cells were removed by centrifugation at 22,000 ×g for 20 min. The supernatant 
was then extracted by ethyl acetate (1:1) once, followed by an extra ethyl acetate extraction 
after the aqueous was acidified to pH 5.0. The two extracts were combined and ethyl acetate 
was evaporated in vacuo. The residue was collected by MeOH for LCMS analysis. All the 
samples were dissolved in 4.0 ml MeOH.  Analytical samples were prepared by 10-fold 
dilution with MeOH and analysed by LCMS using a Waters HPLC system (Waters 2545 
Binary Gradient Module and Waters SFO System Fluidics Organizer). Detection was 
achieved by UV between 200 and 400 nm using a Waters 2998 diode array detector, and by 
simultaneous electrospray (ES) mass spectrometry using a Waters Quattro Micro™ API 
spectrometer detecting between 150 and 600 m/z units. Chromatography (flow rate 1 ml·min-
1) was achieved using Phenomenex Kinetex column (5 μ, C18, 100 Å, 4.6 × 250 mm). 
Solvents were: (A) HPLC grade H2O containing 0.05% formic acid; (B) HPLC grade CH3CN 
containing 0.045% formic acid. Analytical gradients were as follows: 0 min, 5% B; 22 min, 
60% B; 24 min, 95% B; 26 min, 95% B; 27 min, 5% B; 30 min, 5% B. LCMS purification of 
target compounds was performed on prep Phenomenex Kinetex column (5 μ, C18, 100 Å, 
AXIA 21.2 × 250 mm). Collection of target peaks was triggered by masses. Both positive 
(PI) and negative (NI) mode were employed for the characterization of the target compounds 




















3 CHAPTER 3 
Investigations on the role of 
tailoring/auxiliary genes of the tml cluster 













 Introduction   
  As explained in Chapter 1, thiomarinols are more effective than mupirocin in 
antibacterial properties and therefore can be a potent antibiotic or can be used to develop a 
more efficient antibiotic.  pTML1 is the 97 kb plasmid that is naturally present in marine 
bacterium Pseudoalteromonas rava SANK 73990 that produces thiomarinols.  Fukuda et al., 
(2011) had proposed that all the genes that are needed to code for thiomarinols are entirely 
found on this plasmid.  Genetic annotation of thiomarinol cluster on pTML1 has showed that 
it consists of 45 ORFs (Fukuda et al., 2011).  
Very little is known about biosynthetic steps in the thiomarinol biosynthetic pathway. 
But by sequence homology it has been shown that 27 out of total 45 ORFs of the gene 
functions of thiomarinol cluster have significant amino acid identity with those of mupirocin 
biosynthetic cluster of Pseudomonas fluorescens NCIMB 10586.  Bioinformatics analysis has 
shown that there has been clear conservation of PKS and associated gene functions between 
the thiomarinol and mupirocin gene clusters, which is also reflected as striking similarity in 
the structure of these two molecules (Fukuda et al., 2011).  Sequence homology indicates that 
the thiomarinol cluster, like mupirocin biosynthetic cluster, also has an unusually large 
number of accessory/tailoring region genes (Thomas et al., 2010, Fukuda et al., 2011).  
By comprehensive in-frame deletion studies in the accessory/tailoring open reading 
frames of mupirocin biosynthetic cluster, functions of most of these ORFs have been deduced 
(Hothersall et al., 2007). By in trans complementation studies of defined knockouts of 
mupirocin biosynthetic cluster, it has been shown that all of these are required for mupirocin 
production with role of most of the specific genes in the biosynthetic pathway determined 
(Hothersall et al., 2007). While in the tml cluster, gene knockout studies have not been so 





using the pAKE604 suicide vector, it has been shown that tmpD (PKS) mutant produced only 
the acyl pyrrothine while mutation in holA (NRPS) resulted in the production of marinolic 
acid only. Mutation in tmlU leads to the production of both marinolic acid and acyl 
pyrrothines but no thiomarinol was produced (Fukuda et al., 2011). Using the same strategy 
knockout of tmlF accessory/tailoring gene function of thiomarinol gene cluster could also be 
made recently by Thomas laboratory at the University of Birmingham which is under study 
for any changes in the phenotype that this specific knockout might cause. 
By applying similar approach of creating logically defined in-frame mutations in the 
various accessory/tailoring functions of thiomarinol gene cluster and studying the resulting 
phenotype of mutants it should be possible to deduce steps in the biosynthetic pathway of 
thiomarinols.  Each of the defined deletion of a gene function may result in non-production or 
deficient production of thiomarinols. And it may also not affect production of thiomarinols at 
all.  It is also possible that a new metabolite or a novel derivative of thiomarinol is produced 
by the mutant.  This way, by characterizing the product it should be possible to pin point the 
physiological role for which a particular specific gene function is responsible if the same 
effect is not caused as a result of actions of two or more gene functions that act 
simultaneously on the metabolic intermediate in the pathway.  Any of these many situations 
depend on the specific contribution made by each gene of the tailoring/accessory region in 
the biosynthetic pathway of thiomarinols.  It will also depend upon the relative role like 
specific catalytic function played by the specific gene function in the biosynthetic pathway 
that is mutated. At the same time, by in trans expression of the knocked out function in the 
mutant strain, it can be ensured that the resulting phenotype of the mutant strain is not caused 






The importance of accessory/tailoring genes has been shown in the biosynthesis of 
active secondary metabolites. Their role has been shown as accessory genes in the 
intermediate biosynthetic steps in the biosynthesis of daptomycin, lovastatin and mupirocin 
(Kennedy et al., 1999, Nguyen et al., 2006, Hothersall et al., 2007). While their role as post 
PKS tailoring- genes has been shown in the biosynthesis of erythromycin and anthracyclines 
(Katz, 1997, Weymouth-Wilson, 1997, Weissman and Leadlay, 2005). The importance of 
manipulating tailoring enzymes has been shown in the development of molecules with novel 
activities.  It has been shown that minor modifications in the tailoring region genes have 
resulted in novel activities (Katz and Donadio, 1993, Rix et al., 2002, Olano et al., 2010).                                                                  
This work was aimed at investigating gene functions of specific tailoring region genes 
of the thiomarinol cluster by defined in-frame deletion of singular genes.  The initial 
knockouts attempted were of tmlT, tmlS, tmlO and tmlW with an aim of extending such 
approach towards understanding roles of tacpD, tmlQ and tmpF as well. 
By in silico studies it has been predicted that tmlT and tmlW are ferredoxin and 
dioxygenases, respectively.  By knockout and complementation studies it has been shown 
that mupT and mupW, with which tmlT and tmlW share significant amino acid sequence 
identity of 39% and 56% respectively, are involved in the closure of pyran ring found in the 
polyketide component of mupirocin (monic acid).  It has been shown that formation of pyran 
ring involved attack of the 5-OH onto an activated 16-hydroxy group to finalise (close) the 
pyran ring (Cooper et al., 2005b, Hothersall et al., 2007, Thomas et al., 2010).  Mutants of 
mupW of Pseudomonas fluorescens NCIMB 10586 resulted in the isolation of PA-W which 
is essentially pseudomonic acid but with open pyran ring (Cooper et al., 2005a) while 
mutants of mupT resulted in significant loss in the production of pseudomonic acids (Cooper 
et al., 2005b).  On this basis and in view of bioinformatics analysis it could be predicted that 





completed pyran ring that is also present in it as part of polyketide component of the 
molecule that has similarity with monic acid component of Pseudomonic acids (Fukuda et al., 
2011).  Knockouts of tmlT should also drastically affect the production and/or activity of 
thiomarinols. 
Similarly, knockout of tmlO which is predicted to be a cytochrome P450 enzyme, is 
expected to result in changes in the oxidation state around the pyran ring found in polyketide 
moiety of thiomarinols. Which is because this enzyme shared significant amino acid 
sequence identity with mupO (44%), a cytochrome P450 enzyme and the knockout yielded 
the same result in the mupirocin biosynthesis (Cooper et al., 2005b). 
tmlS, tmlQ, tacpD and tmpF were the other accessory/tailoring genes, knockouts of 
which were planned to be made.  On the basis of bioinformatics studies tmlS, tmlQ, tacpD 
and tmpF are predicted, like equivalent Mup proteins, to be 3-oxoacyl-ACP reductase, acyl-
CoA synthase, acyl carrier protein and ketosynthase domain, respectively.  MupS, MupQ, 
MacpD and MmpF have been found to share amino acid identity of 62%, 46%, 46%, and 
43% with their corresponding Tml protein respectively.  In silico studies indicated that 
proteins like MupS are often found to act together with other proteins in the furnishing of 
starter unit/primer unit for the biosynthesis of fatty acids (Wu et al., 2008).  Gene functions of 
such proteins that act together are also found located together like such genes of defficidin 
polyketide system of Bacillus amyloliquifaciens (Chen et al., 2006) in which these are also 
found located together as in mup cluster (Thomas et al., 2010).  Knockouts of mupS, mupQ, 
macpD and mmpF have been reported to result in abolition of production of pseudomonic 
acids (or in steep decrease in their production) as confirmed by plate bioassay and HPLC 
(Cooper et al., 2005b, Hothersall et al., 2007).  Therefore, based on bioinformatics evidence 
and structural similarities in these two molecules, mupirocin and thiomarinol, knocking out 





the genes tmlQ, tacpD and tmpF might result in the abolition or drastic decrease in the 
production of thiomarinols by the corresponding mutants. 
To confirm that the engineered mutation was the only cause of change in the 
phenotype of the mutant strain and was not because of polar effects, it may be complemented 
by in trans expression of the knocked out gene.  If there was no polar effect, then this should 





























Objective of this study was to create defined in-frame deletions of specific genes in 
the thiomarinol cluster of wild type Pseudoalteromonas sp. SANK 73390 present on the 
pTML1 plasmid and to study the effect of each deletion on the phenotype. Defined knockouts 
of tmlT, tmlW, tmlO, tmlS, tacpD, tmpF and tmlQ were planned to be made.  
  As described in Chapter 2 (section 2.4.14) suicide vector insertion and excision 
technique that depended on homologues recombination taking place, was used in order to 
delete each gene.  First of all, two arms of DNA of about 500 base pairs on either side of each 
of these genes to be deleted were identified/ designed. Unique restriction sites were identified 
to facilitate ligation of these arms with each other and to incorporate joined arms into the 
suicide vector pAKE604 (El-Sayed et al., 2001). Scheme for the deletion of each of these 
seven genes is outlined in Figures 3.1 to 3.7.  Primers were designed accordingly to include 
selected restriction sites in the arms.  Details of all the primers designed to amplify arms to 
delete above said seven genes are given in Table 2.9 giving name of each primer, size, 5’-
coordinate, incorporated restrictions sites etc. Arms were then amplified by PCR using 
specific pair of primers for each of the arm designed for the deletion of a specific gene.  
 PCR amplified arms were A-tailed as described in Chapter 2, to facilitate their cloning into 
pGEM-T Easy vector, in which these were cloned to confirm their sequence by sequencing 
using universal primers.  All the pGEM-T Easy derivative vectors that were constructed for 
the deletion of tmlT, tmlW, tmlO, tmlS, tacpD, tmpF and tmlQ genes are listed in Table 2.5 
which gives name and size of each plasmid constructed this way with the size of each arm 
that was cloned into it.   
Following sequencing and cloning into pGEM-T Easy vector of each of the two arms 





by three-way ligation as a fragment of size about 1 kb using restriction sites that were 
incorporated during the PCR amplification of respective pair of arms.  Table 2.5 also details 
suicide vectors made for the deletion of genes tmlW, tmlT, tmlS and tmlO giving names of 
suicide vectors, size of specific pair of arms cloned, the restriction sites into which it is 
cloned and the size of vector.  
Suicide vectors so constructed were transformed into E. coli S 17-1 in order to 
transfer the constructed specific suicide vector into wild type Pseudoalteromonas sp. SANK 
73390 by way of mobilization through conjugation as explained in Chapter 2.  Briefly, for 
mating 5 ml cultures of E. coli S 17-1 strain carrying constructed suicide vector of interest 
were grown overnight at 37 oC in L broth medium supplemented with kanamycin (50 µg/ 
ml).  Similarly, 5 ml culture of wild type Pseudoalteromonas sp. SANK 73390 was set up in 
5 ml of M broth and allowed to grow at 23 oC for 1-2 days until there was dense growth.  
Thereafter, 1 ml of both the cultures was mixed and vortexed for 10 sec. 100 µl of the mix 
was plated onto M agar plate with no antibiotic selection and was incubated for 2-3 days at 
23 oC to allow conjugation to takes place.  After incubation, serial dilutions were prepared in 
M broth for up to 10-5 fold and 100 µl of the serial dilutions were plated onto M agar plates 
with kanamycin, for the selection of wild type Pseudoalteromonas sp. SANK 73390 with 
suicide vector integrated in pTML1 plasmid (first homologous recombination event).  That is 
because in the first place suicide vector cannot replicate by itself and secondly, it has got 
kanamycin resistance in its genotype.  This ensured that the selected transconjugants had 
suicide vector integrated into the wild type pTML1 at sites dictated by homology of specific 
two arms incorporated in the suicide vector.  Plates were incubated for up to 2-3 days at 23 oC 
for selection to take place. Single colonies that were typical of wild type Pseudoalteromonas 
sp. SANK 73390 were then re-streaked on M agar plates supplemented with kanamycin (50 





cultures were inoculated in 5 ml M broth without antibiotic to allow excision of the suicide 
vector integrated into plasmid pTML1 to take place (second homologues recombination 
event). Cultures were incubated for 1-2 days at 23 oC in the shaker.  Thereafter, serial 
dilutions were prepared in M broth for up to 10-5 fold and 100 µl of serial dilutions were 
plated onto M agar plates containing sucrose (5.5% w/v) to allow counter selection of those 
transconjugants in which suicide vector had excised from pTML1.  In order to allow this to 
happen, plates were incubated for 2-3 days at 23 oC.  Colonies having integrated suicide 
vector did not grow because of the presence of sucrose in the medium which was 
polymerised by the product of sacB gene present in the integrated suicide vector, into solid 
levan-sucrose accumulation of which in the periplasm of the cell caused cell death.  This 
ensured that colonies that grew had no suicide vector in their genotype.  Single colonies were 
then selected from these plates and checked for their sensitivity to kanamycin.  Sensitivity to 
kanamycin confirmed excision of the suicide plasmid from the pTML1.  Such colonies that 
grew on sucrose but did not grow on kanamycin were then checked for the desired mutation 
by PCR using specific pair of outer primers that were used to amplify arms designed for 
deletion of a particular gene. Wild type Pseudoalteromonas sp. SANK 73390 and specific 
suicide vector were used as negative and positive controls, respectively, to confirm the 
desired mutation.  Results for the knock-outs of tmlO and tmlW turned out to be negative as 
confirmed by of PCR because band of desired size could not be seen in any case.  In case of 
knockouts of tmlS and tmlT, no colony that was resistant to the presence of sucrose in the 
culture media (and sensitive to the kanamycin) could be obtained indicating failure of second 



























Figure 3.1 Construction for the deletion of tmlW gene from pTML1 plasmid of 
Pseudoalteromonas sp. SANK 73390. 
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Figure 3.2 Construction for the deletion of tmlS gene from pTML1 plasmid of 
Pseudoalteromonas sp. SANK 73390. 
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Figure 3.3 Construction for the deletion of tmlT gene from pTML1 plasmid of 
Pseudoalteromonas sp. SANK 73390. 
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Figure 3.4 Construction for the deletion of tmlO gene from pTML1 plasmid of 
Pseudoalteromonas sp. SANK 73390. 
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Figure 3.5 Construction for the deletion of tacpD gene from pTML1 plasmid of 
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Figure 3.6 Construction for the deletion of tmlQ gene from pTML1 plasmid of 
Pseudoalteromonas sp. SANK 73390. 
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Figure 3.7 Construction for the deletion of tmpF gene from pTML1 plasmid of 
Pseudoalteromonas sp. SANK 73390. 
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Figure 3.8 Map of suicide vectors pMY26 (A) and pMY29 (B) constructed for the 









































Figure 3.9 Map of suicide vectors pMY32 (A) and pMY35 (B) constructed for the 
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Figure 3.10 Screening for mutants of tmlW and tmlO using PCR. Excisants- the 
cells that had lost suicide vector from pTML1 plasmid which were identified by their 
resistance to sucrose and sensitivity to kanamycin were screened by PCR using (A) 
vector pMY26 as template for the deletion of tmlW (positive control) and (B) vector 
pMY32 as template for the deletion of tmlO (positive control). For negative control, 
wild type Pseudoalteromonas sp. SANK 73390 was used as template. In both the 








(1057 bp amplicon) 
 
10 kb 
  2.5 
1 kb  
 (A) 
-ve control 










Failure to get expected result (mutants) using strategy given in Chapter 2 (section 2.4.15) 
(Rahman et al., 2005),  might be because of similar unknown reasons for which several other 
researchers of Thomas laboratory who used this strategy failed to get knockouts of many 
other genes of tml cluster.  Defined in-frame knockouts of tmlC, holE, holA, tmuA, tmuB, 
module 2 of tmpB genes were attempted by several researchers of this laboratory using this 
strategy but expected mutants of none of these could be obtained. On the other hand, this 
strategy worked well for creating some other mutants like disruptive point mutations in holA, 
tmuB, tmpD and for creating defined in-frame knockouts of tmlU (Fukuda et al., 2011), and 
tmlF (Thomas, 2015), which was supportive of the fact that all the processes on which this 
strategy relied upon, were effective in these cases. Though, the tmlF mutants could be 
obtained but only after several attempts while repeated attempts made about other genes by 
various researchers of Thomas laboratory did not yield any mutants. Pseudoalteromonas 
species despite having multidrug resistance genes and drugs efflux pumps that may render it 
to survive antibiotic pressures and develop resistance, was sensitive to 50 µl/ ml 
concentration of kanamycin which was used to select its transconjugants (Webber and 
Piddock, 2003, Qin et al., 2011, Yu et al., 2013).  Use of 5.5% w/v concentration of sucrose 
also worked to induce expression of Bacillus subtilis sacB gene to promote cell death thus 
permitted counter selection. Growth conditions that were used to perform conjugation also 
worked with E. coli S-17 strain grown O/N at 37 oC and wild type Pseudoalteromonas sp. 
SANK 73390 grown at 23 oC for 1-2 days until there was good growth.  Selection of 
transconjugants also worked well at 23 oC whereby colonies, which were selected by plating 
on M agar containing 50 µl/ ml concentration of kanamycin, indicated that mating had been 





excision step.  None of the transconjugants that were counter-selected because of being 
sensitive to kanamycin and insensitive to the presence of sucrose in the growth medium, 
turned out to be expected knockouts but wild type as confirmed by colony PCR for tmlW and 
tmlO.  In case of tmlS and tmlT knockouts, none of the transconjugants turned out to be 
insensitive to the presence of sucrose in the growth medium when these were selected after 
the step that promoted second homologous recombination event. 
Factors that might be responsible for the failure to get knockouts could be on account 
of the fact that the bacteria that are found in sea habitat have some features significantly 
different from those found in other habitats. Marine bacteria grow under extreme conditions 
of high salinity, lower temperature and higher pressure. As a result, they have different 
adaptations to survive in such environment. They have higher solute concentrations and 
therefore, integrity of cell membrane becomes very important to maintain it (Wood, 2015).  
Cell membrane is home to various processes like electron transport chain, various membrane 
transport systems/channels etc. Correct physical state of cell membrane is required for proper 
functioning of gene regulation, for intracellular signal transduction and for protein-protein 
interactions that takes place within it. The ability to survive under adverse conditions is 
achieved by changes in various factors including protein contents and mainly the lipid 
content of the cell. Various protein factors/enzymes of marine bacteria require high salt 
environment to become functional. Membrane lipids are modified to maintain the membrane 
fluidity according to the extreme habitat (Allen et al., 1999, Allen and Bartlett, 2000).  It is 
well known that with the increase in temperature, percentage of monounsaturated fatty acid 
(MUFA) increases in the membrane phospholipids of bacteria.  In marine bacterium P. 
profundum SS9 it has been shown that MUFA is essential for growth at low temperature 





To support various adaptations to the extreme marine habitat, bacteria are often found 
to have many special genetic features. It has been reported that recombination and repair gene 
recD found in deep sea bacteria Photobacterium profundum ss9 is critical for growth at high 
pressure and, therefore, is different from recD found in E. coli (Bidle and Bartlett, 1999). 
Similarly, the fabF gene found in this bacteria codes for a beta-ketoacyl-acyl carrier protein 
synthase II which can adapt to changes in pressure compared to the one coded by fabF gene 
found in E. coli (Allen and Bartlett, 2000).  In P. profundum ss9, this enzyme is involved in 
the production of unsaturated fatty acid, cis-vaccenic acid, which is required for normal 
growth at higher hydrostatic pressure (Allen and Bartlett, 2000).  E. coli did not regulate its 
fatty acid composition in an adaptive response to high pressure.  Several genetic loci have 
been reported from P. profundum ss9 that are associated with the growth at lower 
temperature and/or at high temperature. Mutations in any of these loci affected adaptations of 
these bacteria to grow in their natural environment as they affected various regulatory and 
other related processes for example those involved in ribosome assembly and function, cell 
envelope or chromosome structure etc. (Lauro et al., 2008). As part of adaptations for 
survival in its natural environment marine bacteria also develop resistance mechanisms to 
counter various adverse conditions and substances, and produce various secondary 
metabolites in order to have competitive edge over others (de Carvalho and Fernandes, 2010).  
All these adaptations are genetically represented.  There are gene clusters in marine bacteria 
responsible for the production of secondary metabolites and genes that confers it resistance to 
survive in the multidrug environment (de Carvalho and Fernandes, 2010, Cordero et al., 
2012, Yu et al., 2013, Giordano et al., 2015). It has been shown in Pseudoalteromonas 
flavipulchra JG1 strain that its genome represented several advantages over others as it 
encoded for adaptations to marine environment (Yu et al., 2013). This included expression of 





its involvement in the biosynthesis of small molecules, which may be part of several of 
antagonizing and biocontrol mechanisms of this bacterial strain (Yu et al., 2013).  Such 
genetic variations in Pseudoalteromonas sp. SANK 73390 species that are due to its marine 
habitat but currently unknown, might have affected the fidelity of various cellular and 
biochemical processes on which gene knockout protocol depended (that included DNA-DNA 
and DNA-protein interactions) resulting in the failure to get any mutants. Culturing of marine 
bacteria under laboratory conditions on artificial media (M agar/ M broth) might have also 
contributed towards this because these organisms normally grow under stressful conditions 
prevailing in their natural habitat where they may depend on the associated ecology for their 
various requirements like nutrition etc. (de Carvalho and Fernandes, 2010, Giordano et al., 
2015).    
In Pseudoalteromonas sp. SANK 73390, there could also be a different and varied set 
of restriction-modification systems that this species harboured that might have caused 
degradation of foreign DNA. This could have been the reason behind failure of 
recombination events to take place in the first place.  It may also be the case of failure in the 
maintenance of acquired sequence even if it got integrated by recombination or by any other 
genetic method because of not being supported by host’s replicative machinery for various 
adaptive reasons discussed above. Various protein factors/enzymes involved in the 
replication or regulation of replication of plasmid pTML1 (into which integration and 
excision events are supposed to occur) either did not function properly for the changed 
homeostatic conditions inside the cell or were expressed in sub-optimal concentrations 
because of bacteria being grown out of its natural marine habitat but under laboratory 
conditions and on artificial medium. Improper folding of concerned enzymes/proteins could 
also be one of the reasons behind failure of recombination events to take place. The fact that 





was supportive of the fact that these restriction-modification systems and/or the host’s 
replicative machinery / processes were not very rigid for foreign DNA which it received from 
distantly related species E. coli S17-1 strain.  These systems/processes may also be dependent 
on the sequence (GC content or nature of sequence) that was introduced in the host strain as 
suicide vector. Ability to get some knockouts by others using this method also indicated that 
the various cellular processes of the bacteria were not drastically affected by its growth in 
laboratory on artificial medium.  This may explain why same strategy failed in case of 
creating knockouts of other genes of same bacteria (this study and by others). 
Pseudoalteromonas species are thus not amenable to ordinary methods of genetic 
manipulations. New protocols are being developed to knockout genes effectively in these 
species (Yu et al., 2014, Wang et al., 2015). 
One of the other reasons for failure to get expected mutants might be that knocking out 
of any of these particular gene(s) resulted in the loss of cell viability. This could have been 
the case because the product of that specific gene was critical for the survival of bacterium or 
knocking it out induced polar effects that rendered inactivation/lowered (than required) 






















4 CHAPTER 4    
Investigations on functional cross-
complementation between products 






















As described in Chapter 1, in recent years there has been a growing problem of rising 
resistance to antibiotics among pathogens. As a result, there have been attempts to find newer 
antibiotic molecules with higher potency and broad spectrum. Newer molecules having novel 
activities have been reported from organisms from diverse environments including extreme 
habitats ranging from deep seas to deserts (Bredholt et al., 2008, Cragg and Newman, 2013, 
Orlova et al., 2015, Tiwari et al., 2015, Kozuma et al., 2016, Newman and Cragg, 2016).  On 
the other hand, there have also been attempts to develop new antibiotic molecules from 
existing antibiotic biosynthetic clusters by using the approaches of combinatorial biosynthesis 
and applying the techniques of genetic engineering (Walsh and Fischbach, 2010, Wong and 
Khosla, 2012, Sun et al., 2015).  Fully rational application of combinatorial biosynthesis to 
develop newer molecules with enhanced properties depends on the complete understanding 
of the antibiotic biosynthetic cluster, its gene functions, complete biosynthetic pathway 
including all the biosynthetic steps and intermediates involved their timings, the gene 
functions involved and protein-protein interactions taking place in those steps.  It has been 
shown that tailoring functions apart from the core polyketide functions play an important role 
in deciding the final bioactive molecule (Rix et al., 2002, Olano et al, 2010). In recent years, 
manipulation of tailoring region genes has been a great source of novel or improved 
bioactivities of molecules as well as a way for making them less/non-toxic with enhanced 
stability (Rix et al., 2002, Olano et al., 2010).  In efforts to get novel molecules or to get 
improved activities/properties of existing antibiotics, focus has also been on the group of 
antibiotics belonging to the trans-AT class (Till and Race, 2014, Helfrich and Piel, 2016).  





antibiotics and was focussed on finding common biosynthetic steps/intermediates in the two 
biosynthetic systems by studying protein- protein interactions.  
 
Fukuda et al. 2011 has shown that trans-AT antibiotics; mupirocin and thiomarinol, 
have very similar structures which is explained in Chapter 1 (section 1.18).  It raised the 
hypothesis that this structural similarity between the two antibiotics might be reflected at the 
genetic level.  The biosynthetic systems of these antibiotics must have things in common 
(Figures 1.30 and 1.34) including individual biosynthetic steps, enzymes and/or biosynthetic 
intermediates. It has been pointed out that out of the total 45 ORFs of the thiomarinol cluster, 
27 ORFs encode products that one can expect for a mupirocin like biosynthetic cluster 
producing marinolic acid (Figure 1.32) (Fukuda et al., 2011).  Marinolic acid is the name 
derived by analogy with pseudomonic acid on account of the similarities between the 
structures of thiomarinol without pyrrothine (thiol group) and pseudomonic acid (Figure 
1.30) (Fukuda et al., 2011).  Although in thiomarinols, 9-HN is replaced with 8-HO, the only 
major difference from pseudomonic acids is the presence of pyrrothine moiety in 
thiomarinols that is attached to fatty acid via an amide bond.  In both the molecules, 
mupirocin and thiomarinol, fatty acid moiety is in ester linkage with the monic acid 
component.   
As stated above, the genetic setup for the type I PKS of the thiomarinol cluster is 
similar to mup cluster. Though there are differences in the number of ACP’s, tailoring regions 
and regulatory aspects and there is an extensive rearrangement of tailoring/auxiliary genes 
compared to mup cluster which is detailed in Chapter 1 (Figure 1.34) (El-Sayed et al., 2003, 
Fukuda et al., 2011).  By gene knockout, complementation and refeeding studies, much 
knowledge has been gathered about the mupirocin biosynthetic pathway of Pseudomonas 





various biosynthetic steps in the biosynthetic process and about the role of some gene 
functions and interaction of various gene products resulting in specific modifications in the 
final molecule (Thomas et al., 2010, Gao et al., 2014).  Relatively very little is known by 
experimental evidence (rather most is predicted) about gene functions of the thiomarinol 
cluster and biosynthetic steps involved in its biosynthesis (Fukuda et al., 2011). This situation 
warrants studying the homologous gene functions, products of which share a significant 
amino acid sequence identity, between the two biosynthetic clusters.  
Gene knockout and complementation studies have been routinely used to study 
functional cross-complementation between homologues of different genetic systems.  In vivo 
complementation studies have helped to elucidate functional organization of genes in the 
genome and to confirm whether specific phenotype relates to specific gene function.  By in 
vivo cross-complementation studies using various regulatory genes of the nystatin 
biosynthetic gene cluster of Streptomyces noursei ATCC11455, hierarchy of differential 
control exerted by them in nystatin biosynthesis could be established (Sekurova et al., 2004). 
By cross-complementation studies in chlorothricin and tetrocarcin gene clusters it has been 
shown that the homologues of AbyA3 and AbyA4 that encode an ACP and dehydrogenase, 
respectively, are interchangeable (Gottardi et al., 2011).  Interspecies cross-complementation 
in Sacchropolyspora erythraea has been used to elucidate the functions of oleP1, oleG1 and 
oleG2 genes of oleandomycin biosynthetic cluster of Streptomyces antibioticus which also 
led to the isolation of novel erythromycin derivatives (Doumith et al., 1999).  Zhang et al. 
(2008) used cross-complementation studies between SgcE and NcsE PKS biosynthetic 
clusters to show that there is common mechanism for initiation of enediyne biosynthesis in 
nine-membered enediynes (Zhang et al., 2008).  By complementation, it has been 
demonstrated that regulatory elements lanI, lndI and jadR1 from different biosynthetic 





cyanogenus lanI7 regulatory mutants, respectively (Rebets et al., 2008). Complementation 
studies have also been used to shed more light on enzyme promiscuity.  A survey of enzyme 
promiscuity and ambiguity in E. coli was conducted using self-complementation by which it 
was shown that 20% of the 104 auxotrophs, that were tested, survived as a result of 
overexpression of at least one of its noncognate gene (Patrick et al., 2007, Khersonsky and 
Tawfik, 2010).  Using in vivo complementation studies together with other techniques it was 
shown that PTPS-I proteins (COG0720 subfamily involved in queuosine biosynthesis) in 
prokaryotes were inherently promiscuous as they catalysed same reaction on different 
substrates as well as different reactions on the same substrate  (Phillips et al., 2012).  Using 
complementation studies it has been shown that Chlamydia species have evolved a variant of 
tetrahydrofolate biosynthesis pathway that involve promiscuous and adaptable enzymes 
(Adams et al., 2014). 
Studies for functional cross-complementation across the two systems; mupirocin and 
thiomarinol, for such specific homologous gene functions will shed more light on the 
similarity and differences in the two biosynthetic systems/pathways particularly about 
protein-protein interactions. It will also tell us about the extent of conservation and 
divergence of homologous gene functions during evolution in the two distantly related 
systems involved in the biosynthesis of similar structures. 
Gene knock out and in trans complementation studies in the thiomarinol system could 
provide useful information to identify and assign the putative function of various genes in the 
tml cluster and help to elucidate biosynthetic steps much in the same way, as was done for the 
mup biosynthetic pathway and for other biosynthetic systems (Hothersall et al., 2007, 
Thomas et al., 2010, Gao et al., 2014). The cross-complementation studies between the two 
systems; mup and tml, may also reveal additional information about both systems as these 





protein interactions taking place etc. in the two clusters. Complementation of a mup knockout 
by its corresponding homologous Tml protein will indicate whether the concerned metabolic 
intermediate in the two biosynthetic pathways is similar or not.  This will also reveal about 
similarity or differences in the sequence of biosynthetic steps up to that stage i.e. actions of 
preceding enzymes and structure of metabolic intermediates between two systems.  Lack of 
complementation by specific gene/product will indicate differences in the biosynthetic 
pathways in these two systems and/or the stringent specificity of respective enzymes for their 
specific substrate- the metabolic intermediates in the biosynthetic pathway. Such studies will 
also help in identifying the differences in these two biosynthetic pathways concerning 
different biosynthetic intermediates/steps employed for otherwise structurally very similar 
molecules.  The outcome of the study should also provide useful data to shed more light on 
some of the questions that are still unanswered about mupirocin biosynthetic pathway.  
Complementation was expected in view of the fact that both these systems produce 
polyketide molecules with similar structures which is also reflected as homology of proteins 
of two clusters that are proposed to utilize the same building blocks (the starter units as 
acetate and the extender units as malonate). 
One of the important unanswered questions is how fatty acid components in both the 
antibiotics are synthesized and what gene functions are responsible for their biosynthesis? 
One such question is why, despite the two biosynthetic systems coding for structurally similar 
polyketide molecules there are some enzyme functions present in one biosynthetic pathway 
but are missing in the other? And how do these two biosynthetic pathways differ from each 
other which otherwise produce structurally similar molecules that differ in their fatty acids by 
just one carbon? In addition, in neither system the gene functions responsible for 6-
hydroxylation are known yet. By such cross-complementation studies between the two 





responsible for the hydroxylation of the fourth carbon of the polyketide moiety in 
thiomarinols (Mohammad, 2016).  It has been demonstrated by in trans expression of tmuB in 
Pseudomonas fluorescens NCIMB10586 that it can hydroxylate the fourth carbon of the 
polyketide moiety of pseudomonic acids which is similar to the one that is found in 
thiomarinols indicating that there is some similarity in the biosynthetic steps in the two 
systems.  
 It was proposed to study all of the 22 tailoring/auxiliary genes of the tml cluster, 
products of which shared significant amino acid sequence identity with their mup equivalents. 
The genes were tested in the order based on information available about their putative 
functioning as groups whereby either they worked together or processed biosynthetic 
intermediates one after the other in the predicted mup biosynthetic pathway.  In this regard 
their order of occurrence in the gene cluster was also taken into account.  Gene knockout, 
complementation and refeeding studies in mup cluster by Hothersall et al. (2007) and Gao et 
al. (2014) have established the way in which products of various genes collaborated/acted, to 
process biosynthetic intermediates in the mup biosynthetic pathway. Based on this 
information, biochemical nature of gene products and significant homology shared by them 
in these two systems, complementation by tmlS, tmlQ, tmpF, and tacpD was studied because 
their corresponding mup equivalents have been predicted to be involved in furnishing the 
starter unit for the biosynthesis of the fatty acid component of pseudomonic acids. 
Similarly, tmlO, tmlC and tmlF were studied, as all of their mup counterparts have 
been shown to be involved in determining oxidation state acting one after the other around 
the pyran ring common to both the molecules (Figure 1.28). tmlJ and tmlK gene functions 
were studied together because their mup counterparts have been implicated along with a 





insertion of a methyl group (C-15) at β- position at C-3 and which is present in both the 
molecules. 
Knowledge gained as a result of this study about these and other biosynthetic 
pathways may be used to reengineer them using approaches of combinatorial biosynthesis to 
generate novel molecules; derivatives of pseudomonic acids and thiomarinols, with improved 
























 Result  
Functional cross-complementation studies of nine tailoring region genes out of the initial plan 
to test 22 were completed. Nine genes of the tailoring region of thiomarinol cluster namely 
tmlJ, tmlK, tmlS, tmlQ, tacpD, tmpF, tmlO, tmlF and tmlC were tested by in trans expression 
of their ORFs in the corresponding mutants of Pseudomonas fluorescens NCIMB 10586.  
Primers were designed to amplify each of these nine ORFs incorporating unique restriction 
sites at their either end, details of which are given in Table 2.10.   
 PCR was carried out as described in Chapter 2 to amplify each of the ORFs.  
Amplification of most of the ORFs could be completed in the first attempt by using 
VelocityTM DNA polymerase. For amplifying tmlO ORF, initially 49 oC was used as the 
annealing temperature but that yielded no result. While product of expected size was obtained 
on repeating the PCR with the annealing temperature raised to 53 oC.  ORFs tmlC, tmlF, tmlJ, 
tmlK, tmlQ and tacpD could be amplified in the first attempt. ORFs of tmlC, tmlF and tmlJ 
could be amplified at an annealing temperature of 51oC, while good yield of product of 
expected size for tacpD and tmlQ ORFs could be obtained at annealing temperature of 55 oC. 
The tmlK ORF could be amplified at annealing temperature of 53 oC.  For amplification of 
tmlS ORF, initially 49 oC was used as the annealing temperature but after optimising 
temperature to 53 oC, a good yield of product of expected size was obtained.  It took several 
attempts to get PCR product of tmpF ORF for which KOD DNA polymerase was also used 
for amplification (see section 2.3).  Initially,  53 oC was used as the annealing temperature for 
amplification but it is only after optimising annealing temperature to 55 oC and extension 
period of 2 min 30 s,  a good yield of product of expected size could finally be obtained using 





  PCR products were purified, A-tailed and cloned into pGEM-T Easy vector in each 
case in order to sequence them. For every ORF after confirming their sequence to be correct, 
these fragments were cloned into inducible pJH10 expression vector (induced by IPTG) by 
digestion/ligation using incorporated restriction sites.  All the plasmids thus developed are 
listed in Table 2.6.  Before proceeding to the next stage presence of PCR amplified ORFs was 
confirmed in the respective expression vectors by restriction/digestion (Figures 4.2, 4.7, 4.11, 
4.15, 4.21, 4.23, 4.28 and 4.36). 
Each of the expression plasmids so constructed was then introduced into E. coli S17-1 
by transformation and the purified strain was used to transfer this plasmid into the 
corresponding Pseudomonas fluorescens NCIMB 10586 mutant strain by conjugative transfer 
as described in Chapter 2 (section 2.4.14). Complementation was assessed by bioassay which 
was performed as described in Chapter 2 (section 2.6).  In each case, visual inspection of the 
plate bioassay was followed by quantitative analysis displayed as a bar-diagram.  
4.2.1 Complementation by TmlO 
It could be seen from figures 4.3A, 4.3B, 4.4 and 4.5, that TmlO did not complement 
functions of its mup equivalent when expressed in the corresponding mutant strain 
Pseudomonas fluorescens NCIMB10586ΔmupO. Which was despite TmlO shared significant 
amino acid sequence identity with MupO (Fukuda et al., 2011). Figure 4.1 gives global 
alignment of these two proteins. In TmlO complementation, it was observed in bioassay 
plates that the zone of clearance was further reduced when IPTG was included in growth 
medium indicating that enhanced expression of TmlO interfered with the biosynthesis of 
active moiety that was responsible for the development of clearing zone (Figure 4.3).  HPLC 
analysis of the supernatant from constructed strain also showed chromatogram different from 





Presence of new peaks in the chromatogram compared to that of wild type strain indicated 
existence of new moieties. Results of LC-MS also confirmed non-complementation of mupO 
by tmlO (Figure 4.5).  HPLC and LC-MS chromatograms of tmlO complementation showed 
peaks confirming the production of PA-B which is produced by ΔmupO strain (Figures 4.4 
and 4.5) (Cooper et al., 2005b). 
 
Figure 4.1 Global alignment of TmlO and MupO proteins using EMBOSS 
Needle.(Rice et al., 2000). Default parameters for Needleman-Wunsch algorithm used 
(Needlema.Sb and Wunsch, 1970). Percent similarity between protein sequences 
60.1% which is identified, depending on the level of similarity, as ‘:’ (more similar) 















Figure 4.2 Confirmation of the tmlO insert in pMY2 expression vector. Double 
digest with KpnI and XbaI yielded a fragment size of 1.35 kb that confirmed the 
presence of cloned tmlO gene in these clones (lane 1 and 2). Other fragment of size 
larger than 10 kb in these clones corresponds to linearized pJH10 in which it was 









































Figure 4.3 Bioassay to determine complementation by tmlO of the mupO single 
mutant of P. fluorescens NCIMB10586. (A) Bioassay plates showing clearing zones 
with (2 and 3) and without (1) induction by 0.5 mM of IPTG (B) Chart of quantitative 
bioassay (clearing zone measurements). WT, ΔmupO and ΔmupO(pJH10) strains of 
P. fluorescens NCIMB 10586 used as controls while ΔmupO(pMY2) was the test 
strain. Three replicates were used to collect data. Each bar represents the mean ± 
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Figure 4.4 HPLC analysis of extracts from strains of P. fluorescens NCIMB 
10586 for the complementation by tmlO of ΔmupO single mutant. Test strain 
ΔmupO(pMY2) did not produce PA-A both in the presence (C) or absence (B) of 0.5 
mM IPTG and instead produced PA-B only (retention time 18.4 min). Positive control 
















Figure 4.5 LC-MS chromatograms of extracts from strains of P. fluorescens 
NCIMB 10586 for the complementation by tmlO of ΔmupO single mutant. 
Neither of the three strains (A), (B) or (C) produced PA-A (retention time 20.4 min) 
despite induction by 0.5 mM IPTG but only PA-B (retention time 16.59 min) (done 
by Dr Song of University of Bristol, UK). (A) and (B), strains 10586ΔmupO(pMY2); 
(C), 10586ΔmupO(pJH10); LSU, light scattering units.  
 
4.2.2 Complementation by TmlC 
It can be observed from the results of plate bioassay (Figures 4.8A and 4.8B) that TmlC did 
not complement functions of its mup equivalent, MupC, when tmlC ORF was expressed in 
trans in the corresponding mutant strain Pseudomonas fluorescens NCIMB 10586ΔmupC.  
This was despite TmlC shared significant amino acid sequence identity with MupC protein 
(Fukuda et al., 2011). A global alignment of these two proteins is shown in Figure 4.6.  In 
TmlC complementation study the presence of tmlC ORF, in trans, decreased the clearing 
zones in bioassay plates almost to the same level when no insert was present in the expression 
vector used, which was suggestive of an active effect (Figure 4.8).  As a control, it could be 









expressed in trans, in the absence of IPTG in the growth medium which was in agreement 
with previous findings (Hothersall et al., 2007). LC-MS chromatograms of tmlC 
complementation showed peaks for the production of mupirocin C instead of that for PA-A 

















Figure 4.6 Global alignment of TmlC and MupC proteins using EMBOSS 
Needle(Rice et al., 2000). Default parameters for Needleman-Wunsch algorithm used 
(Needlema.Sb and Wunsch, 1970). Percent similarity between protein sequences 61.4%, 
which is identified, depending on the level of similarity as ‘:’ (more similar) and as ‘.’ less 









           
Figure 4.7 Confirmation of the tmlC insert in pMY14 expression vector. Double 
digest with KpnI-SacI yielded a fragment size of 1.14 kb that confirmed the presence 
of cloned tmlC gene all the 12 clones analysed (lane 1 to 12).  Other fragment of size 
larger than 10 kb in these lanes corresponds to linearized pJH10 in which it was 
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Figure 4.8 Bioassay to determine complementation by tmlC of the mupC single 
mutant of P. fluorescens NCIMB10586. (A) Bioassay plates showing clearing zones 
with (2) and without (1) induction by 0.5 mM of IPTG (B) Chart of quantitative 
bioassay (clearing zone measurements). WT, ΔmupC, ΔmupC(pJH10) and 
ΔmupC(mupC-pJH10) strains of P. fluorescens NCIMB 10586 used as controls while 
ΔmupC(pMY14) was the test strain. Three replicates were used to collect data. Each 
bar represents the mean ± standard error of the mean. 
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Figure 4.9 LC-MS chromatograms of extracts from strains of P. fluorescens 
NCIMB 10586 for the complementation by tmlC of ΔmupC single mutant. Test 
strains (A) and (B) did not produce and restore production of PA-A (retention time 
20.4 min), (C) and (D) were the two control strains (done by Dr Song of University of 
Bristol, UK). (A) and (B), strain 10586ΔmupC(pMY14); (C), 10586ΔmupC(pJH10); 
(D), 10586ΔmupC(mupC-pJH10); LSU, light scattering units. 
 
4.2.3 Complementation by TmlF 
From figures 4.12A and 4.12B that show results of plate bioassay, it can be observed that 
TmlF, similarly like TmlC, also did not complement function of its mup equivalent, MupF, 
when tmlF ORF was expressed in trans, in the corresponding single mutant strain 
Pseudomonas fluorescens NCIMB 10586ΔmupF.  This was despite TmlF shared significant 
amino acid sequence identity with MupF protein (Fukuda et al., 2011). Figure 4.10 gives 
global alignment of these two proteins.  LC-MS analysis of the supernatant from both the test 
strains confirmed non-complementation by TmlF as the chromatogram did not show peak 










Figure 4.10 Global alignment of TmlF and MupF proteins using EMBOSS. 
Needle(Rice et al., 2000). Default parameters for Needleman-Wunsch algorithm used 
(Needlema.Sb and Wunsch, 1970). Percent similarity between protein sequences 
52.7%, which is identified, depending on the level of similarity, as ‘:’ (more similar) 
































Figure 4.11 Confirmation of the tmlF insert in pMY12 expression vector.  Double 
digest with KpnI-SacI yielded a fragment size of 1.05 kb that confirmed the presence 
of cloned tmlF gene in all the 8 clones analysed (lane 1 to 8). Other fragment of size 
larger than 10 kb in these lanes corresponds to linearized pJH10 in which it was 
cloned. M, 1 kb ladder. 
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Figure 4.12 Bioassay to determine complementation by tmlF of the mupF single      
mutant of P. fluorescens NCIMB10586.(A) Bioassay plates induced by 0.5 mM of 
IPTG showing clearing zones (B) Chart of quantitative bioassay (clearing zone 
measurements). WT, ΔmupF and ΔmupF(mupF-pJH10), ΔmupF(pJH10) strains of P. 
fluorescens NCIMB10586 used as controls while ΔmupF(pMY12) was the test strain. 
Three replicates were used to collect data. Each bar represents the mean ± standard 
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Figure 4.13 LC-MS chromatograms of extracts from strains of P. fluorescens 
NCIMB 10586 for the complementation by tmlF of ΔmupF single mutant. Under 
similar conditions neither of the test strains (A) or (B) and control strain (C) produced 
PA-A (retention time 20.4 min) but test strains still produced mupirocin F (mw498) 
like NCIMB 10586ΔmupF strain (done by Dr Song of University of Bristol, UK). (A) 
and (B), strain 10586ΔmupF(pMY12); (C), 10586ΔmupF(pJH10); LSU, light 
scattering units. 
 
4.2.4  Complementation by TmlJ 
In case of complementation by TmlJ, observation of bioassay plates and the quantitative 
analysis that was displayed as bar diagram (Figures 4.16A and 4.16B) indicated that TmlJ 
complemented functions of MupJ only when in trans expression of tmlF ORF in the 
corresponding single knockout strain Pseudomonas fluorescens NCIMB 10586ΔmupF was 
induced by IPTG, supporting the in silico predictions which indicated that these proteins 
shared significant amino acid sequence identity (Fukuda et al., 2011).  A global alignment of 
these two proteins is given in Figure 4.14. In the absence of IPTG, there was no 
complementation (Figure 4.16).  Findings of bioassay were also supported by the results of 





of IPTG, displayed no peak in the chromatogram that was characteristic of pseudomonic 
acid-A (Figure 4.17).  Instead, additional peaks could be seen at the retention time 
characteristic of pseudomonic acid-A in the presence of IPTG (Figure 4.17).  Result was 










Figure 4.14 Global alignment of TmlJ and MupJ proteins using EMBOSS 
Needle(Rice et al., 2000). Default parameters for Needleman-Wunsch algorithm used 
(Needlema.Sb and Wunsch, 1970).  Percent similarity between protein sequences 
67.3%, which is identified, depending on the level of similarity, as ‘:’ (more similar) 





















Figure 4.15 Confirmation of the tmlJ insert in pMY18 expression vector. Double 
digest with KpnI and XbaI yielded a fragment size of 0.76 kb that confirmed the 
presence of cloned tmlJ gene in these clones. Other fragment of size larger than 10 kb 




































                                                                                                                    
Figure 4.16 Bioassay to determine complementation by tmlJ of the mupJ single 
mutant of P. fluorescens NCIMB 10586 (A) Bioassay plates induced by 0.5 mM of 
IPTG showing clearing zones (B) Chart of quantitative bioassay (clearing zone 
measurements). WT, ΔmupJ and ΔmupJ(mupJ-pJH10), ΔmupJ(pJH10) strains of P. 
fluorescens NCIMB 10586 used as controls while ΔmupJ(pMY18) was the test 
strain. Three replicates were used to collect data. Each bar represents the mean ± 
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Figure 4.17 HPLC analysis of extracts from strains of P. fluorescens NCIMB 
10586 for the complementation by tmlJ of ΔmupJ single mutant.Test strain 
NCIMB10586ΔmupJ(pMY18) complemented in the presence of IPTG and restored 
the peak characteristic of PA-A at retention time of 20.4 min (B), In the absence of 




































Figure 4.18 LC-MS chromatograms of extracts from strains of P. fluorescens 
NCIMB 10586 for the complementation by tmlJ of ΔmupJ single mutant. Test strains 
(A) and (B) restored the production of PA-A in the presence of IPTG (0.5 mM) while 
control strain (C) did not show any complementation (data by Dr Song of University of 
Bristol, UK). (A) and (B), 10586ΔmupJ(pMY18); (C), 10586ΔmupJ(pJH10); LSU, light 
scattering units. 
 
4.2.5 Complementation by TmlK 
Observation of bioassay plates and accompanying bar diagram indicated that there was no 
complementation of functions of MupK protein by TmlK upon in trans expression of tmlK 
ORF in the ΔmupK single mutant strain Pseudomonas fluorescens NCIMB 10586ΔmupK 
(Figure 4.22). This was despite MupK shared significant amino acid sequence identity with 
the N-terminal end of its TmpE protein (Figure 4.20) which represented putative enoyl-CoA 
hydratase similar to MupK (Fukuda et al., 2011).  Figure 4.19 gives global alignment of 
MupK protein with TmpE.  The mupK ORF cloned in pJH10 vector which was used as 
negative control also did not show any complementation as was reported earlier by Hothersall 








Figure 4.19 Global alignment of MupK with TmpE protein using EMBOSS 
Needle.(Rice et al., 2000). Default parameters for Needleman-Wunsch algorithm used 
(Needlema.Sb and Wunsch, 1970). MupK protein has 247 aa that aligns with the N-
terminal of TmpE protein of size 1444 aa, therefore alignment for only 1-700 aa from 
its N-terminal end is shown. Percent similarity between protein sequences 12.7%, 
which is identified, depending on the level of similarity, as ‘:’ (more similar) and as 























Figure 4.20 Local alignment of TmpE and MupK proteins using EMBOSS 
Water. (Rice, et al., 2000). Default parameters for Smith-Waterman algorithm used 
(Smith and Waterman, 1981). Percent similarity between protein sequences 75.9%, 
which is identified, depending on the level of similarity, as ‘:’ (more similar) and as 
‘.’ less similar, while identity is indicated as ‘|’. 
 
 
Figure 4.21 Confirmation of the tmlK insert in pMY16 expression vector.  Double 
digest with KpnI and XbaI yielded a fragment size of 0.749 kb that confirmed the 
presence of cloned tmlK gene in these clones. Other fragment larger than 10 kb 











































Figure 4.22 Bioassay to determine complementation by tmlK of the mupK single 
mutant of P. fluorescens NCIMB 10586. (A) Bioassay plates induced by 0.5 mM of 
IPTG showing clearing zones (B) Chart of quantitative bioassay (clearing zone 
measurements). WT, ΔmupK and ΔmupK(mupK-pJH10), ΔmupK(pJH10) strains of P. 
fluorescens NCIMB 10586 used as controls while ΔmupK(pMY16) was the test 
strain. Three replicates were used to collect data. Each bar represents the mean ± 
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4.2.6  Complementation by TmlQ                  
No complementation was shown by TmlQ as can be observed from bioassay plates and the 
accompanying quantitative analysis displayed as bar diagram (Figures 4.25A and 4.25B), 
when tmlQ ORF was expressed, in trans, in the corresponding single knockout strain 
Pseudomonas fluorescens NCIMB 10586ΔmupQ. This was despite the fact that the two 
proteins, TmlQ and MupQ, shared significant amino acid sequence identity (Fukuda et al., 
2011).  Figure 4.24 gives global alignment of these two proteins.  LC-MS  chromatogram 





Figure 4.23 Confirmation of the tmlQ insert in pMY6 expression vector.  Double 
digest with EcoRI and XbaI yielded a fragment size of 1.33 kb (lane 2, 10 and 14) that 
confirmed the presence of cloned tmlQ gene in these clones. Other fragment of size 
larger than 10 kb in these lanes corresponds to linearized pJH10 in which it was 







Figure 4.24 Global alignment of TmlQ and MupQ proteins using EMBOSS 
Needle(Rice et al., 2000). Default parameters for Needleman-Wunsch algorithm used 
(Needlema.Sb and Wunsch, 1970). Percent similarity between protein sequences 
64.3%, which is identified, depending on the level of similarity, as ‘:’ (more similar) 











































Figure 4.25 Bioassay to determine complementation by tmlQ of mupQ single 
mutant of P. fluorescens NCIMB 10586 (A) Bioassay plates induced by 0.5 mM of 
IPTG showing clearing zones (B) Chart of quantitative bioassay (clearing zone 
measurements). WT, ΔmupQ and ΔmupQ(pJH10) strains of P. fluorescens NCIMB 
10586 used as controls while ΔmupQ(pMY6) was the test strain. Three replicates 
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Figure 4.26 LC-MS chromatograms of extracts from strains of P. fluorescens 
NCIMB 10586 for the complementation by tmlQ of ΔmupQ single mutant. 
Neither of the two test strains (A) or (B) restored the production of PA-A (data by 
Dr Song of the University of Bristol, UK). (A) and (B) are test strains 
10586ΔmupQ(pMY6). LSU, light scattering units. 
 
4.2.7   Complementation by TmlS 
In case of TmlS complementation, inspection of bioassay plates followed by quantitative 
analysis displayed a bar-diagram (Figures 4.29A and 4.29B) as a result of in trans expression 
of tmlS ORF in the corresponding single knockout strain Pseudomonas fluorescens NCIMB 
10586ΔmupS, which indicated that TmlS partially complemented functions of MupS when 
IPTG was included in the culture medium.  The result was in agreement, to some extent, with 
the in silico predictions made on the basis of the fact that these proteins shared significant 
amino acid sequence identity (Fukuda et al., 2011). A global alignemnt of these two proteins 





MS that displayed partial restoration of the peak characteristic of pseudomonic acid-A in 
these chromatograms (Figures 4.30 and 4.31).  
 
             
  
Figure 4.27 Global alignment of TmlS and MupS proteins using EMBOSS 
Needle(Rice et al., 2000). Default parameters for Needleman-Wunsch algorithm used 
(Needlema.Sb and Wunsch, 1970). Percent similarity between protein sequences 
72%, which is identified, depending on the level of similarity, as ‘:’ (more similar) 




































Figure 4.28 Confirmation of the tmlS insert in pMY4 expression vector. Double 
digest with KpnI and XbaI yielded a fragment size of 0.725 kb that confirmed 
presence of cloned tmlS gene. Other fragment of size larger than 10 kb corresponds to 


















































Figure 4.29 Bioassay to determine complementation by tmlS of mupS single 
mutant of P. fluorescens NCIMB 10586 (A) Bioassay plates induced by 0.5 mM of 
IPTG showing clearing zones (B) Chart of quantitative bioassay (clearing zone 
measurements). WT, ΔmupS and ΔmupS(pJH10) strains of P. fluorescens NCIMB 
10586 used as controls while ΔmupS(pMY4) was the test strain. Three replicates were 
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Figure 4.30 HPLC analysis of extracts from strains of P. fluorescens NCIMB 
10586 for the complementation by tmlS of ΔmupS single mutant. (A) Test strain 
NCIMB 10586ΔmupS(pMY4) partially restored the production of PA-A in the 
presence IPTG (of 0.5 mM) (retention time 20.4 min), (B) Non-production of PA-A 
by control strain 10586ΔmupS (pJH10), (C) Non-production of PA-A by control 























Figure 4.31 LC-MS chromatograms of extracts from strains of P. fluorescens 
NCIMB 10586 for the complementation by tmlS of ΔmupS single mutant. Test 
strain C restored the production of PA-A only in the presence IPTG (of 0.5 mM) 
while both of the control strains A and B did not produce any PA-A (data by Dr Song 
of the University of Bristol, UK). A, B, and C are strains 10586ΔmupS, 
















4.2.8   Complementation by TacpD 
TacpD did not complement functions of MacpD protein which can be observed from 
bioassay plates and the accompanying quantitative analysis displayed as bar diagram (Figures 
4.33A and 4.33B) obtained as a result of in trans expression of tacpD ORF in the 
corresponding single knockout strain Pseudomonas fluorescens NCIMB 10586ΔtacpD.  This 
was despite the fact that both TacpD and MacpD proteins shared significant amino acid 
sequence identity (Fukuda et al., 2011).  Figure 4.32 gives a global alignment of these two 
proteins. LC-MS  chromatogram also displayed non-complemntation by TacpD of functions 










Figure 4.32 Global alignment of TacpD and MacpD proteins using EMBOSS 
Needle(Rice et al., 2000). Default parameters for Needleman-Wunsch algorithm used 
(Needlema.Sb and Wunsch, 1970). Percent similarity between protein sequences 
59.8%, which is identified, depending on the level of similarity, as ‘:’ (more similar) 
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Figure 4.33 Bioassay to determine complementation by tacpD of macpD single 
mutant of P. fluorescens NCIMB 10586 (A) Bioassay plates induced by 0.5 mM of 
IPTG showing clearing zones (B) Chart of quantitative bioassay (clearing zone 
measurements). WT, ΔmacpD and ΔmacpD(pJH10) strains of P. fluorescens NCIMB 
10586 used as controls while ΔmacpD(pMY8) was the test strain. Three replicates 
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Figure 4.34 LC-MS chromatograms of extracts from strains of P. fluorescens 
NCIMB 10586 for the complementation by tacpD of ΔmacpD single mutant. None 
of the test strains (A) or (B) or control strain (C) restored the production of PA-A 
despite induction by IPTG (0.5 mM) (data by Dr Song of the University of Bristol, 
UK). (A) and (B), 10586ΔmacpD(pMY8); (C), 10586ΔmacpD(pJH10); LSU, light 
scattering units. 
 
4.2.9 Complementation by TmpF 
Observation of bioassay plates and quantitative analysis that resulted into accompanying bar 
diagram (Figures 4.38A and 4.38B) obtained as a result of in trans expression of tmpF ORF 
in the corresponding single mutant strain Pseudomonas fluorescens NCIMB 10586ΔmmpF 
indicated that there was no complementation of functions of MmpF protein by TmpF. This 
was in disagreement with the in silico prediction made on the basis of the fact that these two 
proteins shared significant amino acid sequence identity (Fukuda et al., 2011). A global 
alignment of TmpF and MmpF proteins is given in Figure 4.35. Results of LC-MS also 















































Figure 4.35 Global alignment of TmpF and MmpF proteins using EMBOSS 
Needle(Rice et al., 2000). Default parameters for Needleman-Wunsch algorithm used 
(Needlema.Sb and Wunsch, 1970). Percent similarity between protein sequences 
57.8% which is identified, depending on the level of similarity, as ‘:’ (more similar) 






Figure 4.36 Confirmation of the tmpF insert in pMY10 expression vector.Double 
digest with EcoRI and XbaI yielded a fragment size of 2.4 kb that confirmed the 
presence of cloned tmpF gene in these clones. Other fragment larger of size than 10 















Figure 4.37 LC-MS chromatograms of extracts from strains of P. fluorescens 
NCIMB 10586 for the complementation by tmpF of ΔmmpF single mutant. Test 
strain (A) and control strain (B) did not show any complementation as there was no 
restoration of peak characteristic of PA-A (done by Dr Song of University of Bristol, 
UK). (A) and (B) are 10586ΔmmpF(pMY10) and 10586ΔmmpF(pJH10), 
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Figure 4.38 Bioassay to determine complementation by tmpF of mmpF single 
mutant of P. fluorescens NCIMB 10586. (A) Bioassay plates induced by 0.5 mM of 
IPTG showing clearing zones (B) Chart of quantitative bioassay (clearing zone 
measurements). WT, ΔmmpF and ΔmmpF(pJH10) strains of P. fluorescens NCIMB 
10586 used as controls while ΔmmpF(pMY10) was the test strain. Three replicates 
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Prior work by Fukuda et al. (2011) has shown that the two antibiotics mupirocin and 
thiomarinol share striking structural similarities, which were also reflected at the genetic level 
as the products of 27 ORFs of the thiomarinol cluster shared significant identity of amino 
acid sequence with their mup equivalents. The 22 ORFs out of these 27 belonged to the 
tailoring region genes that are extensively rearranged in these two clusters. By gene knockout 
and complementation studies, functions of most of the tailoring genes of mup cluster have 
been deduced (Hothersall et al., 2007). On the other hand, very little is known about tailoring 
functions of tml biosynthetic cluster. In view of this, in the present study it was planned to 
test whether these 22 ORFs from tml cluster can complement the functions of their mup 
equivalents in the mup system in vivo.  The idea behind was not just to test convergence and 
divergence of related proteins in these two distantly related systems but also to gather 
information about common biosynthetic steps/ intermediates, by way of protein–protein 
interactions, that might exist in these two systems which produce structures with striking 
similarities.  It has been reported that there is high probability of interaction between products 
of gene pairs that are conserved (Dandekar et al., 1998).  The common biosynthetic steps in 
these two systems can be used to create hybrid molecules with novel/ enhanced properties by 
reengineering these two biosynthetic pathways by using genetic components from either 
(combinatorial biosynthesis) and using the techniques of genetic engineering (Weissman and 
Leadlay, 2005). Genetic manipulation of tailoring region genes in the biosynthetic clusters 
has been a great source of getting novel molecules with improved activities (Rix et al., 2002, 
Olano et al., 2010).  
  Complementation by nine tailoring region genes could be tested. Results indicated that 
out of these nine, only two thiomarinol genes tmlS and tmlJ complemented functions of their 





remaining seven tml genes namely tmlO, tmlC, tmlF, tmlK, tmlQ, tacpD and tmpF did not 
show any complementation when these were expressed, in trans, in the corresponding mutant 
of mup system (NCIMB 10586). There could be several reasons behind non-complementation 
by tml genes that may range from common to specific for each of the concerned gene 
functions. Specific reasons for complementation/non-complementation are discussed 
separately. 
4.3.1 Common reasons behind complementation/ non-complementation by tml 
proteins in mup system for each complementation test 
In the first place, tml genes might not have been efficiently expressed by host machinery 
because these two organisms have significant differences in their GC content (12.8%).  This 
could have caused poor transcription by transcriptional machinery of mupirocin producer 
(Gustafsson et al., 2004, Thomas and Nielsen, 2005, Fukuda et al., 2011).  Even if these were 
expressed, the resulting proteins might be non-functional as these might have failed to fold 
properly in a different milieu in host cell that may have different physiological pH, salt 
concentration or temperature (Nilsson and Anderson, 1991).  This is because the natural 
habitats of both the organisms are very different (Shiozawa et al., 1993, Thomas et al., 2010). 
The two organisms have different optimum temperature for growth and nutritional 
requirements.  Moreover,  there could be problems with the expression  of cloned  gene itself 
as the control of tac promoter  of  pJH10 vector used in this study has been reported to be 
leaky (de Boer et al., 1983, El-Sayed et al., 2003, Cooper et al., 2005b). As a result, there 
could be basal level of expression of cloned genes in the absence of any induction, which in 
itself could have been varied for different genes. Therefore, in case of genes that required 
induction by IPTG for optimal expression of genes to show any complementation, these 
could have been induced to different levels with respect to different cloned genes which 





complementation where a protein could have been expressed at sub-optimal level than 
required for complementation (thus showed false non-complementation) in the presence of an 
amount of IPTG, which was sufficient enough for others to be expressed at levels that 
resulted in complementation.  It may also be possible that the concerned Tml protein 
modified metabolic intermediates altogether into a different intermediate that was not at all 
processed further in the metabolic pathway by downstream processing assembly line to result 
into bioactive molecule. Non-complementation might also be the result of minor differences 
in the structure of polyketide component of two molecules like 4-OH group is unique to 
thiomarinols while none of them have epoxide group which is present in the major forms of 
pseudomonic acids.  Also compared to pseudomonic acids, thiomarinols not only have an 
extra moiety present in them as pyrrothine but also the fatty acid component in these two 
systems differs by one carbon.  Owing to these apparent differences, concerned tml proteins 
might not have been able to process metabolic intermediates without 4-OH group or those 
with epoxide group, which is because the major pathway of pseudomonic acid production 
involves metabolic intermediates with epoxide group (Gao et al., 2014).  Non-
complementation might also be the result of differences in the genetic systems like presence 
of extra module in tmpB gene of tml cluster, presence of extra ACPs in the other modules of 
PKSs and complete absence of equivalent of macpE in the thiomarinol system which 
indicated that molecules might be differently processed in tml system than in mup system 
(Thomas et al., 2010, Fukuda et al., 2011, Gao et al., 2014, Murphy et al., 2014).  Non-
complementation might also be due to the lack of essential specific recognition motifs in tml 
proteins that are required by the components of mup system to process biosynthetic 
intermediates down through mup assembly line.  It has been shown that each of the two ACPs 
at the end of module 6 of mmpA in mup system has unique specific recognition motifs 





involved in 15 methyl β-branching in pseudomonic acids (Haines et al., 2013b).  Non-
complementation indicated that the molecules are processed differently; as a result, two 
pathways have different metabolic intermediates in the biosynthetic pathways, which require 
specific enzymes to process them in different stepwise order.  It is likely because of the 
presence of pyrrothine moiety in thiomarinols, concerned tml protein is involved in the 
processing of a completely different metabolic intermediate from what its mup equivalent 
processes in the mup system.  As a result, concerned tml protein completely failed to 
recognize the substrate of its mup equivalent so as to process the same.  And the similar 
situation might have caused because of the difference of one carbon in the fatty acid 
component of these two molecules. It may also be because the fatty acid component in 
thiomarinols is also in amide linkage with the pyrrothine moiety.  Therefore, it is highly 
likely the tml protein encountered a completely different substrate compared to what its mup 
equivalent processes in the mup system owing to the differences in the biosynthetic steps 
(Gao et al., 2014, Murphy et al., 2014). 
One of the main reasons for non-complementation could be what is indicated from the 
extensive rearrangement of tailoring genes in the two systems (Fukuda et al., 2011).  The 
rearrangement of genes indicates that the equivalent gene functions might be arranged 
differently in these two biosynthetic clusters under different operon organizations (Dandekar 
et al., 1998, Hothersall et al., 2007).  Consequently, the equivalent gene functions of these 
two systems might be under completely different regulatory controls whereby these are 
coregulated in a different manner along with the other genes of the concerned operon 
(Dandekar et al., 1998).  It has been reported from the study of trp operons in seven different 
prokaryotic genomes that the only gene pair that was conserved among them, was trpA-trpB 
gene pair, while other genes of this operon were present in them differently. For example, in 





of stretches of genome sequences or were oriented in opposite direction, while in others the 
two genes were present as fused with each other and which two genes were fused, were 
different in different genomes (Dandekar et al., 1998). The differences in the regulation of 
these two systems become apparent on account of location of their regulatory functions 
whereby mup cluster is found on chromosome while tml cluster is entirely located on a 
plasmid and very little is known about its regulatory aspects (El-Sayed et al., 2001, Fukuda et 
al., 2011).  On the other hand, the singular expression of a gene function out of its natural 
context might not have yielded a functional product, perhaps because it needed to be 
transcribed together with its neighbouring genes as part of the organizational requirements of 
concerned operon (Dandekar et al., 1998, Hothersall et al., 2007).  This also holds true for the 
expression of genes of the mup biosynthetic cluster of the mutants, in which tml genes were 
expressed in trans (Dandekar et al., 1998, Hothersall et al., 2007).  It may also be the 
situation that in the new context, in a heterologous system, a gene is expressed at a different 
level (Nishizaki et al., 2007, Lim et al., 2011).  As a result, it might be possible that the 
expressed protein was  produced in concentrations and at a rate that was either more or less 
than the optimum required, at which it could interact with other partner proteins in the 
biosynthetic pathway to exert its effect in a biochemical reaction, or may be for the same 
reason it failed to diffuse in proximity to its substrate (Hiroe et al., 2012).  This may be the 
case because it has been found that mupirocin biosynthesis involves several protein 
complexes and the concerned tml protein was not produced at the required level (Cooper et 
al., 2005b, Hothersall et al., 2007).  Similarly, some genes need to be transcribed together as 
a pair from the same m-RNA to yield a functional product which may be the case because the 
expressed polypeptides need to fold with each other to get into a conformation which only 
was functionally active (Dandekar et al., 1998, Hothersall et al., 2007).  It has been shown 





pathway as two of its free standing type II ACPs; MacpB and E could be converted to holo 
form only by mupirocin PPTase that is MupN (Shields et al., 2010).   Further studies with 
chimeric ACPs indicated their C-terminal end played critical role in protein-protein 
interactions (Shields et al., 2010, Haines et al., 2013b). 
 The common reasons behind complementation shown by two of the thiomarinol genes; 
tmlS and tmlJ of corresponding mup functions might be because of promiscuity of these 
enzymes (Khersonsky and Tawfik, 2010).  
4.3.2 Complementation by TmlO  
 There could be many specific reasons behind failure of complementation by TmlO.  In the 
first place, failure to complement could be because of different and stringent substrate 
specificity of this enzyme.  MupO has been predicted to be putative cytochrome P450 
monoxygenase with which TmlO shared 44% identity of amino acids (Thomas et al., 2010, 
Fukuda et al., 2011). A number of cytochrome P450 monoxygenases have been implicated in 
polyketide biosynthetic clusters with their roles in tailoring functions.  They are involved in 
electron transfer reactions. Knocking out these genes in biosynthetic clusters often resulted in 
the isolation of final biosynthetic product without a hydroxyl or epoxide group. For example, 
inactivation of cytochrome P450 monooxygenase, in amphotericin B biosynthetic pathway of 
S. nodosus, that inserts 8-OH group in the final molecule resulted in isolation of 8-deoxy 
amphotericin B molecule. While knocking out of AmphN another cytochrome P450   
monooxygenase in this pathway resulted in the isolation of amphotericin B derivative having 
unoxidized methyl group at C-16 position (Carmody et al., 2005).  Cytochrome P450 eryF of 
Saccharopolyspora erythreae is implicated in the C-6 hydroxylation of 6-deoxyerythronolide 
B in the biosynthesis of erythromycin (Weber et al., 1991).  Similar cytochrome P450 





(Mendes et al., 2001). A common feature of cytochrome P450 monoxygenases is that they 
require proteins to transfer electrons and therefore function as part of a multicomponent 
system (Urlacher et al., 2004).  In mup system, it is MupV which is predicted to possess    
NAD(P)H dependent reductase activity that works in association with MupO (Cooper et al., 
2005b).  Some atypical reactions are also catalysed by cytochrome P450 enzymes including 
dehydrations, reductions, isomerizations and dehydrogenations (Mansuy, 1998).  
In mupirocin and thiomarinol biosynthesis, the role that is predicted for MupO/TmlO, 
is hydroxylation of metabolic intermediates of the biosynthetic pathway. MupO is 
particularly involved in determining oxidation state around pyran ring in pseudomonic acids 
(Cooper et al., 2005b).   It has been shown by Gao et al., 2014, that modifications of the 
pyran ring occur after the elaboration of 9-hydroxynonanoic acid moiety on monic acid.  
Acyclic monic acid thioester that is first epoxidised and cyclised, on which elaboration of 
fatty acid takes place, is the putative substrate that is encountered for oxidation by MupO 
through MupU and MacpE, which is then dehydrated by MupV and thereafter reduced by the 
action of MupC and MupF, respectively, to yield PA-A. MupO is predicted to be specifically 
involved in the reduction at 7th carbon of monic acid, to reduce hydroxyl group to keto and is 
found to be essential for the production of pseudomonic acid A but not of pseudomonic acid 
B  (Thomas et al., 2010). 
It is highly likely that TmlO has a specific requirement for an extra hydroxyl group to 
be present at the fourth carbon of the metabolic intermediates to process the same, or it could 
not process an intermediate with 10-11 epoxide group, or it imparted its effect on a metabolic 
intermediate with altogether different number of carbons compared to MupO etc.  Moreover, 
it has been proposed in the biosynthesis of mupirocin that several tailoring proteins work 
together as part of auxiliary complex to make multiprotein complex which processes the 





another probability that TmlO might have failed to become part of this multiprotein complex.  
It has been proposed that these modifying reactions on biosynthetic intermediates take place 
when these are still tethered on mupirocin acyl carrier proteins (MacpE) (Thomas et al., 
2010).  Since TmlO could not become part of such biosynthetic complex of auxiliary proteins 
perhaps because of topographical reasons or owing to the fact that tml cluster lacks macpE, 
TmlO lacked certain key residues (that were present in MupO) that were necessary for it to 
collaborate with the biosynthetic complex of mup proteins (Fukuda et al., 2011). This way it 
could not access the substrate held by the ACP in the multiprotein complex to impart its 
effect.  Another probability is that TmlO might have failed to collaborate with MupV, with 
which it was required to work because of being an oxygenase it has the requirement to 
collaborate with proteins that can transfer electrons. 
 Reason behind reduced zones of clearance when IPTG was added to the medium 
could be interference in pseudomonic acids production by the TmlO protein, which might be 
inhibiting its production, probably by binding to any of the proteins involved in the 
biosynthetic pathway. Otherwise, in mup system MupO has been reported to complement 
when it was expressed in trans using the same vector and complementation was better when 
IPTG was included in growth medium (Cooper et al., 2005b).   
4.3.3 Complementation by TmlC 
MupC enzyme of mupirocin biosynthetic cluster is predicted to be a dienoyl-CoA reductase 
(an oxido-reducatse) (Hothersall et al., 2007, Gao et al., 2014).  The TmlC, product of tmlC 
ORF in the tailoring region of thimarinol cluster is also predicted to be  an oxidoreductase 
with which MupC shared 56% amino acid sequence identity (Fukuda et al., 2011, Thomas et 
al., 2010).  In vivo complementation of ΔmupC mutant by in trans expression of mupC ORF 





reduction that occurred in its production by the ΔmupC mutant (Cooper et al., 2005b).  As a 
result of  gene knockout and complementation studies of several other ORFs of the tailoring 
region of mup cluster, it has been predicted that MupC acts as enone reductase and is 
involved in the reduction of enol ketones metabolic intermediates in the biosynthetic pathway 
that resulted in the production of pseudomonic acid-A (Hothersall et al., 2007). Functional 
activity like that of mupC is also reported from Clostridium sp. which showed high homology 
with dienoyl-CoA reductases (Rohdich et al., 2001).  
 
As per the putative biosynthetic pathway that has been suggested,  MupC  acts after 
the  action of MupV- an oxidoreductase, that reduces the hydroxyl group present at C-8  of 
the metabolic intermediate in the pathway into a double bond, and this metabolic intermediate  
becomes  substrate for the action of  MupC (Thomas et al., 2010). All the tailoring 
modifications by mupO, V, C and F are done while the metabolic intermediate is tethered at 
macpE/15 (Thomas et al., 2010).  It has been predicted that all these enzymes function 
together as part of complex of auxillary enzymes that function as multiprotein complex to 
modify the substrate attached to it (Hothersall et al., 2007). TmlC,  like TmlO might have  
failed to become part of this multiprotein complex of several enzymes acting together.  
Perhaps this is because of  some key residues which other mup proteins  might be having,  by 
virtue of which these could become part of such complex to interact with MacpE, were 
missing  from TmlC.  Moreover, for TmlC which is a putative NADH: flavin oxidoreductase,  
either it failed to recognize the substrate-metabolic intermediate- of MupC which is putative  
dienoyl-CoA reductase   in the  mup pathway or  modified the substrate in a way such that it 
blocked the pathway i.e. created metabolite that is no more substrate  for the action of 





product that no longer had biological activity. While other general reasons explained under 
section 4.3.1 might also be responsible for non-complementation by TmlC.        
4.3.4 Complementation by TmlF 
It has been shown that MupF complemented the ΔmupF mutant strain when expressed in 
trans, cloned in the same IncQ vector which was used for complementation study by in trans 
expression of tmlF (Hothersall et al., 2007).  Production of PA-A was restored to wild type 
level on in trans expression of mupF from less than 2% production by ΔmupF mutant 
(Cooper et al., 2005b, Hothersall et al., 2007). By gene knockout  and complementation 
studies MupF is predicted to be specifically involved in the reduction of keto group present at 
the 7th carbon of the metabolic intermediate in the  biosynthesis of pseudomonic acid-A.  In 
the biosynthetic pathway that is proposed, MupF is predicted to act immediately after the 
action of MupC (Thomas et al., 2010, Gao et al., 2014).  By in silico studies MupF is 
predicted to be ketoreductase (Hothersall et al., 2007).  TmlF, the product of tmlF ORF in the 
tailoring region of thiomarinol cluster shared 34% of identity of amino acids with MupF and 
is also predicted to be a ketoreductase (Hothersall et al., 2007, Fukuda et al., 2011). Possible 
reasons for non-complementation by TmlF might be similar to those for TmlO and TmlC, 
because in mup system all these genes have been proposed to function together as part of 
multiprotein complex (Hothersall et al., 2007).  As was expected in case of TmlO and TmlC, 
TmlF also lacked certain residues which MupF possessed and which were critical for TmlF to 
become part of this multiprotein complex of tailoring genes tethered on MacpE of mup 
system (Figure 1.26).  It might be possible that owing to its high specificity, TmlF completely 
failed to recognize substrate, the metabolic intermediate in mup biosynthetic pathway, that 





homologue in thiomarinols clearly indicated that TmlF processed a completely different 
biosynthetic intermediate than what MupF processed.    
4.3.5 Complementation by TmlJ and TmlK 
  TmlJ complemented the functions in ΔmupJ mutant strain  and restored the production of 
PA-A while TmlK did not show complementation in ΔmupK  mutant and did not restore 
pseudomonic acid production. Both mupJ and mupK mutants show drastically reduced 
production of pseudomonic acids (Hothersall et al., 2007).  These findings are contrary to the 
fact that either mupJ or mupK completely failed to complement when these were expressed 
singularly, in trans, cloned in the same expression vector, which was used for tmlJ or tmlK 
expression under the same growth medium and other conditions in the corresponding mup 
single mutants.  Thas was inspite of induction of their expression by IPTG (Hothersall et al., 
2007).   
Complementation by mupJ or mupK could only be achieved in ΔmupJ mutant when 
both these ORFs were expressed together in trans under a single promoter and transcribed as 
single m-RNA. While insignificant complementation was reported to be achieved when same 
construct was expressed in trans in ΔmupK mutant. Complementation, close to wild type 
levels, could only be achieved when this construct was expressed in trans in the double 
mutant ΔmupJK (Hothersall et al., 2007).  The requirement of expression of both these ORFs 
together to achieve complementation was explained on account of the organization of the 
concerned operon and as a requirement for the correct folding of these two proteins so as to 
make them functional (Hothersall et al., 2007). Decrease in complementation in ΔmupJ 
mutant by mupJ and no complementation in ΔmupK mutant by mupK had been explained, 





non-functional polypeptide by the mup cluster which interfered with the MupJ-MupK protein 
that was expressed in trans from the vector (Hothersall et al., 2007).     
In silico studies have shown that mupJ and mupK are two discrete ORFs in the 
tailoring region of the mupirocin gene cluster with other several genes.  Biochemically, MupJ 
and MupK are predicted to be enoyl-CoA hydratases of the type belonging to crotonase 
superfamilies that are involved in β-oxidation of fatty acids (Hothersall et al., 2007).  
Bioinformatics search have revealed many genes related to mupJ and mupK, the products of 
which have similar or related biochemical function as enoyl-CoA hydratases. One such pair 
of homologous proteins is PksH and PksI of B. subtilis subsp. subtilis str.168 which is present 
within the polyketide biosynthesis cluster and this pair shows highest homology with these 
mup proteins (Albertini et al., 1995).  Though exact roles of these two enoyl-CoA hydratases 
in mupirocin biosynthetic pathway are not deduced till date but bioinformatics analysis 
revealed that MupK homologues, PksH (60.4% identity), Tay (57.8%) and CurF ECH2 
(31.6%) in bacillaene, myxovirescin and curacin biosynthetic clusters, respectively, all 
catalyse decarboxylation in vitro (Hothersall et al., 2007). While MupJ homologues in the 
same clusters, PksI (49.6% identity), Tax (51.1%) and CurE ECH1 (37.6%) have been shown 
to catalyse dehydration (Gu et al., 2006, Calderone et al., 2006, Calderone et al., 2007).  In 
mupirocin biosynthetic pathway both these enzymes are predicted to act along with the 
products of other tailoring region genes mupG, mupH and macpC in the incorporation of C-
15 methyl group (Hothersall et al., 2007) at C-3 of the mupirocin polyketide moiety 
(Hothersall et al., 2007, Thomas et al., 2010, Haines et al., 2013a). In the putative 
biosynthetic pathway that is proposed for β-branching, MupJ acts before MupK as 
dehydratase and subsequently MupK decarboxylates the product (Figure 4.39) (Hothersall et 











Figure 4.39 Scheme predicted for incorporation of C-15 methyl group by MupJ 
and MupK acting along with other proteins(Adapted from Hothersall et al., 2007). 
 
 
  TmlJ that showed 49% amino acid sequence identity with MupJ, is also predicted to be 
enoyl-CoA hydratase while homologue of MupK is not present in the tml cluster.  Instead, the 
N-terminal end of TmpE, which is a multifunctional protein, aligned with MupK sequence 
and is predicted to have enoyl-CoA hydrates activity.  These two proteins share 40% identity 
of amino acid sequence between them (Fukuda et al., 2011).  
  Restoration of PA-A production by tmlJ in the single mutant ΔmupJ clearly indicated 
that its product could actively fold itself on its own so as to be functional in the mup system. 
As a result, it could process the concerned metabolic intermediate  in the mup biosynthetic 
pathway, acting along with all the member proteins encoded by HCS cassette, such that it 
was processed by the downstream functions of the assembly line. TmlJ dehydrated the 
concerned metabolic intermediate in the proposed pathway before decarboxylation by MupK.  
It has been shown in the mup system that each of the ACPs at the end of sixth module of 
mmpA has unique recognition motif specific for their interaction with the HCS cassette 
proteins that are involved in β-branching (Haines et al., 2013a).  It clearly appears that TmlJ 
could collaborate with these unique motifs of the mup assembly line while TmlK might have 
failed to collaborate. Though the complementation by tmlJ was dependent on induction by 
IPTG indicating that higher than basal level of enzymatic protein was required to bring about 





non-interference in its action by MupK which in case of complementation by mupJ, 
interfered  with the expression/action of MupJ thus lowered the degree of complementation. 
  Primary reasons behind non-complementation of the single ΔmupK mutant by TmlK 
protein could be because of its failure to fold  so as to become functional enzyme.  Which is 
because in tml system this hydratase activity exists only as part of a multifunctional protein 
TmpE that includes ketosynthase activity as well.  Therefore, in the first place, expression of 
a part of this multifunctional protein, that is predicted to have enoyl-CoA hydratase activity 
might not have resulted into a functional protein having activity when expressed alone cloned 
in a vector. Which is because it might have required its cognate partner sequence of the tml 
multifunctional protein, to which it originally belonged, in order to fold properly so as to 
retain its enzymatic activity. While there could be any other reasons behind non-
complementation that are discussed above under section 4.3.1.  Presence of this second 
hydratase activity in the tml cluster fused with multifunctional protein and the requirement of 
mup system to express both the hydratases (MupJ and MupK) together to achieve 
complementation, clearly indicated differences in the genetic organization of these two 
systems, which might result into differences in the biosynthetic steps leading to β-branching 
in these two systems.  tml system also has HCS cassette similar to the one found in mup 
system with each of its member proteins which shares significant amino acid sequence 
identity with the corresponding members of mup system.   
4.3.6 Complementation by TmlS  
Results of TmlS complementation indicated that it complemented the functions of MupS 
upon expression of tmlS ORF, in trans, in the ΔmupS mutant and partially restored the 
production of PA-A.  In silico studies have predicted that proteins like TmlS and MupS, 





genes as a group and are implicated in furnishing starter/primer unit for the biosynthesis of 
fatty acids in those biosynthetic systems.  This is supported by the genetic evidence because 
genes for all these proteins that act in a group are found located together in the biosynthetic 
gene cluster.  In mupirocin cluster, mupS (3-oxo acyl carrier protein reductase) is located 
together with mmpF (decarboxylase and ketosynthase), macpD (acyl carrier protein) and 
mupQ (acyl-CoA synthase). On the basis of bioinformatics studies, product of genes like 
mupS, mupQ and macpD are predicted to act together and are implicated in furnishing the 
starter/primer unit for the biosynthesis of the fatty acid component of  pseudomonic acids ( 9-
HN) by mmpB  with the help of associated ACPs (Thomas et al., 2010).  These aspects of 
concerned mup proteins are also supported by the existence of genes for a similar group of 
proteins in other similar trans AT systems like difficidin polyketide system of Bacillus 
amyloliquifaciens in which these are found located together as in mup cluster, indicating that 
these groups of proteins act together.  In difficidin biosynthetic cluster diffE, diffD and diffC 
genes are located together which code for reductase, acyl-CoA synthase and acyl carrier 
protein, respectively.  All of these proteins are predicted to act together with the product of 
another gene diffB (a kinase) located with them to dehydrate 3-hydroxypropionate to derive 
acryl thiol ester which acts as priming unit for the chain elongation in difficidin biosynthesis 
(Chen et al., 2006).  Similarly, proteins encoded by tml cluster namely TmlS, TmlQ, TmpF 
and TacpD each of which share significant amino acid sequence identity with the 
corresponding mup proteins, are also found located together in tml cluster (Fukuda et al., 
2011). As discussed in section 4.3.1, it has been reported that conservation of gene 
pairs/clustering across different systems suggested that the concerned proteins are interacting 
(Dandekar et al., 1998).  Based on these evidences, in tml biosynthetic system this group of 
tml proteins is also predicted to act together in furnishing starter/primer unit for the 





TmpB and associated ACPs.  Apart from other evidences, the mutagenesis studies in which 
knockout or inactivation of any of these genes namely MupS, MupQ, MmpF and MacpD 
proteins resulted into similar phenotype of producing mupiric acid and mupirocin H with 
complete loss in the production of pseudomonic acids, also support that this group of proteins 
functions together (Hothersall et al., 2007, Wu et al., 2008). 
  It has been reported that knockout of mupS could be complemented by in trans expression 
of mupS ORF cloned in an IncQ expression vector (Cooper et al., 2005b).  Therefore, the 
partial complementation of mupS function by TmlS in the ΔmupS mutant under expression 
from same IncQ vector under same growth conditions indicated that these two enzymes 
shared substrate specificities of certain substrates found in both these biosynthetic pathways.  
Complementation indicated that up to the step where substrates could be processed by both 
these enzymes, either two biosynthetic pathways being similar or that the similar substrate 
existed in these pathways which might have other totally different biosynthetic steps.  Since 
TmlS, also a 3-oxo acyl carrier protein reductase, could only partially restore production of 
pseudomonic acid A, this indicated that it could only partially catalyse the reaction in the mup 
biosynthetic pathway to modify the substrate of MupS such that it could be loaded onto 
concerned acyl carrier protein (MacpD) (Figure 1.25). 
While there could be other reasons behind the functional complementation shown by 
TmlS particularly in view of the fact that complementation was only partial indicating that it 
might have been because of the substrate promiscuity shown by TmlS (Khersonsky and 
Tawfik, 2010) as pointed out in section 4.7.1. 
4.3.7 Complementation by TmlQ 
In view of the reported finding that mupQ could complement when expressed in trans, cloned 





in the ΔmupQ mutant of NCIMB 10586,  it could be concluded that TmlQ did not 
complement. Despite sharing significant (46%) amino acid sequence identity with MupQ, 
TmlQ completely failed to act upon the substrate of MupQ in the mup system to produce its 
CoA (Cooper et al., 2005b, Thomas et al., 2010).  Non-complementation, therefore, indicated 
that there has been divergence in the function of these two proteins during evolution.  Non-
complementation specifically indicated that each of these proteins have high specificity for 
their respective substrates (concerned metabolic intermediates) in the respective biosynthetic 
pathways, which probably used different starter units for priming the biosynthesis of their 
fatty acid moieties on account of what is discussed in section 4.3.7 above. While non-
complementation might also be due to other reasons explained above under section 4.3.1. 
4.3.8 Complementation by TacpD 
Results indicated that TacpD did not complement the functions of MacpD in ΔmacpD 
mutants. In trans expression of macpD cloned in the same expression vector (IncQ), as was 
used for tacpD expression, is already reported to have complemented ΔmacpD mutants 
(Hothersall et al., 2007).  In this view, non-complementation by TacpD clearly indicated that 
it failed to recognize substrates that were processed by MacpD protein of the mup 
biosynthetic pathway and that TacpD/MacpD had very high specificity for their specific 
substrates.  This was despite both these proteins are putative acyl carrier proteins that shared 
46% amino acid sequence identity between them which is significant. Non-complementation, 
therefore, indicated that there is divergence in the functions of these proteins during evolution 
and in view of what is discussed above under section 4.3.7 that different priming unit is 
utilized by mup system for the biosynthesis of its fatty acid component (9-HN moiety) from 
that of tml system that has 8-HO (Thomas et al., 2010, Fukuda et al., 2011). Other reasons 





4.3.9 Complementation by TmpF 
TmpF did not complement mutant of mmpF and did not restore the production of PA-A. It 
has been shown by mutating active site of mmpF (C183A) that this gene is necessary for the 
production of mupirocin (Hothersall et al., 2007). This mutation in mmpF could be 
complemented by the in trans expression of the mmpF ORF cloned in IncQ plasmid pJH10 
that was used in this study (Hothersall et al., 2007).  Since deletion of any of the genes of the 
mup cluster so far has completely failed to produce a mutant that either produced monic acid 
or 9-hydroxynonanoic, this has indicated that biosynthesis of pseudomonic acids is a single 
assembly line integrated process (Thomas et al., 2010).  This is also supported by the findings 
of refeeding experiments done by Gao et al., 2014.  Thus, MmpF has a definite role to play in 
this integrated biosynthesis of pseudomonic acids. TmpF and MmpF both are predicted to be 
ketosynthases which share amino acid sequence identity of 43% which is significant.  Though 
specific role could still not be proposed for MmpF in the mup biosynthetic pathway yet based 
on its proximity to mupS, mupQ and macpD in the mup cluster that are predicted to play role 
in furnishing primer unit for the biosynthesis of fatty acid moiety (9-HN) and, on the basis of 
in silico studies pointed out above under section 4.3.6., MmpF is also predicted to be 
involved in furnishing this starter unit in the mup system. The mmpF might be present with 
these group of genes like as diffB is present in difficidin gene cluster to play a role by 
collaborating with the products of other genes of this cluster in furnishing the starter unit (see 
section 4.3.6). Non-complementation of MmpF functions by TmpF, in the first place clearly 
indicated that these two proteins despite sharing significant amino acid sequence identity 
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 As described in Chapter 4, some tml genes were found to complement to their 
corresponding mup knockout mutants but this tended to be the exception rather than the rule. 
One reason for lack of complementation could be the need to interact with partner proteins 
and it may be that at least some of the protein-protein interactions have diverged sufficiently 
between the mup and tml systems that function complexes are no longer able to form.  The 
first example of likely protein-protein interaction in the mup system is the mupD-E pair 
where it has been shown that these two genes need to be expressed together to complement a 
mutation in either gene.  Also an active site point mutation in mupD had no effect on PA-A 
production while an in-frame deletion abolished production, suggesting that MupD now acted 
as chaperone for MupE (Hothersall et al., 2007).    
   Similarly, as described in Chapter 4 (section 4.3.5), complementation of MupJ and 
MupK proteins could only be achieved to wild type levels when these were expressed 
together as part of single m-RNA cloned in the pJH10 expression vector in the double mutant 
ΔmupJ and ΔmupK of Pseudomonas fluorecsens NCIMB10586.  These two proteins are 
implicated in 15 methyl β-branching in mupirocin biosynthesis acting together with the 
products of several other genes as part of “β-hydroxymethylglutarylCo-A synthase” known as 
HCS cassette (Hothersall et al., 2007).       
            In both the above examples, expression of single genes of the pair when expressed 
separately from each other resulted in the production of non-functional elements which in 
turn interfered with the expression of other partners.  As a result, complementation by either 





The other aspect of complementing group of related genes whose products are 
predicted to work together becomes clear by the cross-complementation studies done about  
group of genes that are proposed to be involved in pyran ring formation in these two 
biosynthetic systems (Hothersall, unpublished studies, 2014). These studies gives broader 
understanding of protein-protein interactions taking place between groups of proteins that are 
predicted to work together in the mupirocin and thiomarinol biosynthetic system.  It was 
shown that cross-complementation by tml genes; TmlW and TmlT was close to wild type 
levels when both these ORFs were expressed together, in trans, as a single mRNA cloned in 
an expression vector in the double mutant ΔmupT and ΔmupW of Pseudomonas fluorecsens 
NCIMB10586 compared to when these were expressed singularly in the corresponding single 
mutant.  The mupW and mupT encode a putative dioxygenase and related ferredoxin 
dioxygenase, respectively, and both have been implicated in the closure of tetrahydropyran 
ring (THP) in pseudomonic acid molecules.  Mutation of either of these resulted in the 
isolation of similar compounds named as pseudomonic acid W, which was characterized by 
having an open pyran ring (Cooper et al., 2005a, Gao et al., 2014).   This indicated that 
products of both these genes were required for oxidative closure of THP.  TmlW and TmlT 
are also predicted to be putative dioxygenase and associated ferredoxin dioxygenase like their 
mup counter parts MupW and MupT, with which they share significant amino acid sequence 
identity of 56% and 39%, respectively (Fukuda et al., 2011).  Similarly, tetrahydropyran ring 
(THP) as it is found in pseudomonic acids, is also present in thiomarinols with minor 
differences in side groups (Thomas et al., 2010).   
Considering other groups of tailoring genes, whose products are predicted to work 
together and whose analysis would be useful, led to the group of genes proposed to be 
involved in  production of the starter unit for 9-HN namely mupQ, macpD, mupS and mmpF  





involved in furnishing priming unit for 8-HO biosynthesis namely tmlS, tmlQ, tacpD and 
tmpF in thiomarinol biosynthetic cluster (Feline et al., 1977, Piel, 2010, Murphy et al., 2014, 
Helfrich and Piel, 2016).  In silico studies described in Chapter 4 (section 4.3.6), have 
predicted that proteins from such group of genes which existed together in  biosynthetic 
clusters, were also found to work together.  Studies about conserved gene-pairs/clustering, 
that are conserved as part of operon architecture across different prokaryotic systems, also 
suggested that protein products of such gene pairs interact physically (Dandekar et al., 1998).  
Considering these facts, cross-complementation study of this group of genes between both 
the biosynthetic clusters was planned to study interaction of proteins as a group between the 
two systems.  
The results of cross-complementation studies for singular genes of this group showed 
that TmlS could interact with the other mup proteins of this group such that it partially 
restored the production of pseudomonic acid-A in the corresponding mutant strain 
Pseudomonas fluorecsens NCIMB 10586ΔmupS (see section 4.3.6).  TmlS and MupS are 
both predicted to be reductases that share 62% amino acid sequence identity which is very 
significant (Figure 4.27). Partial complementation of functions of MupS by TmlS indicated 
that to some extent there has been functional conservation of concerned protein-protein 
interactions in the two proteins. Though the results of singular cross-complementation of the 
remaining three genes of this group namely tmpF, tmlQ and tacpD have been negative 
despite product of each of them also shared significant amino acid sequence identity with the 
corresponding mup protein (Chapter 4 section 4.3.7-10) (Figures 4.24, 4.32 and 4.35).  In this 
study, above explained approach of complementation of group of genes was extended to find 
whether extra complementation could be achieved by expressing the four thiomarinol genes 
(tacpD, tmlS, tmlQ and tmpF) together in the Pseudomonas fluorecsens NCIMB10586 with 







5.2.1 Construction of P. fluorescens NCIMB 10586 mutant strain with defined 
chromosomal deletion of macpD, mupS, mupQ and mmpF (quadruple 
mutant)  
 To create in-frame chromosomal deletion of four genes, strategy mentioned in 
Chapter 2 (section 2.4.14) was followed (Figure 5.2).   Accordingly, sequences of around 500 
base pairs were identified on the chromosome in the mup cluster that overlapped with the 
ends of the region that contained mupQ and mmpF.  Sets of primers given in Table 2.11 were 
designed to amplify these arms.  An upstream arm of 547 bp was amplified using primers 
QDA1F and QDA1R that incorporated EcoRI and XbaI sites, respectively, to facilitate its 
cloning into the suicide vector pAKE604 and ligation with the downstream arm.  Similarly, 
downstream arm of size 504 bp was amplified using primers QDA2F and QDA2R that 
incorporated restriction sites XbaI and BamHI, respectively.  QD in the name of primers 
indicated that they were developed for the deletion of a block of four concerned genes from 
the chromosome of Pseudomonas fluorescens NCIMB 10586 while numbers 1 and 2 
indicated that these were meant to amplify upstream and downstream arms, respectively.  The 
letter F and R in primer names represented forward and reverse primers, respectively.  The 
amplified arms were cloned into pGEM-T Easy vector after A-tailing as per method 
mentioned in Chapter 2 (section 2.4.8) to yield vectors pMY19 and pMY20 in which 
upstream and downstream arms were cloned, respectively (Table 2.7).  After sequencing 
using universal primers, to confirm that the sequence of these arms was correct, these 
fragments were cloned into suicide vector pAKE604 using restriction sites EcoRI, XbaI and 
BamHI by three way ligation as a fragment of 1051 bp to yield suicide vector pMY21 (Table 





  The constructed suicide vector pMY21 was transformed into E. coli S17-1 cells and 
purified transformants were then used to mobilize it into wild type Pseudomonas fluorescens 
NCIMB 10586 strain as per methods described in Chapter 2 (section 2.4.13).  In this way 
homologous recombination was promoted to take place that resulted in the insertion of 
suicide vector into the chromosome of wild type P. fluorescens NCIMB 10586.  The resulting 
putative integrants were purified by restreaking to single colonies to remove any bacteria that 
had not received the suicide plasmid.  Purified strains were then grown without selection and 
then spread on L agar sucrose plates to isolate sucrose resistant bacteria and colonies were 
tested for the loss of kanamycin resistance.  Kanamycin sensitive clones were screened for 
deletion of the target region by PCR reaction in which plasmid pMY21 was used as positive 
control while wild type Pseudomonas fluorescens NCIMB 10586 strain was used as negative 
control (Figure 5.3).  Out of 22 colonies tested this way for the desired mutation, twelve 




















































Figure 5.1 Map of suicide vector pMY21 constructed from pAKE604 for the 
deletion of a block of four mup genes; mupS, mupQ, macpD and mmpF in the 

































Figure 5.2 Construction for the deletion of quadruple genes mupQ, mupS, macpD 
and mmpF in the chromosome of P. fluorescens NCIMB 10586. 
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Figure 5.3 The result of PCR to check potential chromosomal mutants of 
NCIMB 10586 for the deletion of fragment containing mupQ, mupS, macpD and 
mmpF. Top and bottom lanes from left: M, 1 kb marker ladder; lane 1 and 3, WT 
NCIMB 10586; lane 17 and 27, positive control; lane 18, negative control. Out of 
total 22 clones analysed 12 confirmed to be mutants; lane 2, 4, 5, 6, 8, 9, 10, 14, 15, 
















5.2.2  Construction of expression vector carrying tmlQ, tmlS, tacpD and tmpF 
(quadruple expression vector)  
For cross-complementation analysis of group of thiomarinol genes in the constructed 
mutant strain of Pseudomonas fluorescens NCIMB 10586ΔmmpFΔmupSΔmupQΔmacpD 
(quadruple mutant), an expression plasmid was constructed to express all the four 
corresponding genes of thiomarinol cluster (tacpD, tmlQ, tmlS and tmpF) cloned under tac 
promoter in broad host range vector pJH10 (Figure 2.4)(El-Sayed et al., 2003).  To create 
plasmid expressing four thiomarinol genes, three of these namely tacpD, tmlQ and tmlS were 
PCR amplified as a fragment of 2.2 kb.  Primers were designed to amplify this fragment that 
incorporated restriction sites XbaI and SacI (Table 2.11). The fragment was amplified using 
VelocityTM DNA polymerase as described in Chapter 2 (section 2.3.2). A good yield of 
product of expected size was obtained at annealing temperature of 54 oC.  The ORF for the 
fourth gene of this group, tmpF was used from the vector pMY10 that was constructed for the 
previous study on singular complementation (Chapter 4, Table 2.6).   
PCR amplified fragment was A-tailed and cloned into pGEM-T Easy vector to give 5.21 
kb plasmid, pMY22, which was subjected for sequencing of the cloned fragment.  It is worth 
mentioning that in view of the large size of the cloned fragment (2.2 kb), internal primers 
have to be designed and used to confirm integrity of its sequence (Table 2.11). Finally, 
cloning of PCR fragment from pMY22 clones that showed no mismatch, was attempted in 
pMY10 vector at sites XbaI and SacI using restriction digestion/ligation as described in 
Chapter 2 (sections 2.4.5 and 2.4.9).  Plasmid pMY10 of 15.99 kb which was derived from 
pJH10 vector, had the tmpF ORF cloned into it as an EcoRI-XbaI fragment under the control 
of tac promoter (Table 2.6). After the failure of repeated attempts made to clone fragment 
from pMY22 carrying three tml genes into pMY10 by restriction digestion/ligation as double 





site for cloning, was used.  As per this strategy, plasmids pMY22 and pMY10 were digested 
with XbaI and ligated to give cointegrate pMY23 that had these two plasmids ligated through 
XbaI site.  This cointegrate was transformed into E. coli C2110 (polA1-) competent cells.  
Transformants that showed resistance to ampicillin were selected confirming success of 
ligation and existence of cointegrate because resistance to ampicillin could only be conferred 
by an intact cointegrate, which was because pMY22 itself could not replicate in this strain of 
E. coli, and expression of its ORF that conferred resistance to ampicillin was driven by the 
tac promoter of pMY10, which was possible only if both these plasmids were present as 
cointegrate. Clones of transformant colonies were analysed to get the clone of cointegrate in 
which the two plasmids were joined together in the desired orientation.  That was the clone in 
which the fragment carrying ORFs of three tml genes in pMY22 was ligated at the end of the 
tmpF ORF of pMY10 vector through the XbaI site.  Out of eight clones analysed by EcoRI 









































Figure 5.4 Map of expression vector pMY23 used for in trans expression of Tml 
proteins; TmlS, TmlQ, TacpD and TmpF in NCIMB 10586.Plasmid pMY23 
constructed as a cointegrate by ligating  pMY10 (another expression vector) with 
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 Figure 5.5 Confirmation of the correct orientation of genes in the constructed 
expression vector pMY23.Created by ligating vectors pMY10 and pMY22 through 
their XbaI sites (A) Top gel EcoRI digestion. No band of 2.4 kb could be seen in any 
of the clones and presence of a band of 4.7 kb in all of the six clones out of 10 
analysed confirmed that they had genes in the correct orientation in the cointegrate. 
(B) Bottom gel EcoRI and SacI double digestion. Correct pMY10 clones used were 
again confirmed by double digestion. Clones in lane 2 and 9 of upper and lower gel 





















Figure 5.6 Schematic presentation of two of the possible orientations of tml genes 
in the expression vector pMY23, a cointegrate created by ligating vectors pMY10 
and pMY22 through their XbaI restriction sites. The desirable orientation was 
orientation I (figures not to scale). 
 
5.2.3 Complementation analysis of constructed P. fluorescens NCIMB10586 
ΔmmpFΔmupSΔmupQΔmacpD strain 
To transfer the constructed vector pMY23, that should express the four chosen 
thiomarinol genes, into the mutant strain to test complementation it was transformed into E. 
coli S17-1 strain.  Purified single colonies were used to mobilize this vector into the mutant 
of P. fluorescens NCIMB 10586ΔmmpFΔmupSΔmupQΔmacpD (quadruple mutant), by 
conjugating the two strains together as per methodology described in Chapter 2 (section 
2.4.14). The resulting strain Pseudomonas fluorescens NCIMB10586 
ΔmmpFΔmupSΔmupQΔmacpD(pMY23) was purified to single colonies before checking for 




















Figure 5.7 Bioassay to show influence of deletion of mmpF, mupS, mupQ and 
macpD in P. fluorescens NCIMB10586 and, to show cross-complementation of 
this mutant by corresponding quadruple tml genes (tmpF, tmlQ, tmlS and tacpD) 
as a group.P. fluorescens NCIMB10586ΔmmpFΔmupSΔmupQΔmacpD strain (A) 
and WT strain (B) taken as controls while NCIMB 10586 ΔmmpFΔmupSΔmupQ 
ΔmacpD (pMY23) was the test strain (C). The zone of clearance around the central 
















Figure 5.8 HPLC analysis of extracts from strains of P. fluorescens NCIMB 
10586 for the complementation by quadruple tml genes (tmpF, tmlQ, tmlS and 
tacpD) of P. fluorescens NCIMB 10586ΔmmpFΔmupSΔmupQΔmacpD quadruple 
mutant strain. Test strain 10586ΔmmpFΔmupSΔmupQΔmacpD(pMY23) (C) 
restored the production of PA-A (retention time 20.4 min). Quadruple mutant strain 





























Figure 5.9 LC-MS chromatograms of extracts from strains of P. fluorescens 
NCIMB 10586 for the complementation by the group of four tml genes tmlS, 
tmlQ, tacpD and tmpF of ΔmupSΔmupQΔmacpDΔmmpF quadruple mutant. Test 
strain C restored the production of PA-A in the presence of IPTG (0.5 mM). None of 
the two types of negative controls B, E or F produced PA-A. The control D is same as 
E or F but it turned out to be false mutant as it produced PA-A (data by Dr Song of 
the University of Bristol, UK). A, WT; B, NCIMB10586ΔmmpFΔmupSΔmupQ    
ΔmacpD(pJH10); C, NCIMB 10586ΔmmpFΔmupSΔmupQΔmacpD(pMY23); D-F, 
NCIMB 10586 ΔmmpFΔmupSΔmupQΔmacpD; LSU, light scattering units.   
 
Results of in trans expression of the group of thiomarinol genes tmpF, tmlQ, tmlS and tacpD 
cloned under tac promoter in P. fluorescens NCIMB 10586 ΔmmpF ΔmupS ΔmupQ ΔmacpD 
mutant strain clearly indicated functional complementation by this group of thiomarinol 
genes expressed together.  All the three test strains restored the production of PA-A as 
confirmed by HPLC. The quadruple mutant strain of P. fluorescens NCIMB 10586 did not 
produce PA-A (Figures 5.7and 5.8).  The results were confirmed by LC-MS study for one test 









  The idea to achieve complementation by in trans expression of a group of genes that 
are predicted to work together, in an heterologous system, when singular complementation by 
all or any gene(s) of this group  in this other system had failed, was based on the fact that it 
might be possible that the product of the single gene did not fit in the host’s biosynthetic 
pathway, but the group of genes might process a metabolic intermediate and turn it into a 
product that could be accepted and processed by the downstream biosynthetic machinery of 
the other biosynthetic system.  It is a widely observed fact that the product of a group of 
genes that are located together, also collaborates together to process the metabolic 
intermediates.  It has also been shown that gene pairs that were conserved as part of operon 
architecture across different prokaryotic systems, also suggested that protein products of such 
gene pairs physically interact (Dandekar et al., 1998).     
It has already been shown that complementation can be achieved by expressing 
related genes together as a group, when either member of the group completely failed to show 
any complementation when it was expressed individually in the respective single mutant.  
This could be because of restrictions that were imposed either genetically or because product 
of action of single gene failed to get processed by the downstream biosynthetic machinery 
without the action of product of another related gene. It had been shown by the 
complementation studies of mupK/mupJ and mupD/mupE genes in P. fluorescens NCIMB 
10586 wherein these gene pairs, that are located next to each other, could only be 
complemented when these were expressed as pairs. Otherwise there was no complementation 
shown by either member of gene pairs when expressed singularly. 
Results for the cross-complementation of group of tml genes namely tmlS, tacpD, 





corresponding quadruple knockout of P. fluorescens NCIMB 10586, have been positive.  All 
the other members of this group of tml genes except tmlS, failed to show any 
complementation when these were expressed singularly in trans in the corresponding single 
knockouts of P. fluorescens NCIMB10586. 
Results of HPLC for the three test mutants that were constructed for this group 
complementation study, clearly showed restoration of pseudomonic acid-A peak while at the 
same time concerned quadruple mutants did not show peak characteristic of pseudomonic 
acid-A (retention time 20.3 min).  The result was also confirmed with LC-MS study which 
was consistent with the earlier results where deletion of mupS, a member of the gene group 
tested, completely abolished the production of pseudomonic acids by P. fluorescens NCIMB 
10586 (Cooper et al., 2005b).  The result of group complementation was positive despite the 
fact that only one member of this group tmlS showed complementation and restored the 
production of pseudomonic acid-A only partially, when it was expressed singularly in trans 
under the same tac promoter in the corresponding single knockout strain (Chapter 4, section 
4.3.6).  
On the basis of bioinformatics studies it has been pointed out that groups of genes like 
as those of tml cluster or of mup cluster, are not only closely located with each other but are 
also involved in the furnishing of starter unit for the biosynthesis of fatty acids (Chen et al., 
2006, Piel, 2010, Gao et al., 2014, Helfrich and Piel, 2016).  In the biosynthesis of mupirocin, 
it has been proposed that enzymes like MupS (reductase), MacpD (acyl carrier protein) and 
MupQ (acyl-CoA synthase) are involved in furnishing of the starter unit from 3-
hydroxypropionate for the biosynthesis of its 9-hydroxynonanoic acid component (Feline et 
al., 1977, Thomas et al., 2010, Murphy et al., 2014).  Though there is no direct evidence to 





(Feline et al., 1977, Murphy et al., 2014).  In the metabolism, 3-hydroxypropionate acts as a 
starter unit for the biosynthesis of fatty acids with odd number of carbon atoms. It has been 
suggested that 9-HN is produced by the three rounds of condensation reactions catalysed by 
MmpB using malonate as extender unit and probably for each cycle of condensation it uses 
its three ACPs. 
Contrary to the results of singular complementation shown by all the members of this 
group of tml genes, result of group complementation indicated that all these enzymes of this 
group in mupirocin biosynthesis were in the same role as they played in thiomarinol 
biosynthesis.  This suggested that some other gene function in thiomarinol biosynthetic 
system causes the difference of one carbon from the fatty acid component of pseudomonic 
acids, or it is the result of some other gene function in mup biosynthetic system that causes its 
fatty acid to have one more extra carbon compared to that of thiomarinols. 
Results of group complementation compared to that for single complementation 
clearly indicated that the biosynthetic intermediates processed by the products of genes tmlS, 
tacpD, tmlQ and tmpF, which have same chemical nature as their corresponding mup 
counterparts, were acceptable to the downstream biosynthetic machinery of mupirocin 
biosynthetic system. While products of tacpD, tmlQ and tmpF when expressed singularly in 
the corresponding single mup mutant completely failed to accept or process biosynthetic 
intermediates of the mupirocin biosynthetic assembly line (see sections 4.3.8, 4.3.7, and 
4.3.9).  This was despite products of each of these gene functions shared significant amino 
acid sequence identity with the corresponding gene functions of the mup system, which 

















Figure 5.10  Predicted scheme for 9-HN and 8-HO acid biosynthesis in 
mupirocin and thiomarinol biosynthesis.(*) It is proposed that TmlS protein is in 
dual role in tml biosynthetic pathway where it is also involved in the reduction of 
succinyl-CoA apart from playing role in its loading onto TacpD protein similarly like 
MupS.   
 
Positive complementation by group of tml genes, individual members of which either 
showed no complementation or complemented partially (tmlS), indicated that concerned 
proteins of the group shared enough homology so that working together these could 
complement the task of similar group of proteins in the other system (mup system).  This 
supported the prediction that groups of  these proteins work together, which was made on the 
basis of close location of their genes in the respective  biosynthetic cluster and on the basis of 
in silico predictions about them.  Since it is already established that 4-hydroxybutyrate is the 
starter unit for the biosynthesis of 8-HO in thiomarinols (Murphy et al., 2014), this indicated 
that the biosynthetic pathway so far as action of these enzymes as a group is concerned, is 
same in both the systems, mupirocin and thiomarinol.  Otherwise, there could not have been 
(similar to acyl-CoA ligase) Succinyl-CoA loaded 
onto MacpD/ TacpD 
Decarboxylation and 
reduction    
(NADPH) 





restoration of pseudomonic acid production by the quadruple mutant strain upon in trans 
expression of corresponding tml genes.  This tells us that the biosynthetic steps in mup 
biosynthetic pathway deviate from tml cluster in the furnishing of starter units for their 
respective fatty acid moieties. Based on this it is proposed that there is some other gene 
function, product of which is involved in the furnishing of 3-HP in mup system from 
succinate, which is the substrate, from which in tml biosynthetic pathway 4-hydroxybutyrate 
is derived by three members of this group of genes for priming the biosynthesis of 8-HO.  
The gene function tmpF, which is located next to this group of genes in the tml 
cluster, complemented the functions of MmpF but only when complemented together with 
this group of genes, otherwise singularly it failed to complement. This indicated that TmpF 
worked along with the product of this group of genes.  It is established that ΔmmpF mutant of 
P. fluorescens NCIMB10586 does not produce PA-As.  Based on the role of other similar 
genes that are often found located near group of genes with which they function in furnishing 
of starter units like role played by diffB in difficidin biosynthetic cluster of Bacillus 
amyloliquifaciens (Chen et al., 2006), it is proposed that mupP which is located next to this 
group of genes in mup cluster, is a putative malonate dehydrogenase.  Probably it is MupP, 
that reduces the malonate derived from the succinyl-CoA, decarboxylation of which to give 
malonate is catalysed may be by MmpF or by some other protein, to yield 3-HP substrate. 
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 General comments  
In the past few decades a large number of polyketides and their derivatives have been 
discovered. Out of these, many have been found to be effective in the treatment of various 
diseases working as immuno-suppressants, anticancer agents, antifungals, anti-parasitic 
agents and antibacterial agents and, therefore, are already in clinical use.  But during the same 
period and with the discovery of new antibiotics, resistance to them has also been growing 
(Davies and Davies, 2010, Ventola, 2015).  In fact, during last few decades there has been 
rapid increase in the rate by which resistance is developing in pathogens against available 
antibiotics because of their unregulated use (Ventola, 2015).  Unfortunately, the rate of 
development of resistance against existing antibiotics has outpaced that of discovery of new 
antibiotic molecules that can tackle the situation.   In fact, for certain human pathogens we 
are left with no effective antibiotic and there are very few available for some other pathogens. 
The scene on growing antibiotic resistance, has become so alarming that the organizations 
like World Health Organization (WHO) and World Economic Forum have taken several 
initiatives to control it (Schaberle and Hack, 2014, Nathan and Cars, 2014).  Now there is a 
lot of pressure to look out for new molecules with novel activities and improved properties 
that can qualify as drugs for clinical use (Doshi, 2015).  As part of new drug discovery 
initiatives, several other compounds like non-ribosomal proteins that have been successfully 
used as drugs in medicine are also being considered (Mootz et al., 2000, Williams, 2013).  
Many compounds from diverse natural sources, some of which are found as polyketide- 
NRPS hybrid molecules of different types, are also being tested for clinical use and 
commercial exploitation.  Apart from chemical methods that are being applied to synthesise 
new molecules or modify existing molecules to get new bioactive molecules, approaches of 





genetic engineering are being applied to exploit and integrate biosynthetic steps from various 
biosynthetic clusters to achieve the production of hybrid or modified bioactive molecules 
with improved properties. Success of combinatorial biosynthesis completely depends on in-
depth knowledge about the biosynthetic steps and metabolic intermediates of the biosynthetic 
clusters involved.  The existence of all the genes at one place in a genome as shown in 
different biosynthetic clusters and the modular architecture of PKS assembly lines along with 
colinearity in their biosynthesis have strongly supported the approaches of combinatorial 
biosynthesis (Weissman and Leadlay, 2005, Cummings et al., 2014). That is also being 
extended to type II and III PKSs after understanding of their pattern of biosynthesis and to 
other modular assembly lines like NRPS and FAS involved in the production of diverse 
secondary metabolites (Weissman and Leadlay, 2005). Despite the small number of 
successful examples, combinatorial biosynthesis is still under development because its 
success depends upon the molecular compatibility of genes or proteins from different 
sources.  Attempts are being made to bypass regularly-encountered bottlenecks by swapping 
gene functions (domains, modules, tailoring functions etc.) from different systems by 
developing standard sets of linkers (inter-domain and inter-modular linkers) that can be used 
to reprogramme components from different PKSs so that they can act as functional assembly 
lines (Weissman, 2004).  Similarly, attempts are being made to develop pairs of docking 
domains that can be used in reprogrammed biosynthetic systems to facilitate interaction of 
proteins in the correct order, thus ensuring their functionality.  All these efforts are aimed at 
getting engineered modular assembly lines to deliver new molecules with high potency and 
desired properties like non-toxicity as well as in large amounts. 
 Mupirocin and thiomarinol are two antimicrobials of importance, biosynthetic clusters of 
which pose new challenges to the approaches of combinatorial biosynthesis, thus adding 





biosynthesis only partially that is shown by type I PKSs like Erythromycin.  As described in 
Chapter 1, mupirocin and thiomarinol are synthesised by mixed clusters which belonged to 
the trans-AT group of polyketides.  Although mupirocin is still an effective drug against 
MRSA, it suffers from structural weakness and, therefore, it cannot be used parenterally.  
While thiomarinols are broad spectrum antimicrobials effective even against some Gram 
negative bacteria, still these cannot be used because of their toxicity to eukaryotic cells.  As a 
result, these molecules are the subject of ongoing research to improve or introduce them as 
drugs (Thomas et al., 2010, Fukuda et al., 2011, Murphy et al., 2011, Hothersall et al., 2011, 
Gao et al., 2014, Dunn et al., 2015)(Fukuda et al., 2011, Murphy et al., 2011, Murphy et al., 
2014, Hothersall et al., 2011, Gao et al., 2014).  Remarkable structural similarities between 
these two molecules that are also reflected at a genetic level are indicative of the fact that 
these two systems might be having certain biosynthetic steps and intermediates in common. 
This further provides an opportunity to exploit the biosynthetic pathways of the two systems 
to engineer hybrid molecules using the approaches of combinatorial biosynthesis.  
Thiomarinols also provide the opportunity to develop new molecules by mutasynthesis 
because it is naturally a hybrid molecule of two known antibiotics.  As a result, the research 
is ongoing in different aspects of these two biosynthetic pathways.  Although most of the 
biosynthetic steps in the mupirocin biosynthetic pathway have been deduced, gene functions 
behind certain modifications and timing of various events still remained to be known.  On the 
other hand, very little is known about thiomarinol biosynthetic pathway.  This study, in 
general, contributes to the field of antibiotics particularly to the trans-AT group of antibiotic 
and more specifically to the biosynthesis of mupirocin and thiomarinol antibiotics. 
 






6.2.1 There is divergence in the evolution of pair of proteins that are tested belonging to the      
tailoring region of the biosynthetic clusters of these two antibiotics    
Each of the thiomarinol tailoring region proteins namely TmlO, TmlC, TmlF, TmlK, 
TmlQ, TmpF and TacpD shared significant amino acid sequence identity with its equivalent 
mup protein encoded by the tailoring region functions of the mupirocin biosynthetic cluster.  
But despite this, all of these failed to show functional cross-complementation when expressed 
in the mupirocin system indicating divergence in the function of pair of these enzymatic 
proteins of the two clusters during evolution. 
 
6.2.2 There has been convergence in the evolution of reductases and hydratases belonging to 
the tailoring region of the thiomarinol/mupirocin biosynthetic cluster.  
Both of these tested enzymatic proteins belonging to the tailoring regions of tml 
cluster namely TmlS and TmlJ that shared significant identity of amino acid sequence with 
the respective Mup proteins, showed positive complementation. TmlS and MupS both are 
putative reductases while TmlJ and MupJ are putative enoyl-CoA hydratases.  This indicated 
that there has been convergence during the evolution of these protein pairs as a result of 
which there is conservation of function between them.      
 
 6.2.3 The biosynthetic steps in β-methyl branching (C-15) in the thiomarinol biosynthesis are 
different from those involved in this branching in mupirocin biosynthesis. 
Based on analysis of the products of defined in-frame knockouts of genes like mupH, 
mupJ, mupG, mupK and macpC which yielded same product (mupirocin H) for all these 





β-methylation (C-15) of C-3 of the pseudomonic acids.  This is also supported by analogy of 
existence of similar gene functions in other similar biosynthetic clusters.  Biochemically, 
mupJ and mupK are predicted to be enoyl-CoA hydratases. The mupJ and mupK are found 
associated in mup cluster with the group of other genes that are HMG-CoA synthase, ACP 
and KS.  Genes of this kind, which are found as a group called as “HMG cassette”, are also 
found together in other biosynthetic clusters.  This group of genes has been proposed to 
introduce a methyl group onto the polyketide backbone from acetate. In the mupirocin 
biosynthetic pathway, two enoyl-CoA hydratases MupJ and MupK have been proposed to act 
one after the other on the metabolic biosynthetic intermediate to dehydrate and then to 
decarboxylate it, respectively.  It has also been observed that these enzymes act as protein 
complexes in a group.  This was evident from the gene knockout and complementation 
studies done by Hothersall et al. (2007) by which it was shown that these genes could only be 
complemented to wild type levels when they were expressed together such that they were 
transcribed from a single mRNA in the double mutant of mupJ and mupK.  Therefore, 
positive complementation shown by TmlJ in the corresponding single mutant of NCIMB 
10586, which is also an enoyl-CoA like MupJ and with which it shares significant amino acid 
sequence identity, clearly indicated that the biosynthetic steps for β-methylation (C-15) of C-
3 in thiomarinol biosynthetic pathway are completely different from that of mupirocin.  
Though the second enoyl-CoA hydratase is present in thiomarinols as fused protein TmpE, 
the N-terminal end of which shares significant amino acid sequence identity with MupK.  But 
because TmlJ alone could complement functions of MupJ to the wild type levels in the single 
mutant, NCIMB10586 ΔmupJ, and also because MupJ failed to complement the same mutant 
alone without MupK, this indicated that TmlJ could act in the concerned biosynthetic 
pathway alone without the requirement of forming any protein complex with MupK of the 





β-branching pathway in two biosynthetic clusters also become evident from the fact that 
MupK in the ΔmupJ mutant did not interfere with the expression of TmlJ while it interfered 
when MupJ was expressed in it (Hothersall et al., 2007).  Since complementation could be 
achieved only in the presence of IPTG, this indicated that higher amount of enzyme was 
required to restore the production of pseudomonic acids.   
 
6.2.4 The gene functions involved in furnishing starter unit for the biosynthesis of fatty acid 
component in both the system are homologous and share same substrate for deriving primer 
unit biosynthesis.  With respect to this, both the biosynthetic pathways overlap to some extent 
but divulges later as far as functioning of three enzymes MupS, MupQ, and MacpD and their 
tml equivalents is concerned. The TmpF and MmpF are also proposed to have some role with 
them in the respective pathways. But because mup cluster has some other gene functions 
probably a dehydrogenase and/or a decarboxylase which together furnish a three carbon 
primer unit from the same substrate from which tml system derives its four carbon primer 
unit for the biosynthesis. 
Mupirocin antibiotic has fatty acid 9-hydroxynonanoic acid attached to the monic acid 
moiety by ester linkage while in thiomarinols this fatty acid is 8-hydroxyoctanoic acid. The 
biosynthetic steps involved in the biosynthesis of fatty acid components in these antibiotics 
are not known.  In mup cluster, mmpB gene function is predicted to be involved in its 
biosynthesis by iterative mechanism only on the basis of indirect evidence (Thomas et al., 
2010).  Equivalent tml protein TmpB shares 36% identity of its amino acid sequence with 
MmpB.  In mupirocin, biosynthesis of 9-HN is predicted to be from 3-hydroxypropionate. 
Based on in silico studies, it has been found that genes like mupS, macpD, mupQ and their 
thiomarinol equivalents are found to be involved in furnishing starter unit for furnishing of 3-





condensations of malonate units.  Since extender unit in thiomarinol system is also malonate, 
therefore, the difference of one carbon in these two fatty acids, 9-HN and 8-HO acid, is 
proposed to occur at the level of starter unit.  The starter unit in thiomarinols is a four carbon 
unit and 8-HO is biosynthesised by the condensation of two malonates. Restoration of 
pseudomonic acid A production in NCIMB10586ΔmupsΔmupQΔmmpFΔmacpD quadruple 
mutant on expression of group of tml genes tmlQ, tmlS, tmpF and tacpD indicated that some 
other gene functions were responsible for this difference of one carbon in the fatty acid 
components of these two antibiotics.  
 
6.2.5   Complementation by a group of genes that are predicted to work together can be used 
as a tool to extend complementation between two systems, even when, complementation by 
any or all of the members of that group failed to show complementation when expressed 
singularly. 
As described in Chapter 4, gene knockout and complementation studies in the 
mupirocin biosynthetic pathway have established that the products of genes mupQ, macpD, 
mupS and mmpF are necessary for the production of PA-A (Cooper et al., 2005b, Hothersall 
et al., 2007).  In silico studies in other similar biosynthetic clusters have indicated that the 
products of genes of this type that are found located close to each other, also work together to 
furnish the starter unit for the biosynthesis of fatty acids (Chen et al., 2006, Thomas et al., 
2010). Both pseudomonic acids and thiomarinols have a fatty acid component.  In 
thiomarinol system such genes are tmlQ, tmpF, tacpD and tmlS, products of which share 
significant amino acid sequence identity with the products of corresponding gene functions of 
the mup system (Fukuda et al., 2011).  Results in the chapter 4 (section 4.3) concluded that in 
trans complementation by each of the tmlQ, tmpF and tacpD, singularly, did not restore the 





however, it was only tmlS that restored the production of PA-A in the ΔmupS mutant but only 
partially.  Contrary to this, complementation fully restored the production of PA-A when all 
these thiomarinol genes were expressed together, in trans, as a group in the corresponding 
mup (quadruple) mutant strain in which all the corresponding four genes were knocked out.  
This extended complementation supported in silico prediction that the products of group of 
corresponding four genes in both these clusters function together in the respective 
biosynthetic pathway. Products of these tml genes shared enough homology with their mup 
equivalents so that these were able to extend complementation while working together, 
compared to what was shown by individual members of tml group.  
 
6.2.6 The method for making defined gene knockouts that relied on suicide mutagenesis using 
pAKE604 (El Sayeed et al., 2001), which was used by Rahman et al. (2005) for making 
defined in-frame chromosomal mutations in Pseudomonas fluorescens NCIMB 10586, is not 
very efficient in Pseudoalteromonas sp. SANK 73390 and, therefore, does not guarantee 
mutations in pTML1.    
The method used for making mutants relied upon suicide mutagenesis and homologous 
recombination between the derivatives of suicide vector pAKE604 and the pTML1 plasmid 
of Pseudoalteromonas sp. SANK 73390. The site of homologous recombination was 
directed by cloning of specific pTML1 sequences in the suicide vector. Apart from this, 
method depended on conjugative transfer of suicide vector into SANK 73390 strain and 
effective selection of transconjugants using kanamycin (at the concentration of 50 µl/ml) and 
on negative selection of clones at a concentration of 5.5% w/v sucrose in M Agar.  Negative 
selection of clones depended on effective expression of sacB gene in the SANK73390 strain.  
Failure to get knockouts of pTML1 in this study and of some different genes by others using 





(Fukuda et al., 2011), raise doubts about the utility of this method for making SANK 73390 
knockouts.  This is strengthened by the fact that knockouts of some genes could only be 
made after several attempts by several workers while some other genes could not be deleted 
at all despite repeated attempts. Failure to get knockouts could be because of failure of 
cellular machinery of Pseudoalteromonas sp. SANK 73390 to support the suicide vector in 
the cell or to support the processes on which this method depended.  This could be because 
of specialized adaptations of its cellular components, that are currently unknown, owing to 
its marine habitat. A variety of adaptations for survival in marine environment has been 
reported in the cellular components of marine bacteria (Bidle and Bartlett, 1999, Allen et al., 
1999, Allen and Bartlett, 2000, Qin et al., 2011, Yu et al., 2013). As a result, the cellular 
processes on which success of this method depended were not supported in the laboratory 
environment where it was grown on artificial media out of its ecological habitat. New 
methods are being developed with improved protocols for achieving gene knockouts in 
Pseudoalteromonas sp. (Yu et al., 2014, Wang et al., 2015). 
  Future work       
Creating defined knockouts of specific genes has been one of the most widely used 
method to elucidate the basic information about the role played by different gene functions 
in a biosynthetic system/cluster that involves examining changes in the phenotype by 
characterizing the biosynthetic intermediates with respect to every mutation that is made. 
Complementation studies using such defined knockouts have also been widely used as the 
next step to shed light on the organization of a gene cluster and to question the results of 
knockout studies made about specific genes to enquire their specific roles.  A comprehensive 
analysis of various defined knockouts and their complementation about a biosynthetic cluster 





biosynthetic system. The specific protein-protein interactions can then be identified using 
various methods available to study protein-protein interactions which depend on the 
detection or estimation of specific proteins, for example by co-immunoprecipitation, by 
quantitative immunoprecipitation combined with knock-down (QUICK) or by bimolecular 
fluorescence complementation (BiFC) to visualize the protein interactions etc. As mentioned 
earlier that though most of the steps in the biosynthesis of mup biosynthetic pathway have 
been determined mainly by using comprehensive gene knockout and complementation 
studies, timing for various biosynthetic steps as well as gene functions responsible for certain 
modifications still remained unknown.  For example, it is still not known which gene 
function is responsible for 6-hydroxylation and what are the biosynthetic steps that lead to 
the formation of ester linkage between polyketide moiety and the fatty acid component.  On 
the other hand, very little is known about the thiomarinol biosynthetic pathway.  Knowledge 
of biosynthetic steps in these two systems mupirocin and thiomarinol is needed in order to 
genetically manipulate them to develop strains that produce molecules with better properties 
like high stability and no toxicity. Knowledge about common biosynthetic steps and 
intermediates in these two biosynthetic pathways is needed to develop novel molecules with 
improved activities and properties by applying the knowledge of combinatorial biosynthesis. 
This knowledge can be used to develop novel hybrid molecules out of these two molecules 
like pseudomonic acid derivatives with 8-HO acid or thiomarinol derivatives with 9-HN etc. 
which can be tested for novel activities and other beneficial properties. 
There is need to develop a new method for making defined in-frame knockouts of the 
gene functions in the thiomarinol biosynthetic cluster because the method used did not 
always yield a result (El Sayeed et al., 2001, Fukuda et al., 2011).  Qualitative analysis and 
quantitative estimation of products from defined mutants and elucidating their structures will 





Functional complementation of remaining ORFs of the mupirocin biosynthetic 
cluster, products of which show significant similarity of amino acid sequence identity with 
those of thiomarinol cluster, should also be completed. This will give a broader view of the 
common biosynthetic steps by way of protein-protein interaction taking place and gene 
functions between the two systems. On the other hand, results of negative complementation 
could be verified by confirming that there was actual expression of the concerned protein that 
was being tested. This could be done by various methods for example by mass-spectrometry 
or by using antibodies raised specifically against selected epitopes on purified proteins of 
interest.   
Though the negative result of complementation of singular proteins that has been 
tested tells about their divergence, a better answer can be obtained by testing them by in vitro 
assay. Because of different cellular environment apart from genetic rearrangement of 
tailoring functions in the mup system, the tml enzymes might not have been active or did not 
pair up with the protein complex formed by other mup proteins to bring out the desirable 
phenotype.  It has been shown that several mup proteins work as part of protein complexes. In 
this regard, interaction of TmlJ protein with the mup proteins should be investigated because 
of the positive result of its complementation. It is interesting because its equivalent partner 
protein MupJ itself failed to show complementation in the mup system when mupJ was 
expressed singularly without the gene function mupK which encodes another enoyl-CoA 
hydratase (MupK) proposed in the mup pathway. 
In view of the failure of complementation of tmlF and tmlC genes to complement 
corresponding singular mup mutants of NCIMB 10586, group complementation by 
expressing them together in the concerned double mutant might help to achieve 





cluster and may have a requirement for being transcribed together as a single unit for efficient 
transcription. This will also shed light on question whether their polypeptides need to be 
folded together before they can become functionally active.  
Cross-complementation by different gene combinations (sub-groups) among the 
group of genes that were tested along with those that are predicted, will reveal much more 
information about the key biosynthetic steps involved in furnishing primer unit for the 
biosynthesis of fatty acid component in pseudomonic acids. 
The approach of reverse complementation for testing functional complementation by 
all the mup proteins that show significant similarity of amino acid sequence identity with the 
thiomarinol functions in the corresponding thiomarinol knockouts, should also be pursued. 
This could be done not only for singular gene functions but also to test complementation by 
group of genes, products of which are predicted to act together.  This will help to get 
complete picture about the functional organization of different gene functions in these two 
biosynthetic clusters and will reveal similarities and differences in the biosynthetic steps and 
intermediates between the two when compared with the results of forward singular and group 
complementation studies. Complementation of various gene groups in view of their proposed 
functionality on account of in silico predictions or experimental results or their location in the 
respective biosynthetic cluster, should also reveal their functional organization in the cluster 
like regulatory requirements, operon organization and transcriptional requirements to become 
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